{
 "cells": [
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "# Exploratory Data Analysis\n",
    "\n",
    "Our task is to develop a system that provides accurate medical information that successfully answers the question given by the user. Provided to us is a dataset of questions and answers. We may use this dataset to understand the kind of data our model is expected to work with, as well as the desired level of performance"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 1,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "application/vnd.microsoft.datawrangler.viewer.v0+json": {
       "columns": [
        {
         "name": "index",
         "rawType": "int64",
         "type": "integer"
        },
        {
         "name": "question",
         "rawType": "object",
         "type": "string"
        },
        {
         "name": "answer",
         "rawType": "object",
         "type": "string"
        }
       ],
       "conversionMethod": "pd.DataFrame",
       "ref": "f745bfd3-c20d-49fb-a9d9-2961c10f2338",
       "rows": [
        [
         "0",
         "What is (are) Glaucoma ?",
         "Glaucoma is a group of diseases that can damage the eye's optic nerve and result in vision loss and blindness. The most common form of the disease is open-angle glaucoma. With early treatment, you can often protect your eyes against serious vision loss. (Watch the video to learn more about glaucoma. To enlarge the video, click the brackets in the lower right-hand corner. To reduce the video, press the Escape (Esc) button on your keyboard.)  See this graphic for a quick overview of glaucoma, including how many people it affects, whos at risk, what to do if you have it, and how to learn more.  See a glossary of glaucoma terms."
        ],
        [
         "1",
         "What is (are) Glaucoma ?",
         "The optic nerve is a bundle of more than 1 million nerve fibers. It connects the retina to the brain."
        ],
        [
         "2",
         "What is (are) Glaucoma ?",
         "Open-angle glaucoma is the most common form of glaucoma. In the normal eye, the clear fluid leaves the anterior chamber at the open angle where the cornea and iris meet. When the fluid reaches the angle, it flows through a spongy meshwork, like a drain, and leaves the eye. Sometimes, when the fluid reaches the angle, it passes too slowly through the meshwork drain, causing the pressure inside the eye to build. If the pressure damages the optic nerve, open-angle glaucoma -- and vision loss -- may result."
        ],
        [
         "3",
         "Who is at risk for Glaucoma? ?",
         "Anyone can develop glaucoma. Some people are at higher risk than others. They include - African-Americans over age 40  - everyone over age 60, especially Hispanics/Latinos  - people with a family history of glaucoma. African-Americans over age 40 everyone over age 60, especially Hispanics/Latinos people with a family history of glaucoma.  See this graphic for a quick overview of glaucoma, including how many people it affects, whos at risk, what to do if you have it, and how to learn more."
        ],
        [
         "4",
         "How to prevent Glaucoma ?",
         "At this time, we do not know how to prevent glaucoma. However, studies have shown that the early detection and treatment of glaucoma, before it causes major vision loss, is the best way to control the disease. So, if you fall into one of the higher risk groups for the disease, make sure to have a comprehensive dilated eye exam at least once every one to two years.  Get tips on finding an eye care professional. Learn what a comprehensive dilated eye exam involves."
        ]
       ],
       "shape": {
        "columns": 2,
        "rows": 5
       }
      },
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>question</th>\n",
       "      <th>answer</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>What is (are) Glaucoma ?</td>\n",
       "      <td>Glaucoma is a group of diseases that can damag...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>What is (are) Glaucoma ?</td>\n",
       "      <td>The optic nerve is a bundle of more than 1 mil...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>What is (are) Glaucoma ?</td>\n",
       "      <td>Open-angle glaucoma is the most common form of...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>Who is at risk for Glaucoma? ?</td>\n",
       "      <td>Anyone can develop glaucoma. Some people are a...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>How to prevent Glaucoma ?</td>\n",
       "      <td>At this time, we do not know how to prevent gl...</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "                         question  \\\n",
       "0        What is (are) Glaucoma ?   \n",
       "1        What is (are) Glaucoma ?   \n",
       "2        What is (are) Glaucoma ?   \n",
       "3  Who is at risk for Glaucoma? ?   \n",
       "4       How to prevent Glaucoma ?   \n",
       "\n",
       "                                              answer  \n",
       "0  Glaucoma is a group of diseases that can damag...  \n",
       "1  The optic nerve is a bundle of more than 1 mil...  \n",
       "2  Open-angle glaucoma is the most common form of...  \n",
       "3  Anyone can develop glaucoma. Some people are a...  \n",
       "4  At this time, we do not know how to prevent gl...  "
      ]
     },
     "execution_count": 1,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "import pandas as pd\n",
    "import matplotlib.pyplot as plt\n",
    "import seaborn as sns\n",
    "\n",
    "dset_path = \"../data/intern_screening_dataset.csv\"\n",
    "original_qa_df = pd.read_csv(dset_path)\n",
    "\n",
    "qa_df = original_qa_df.copy()\n",
    "\n",
    "qa_df.head()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 2,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "application/vnd.microsoft.datawrangler.viewer.v0+json": {
       "columns": [
        {
         "name": "index",
         "rawType": "object",
         "type": "string"
        },
        {
         "name": "question",
         "rawType": "object",
         "type": "unknown"
        },
        {
         "name": "answer",
         "rawType": "object",
         "type": "unknown"
        }
       ],
       "conversionMethod": "pd.DataFrame",
       "ref": "f31c4166-e89f-472a-8908-d8bbe525bd83",
       "rows": [
        [
         "count",
         "16406",
         "16401"
        ],
        [
         "unique",
         "14981",
         "15811"
        ],
        [
         "top",
         "What causes Causes of Diabetes ?",
         "This condition is inherited in an autosomal recessive pattern, which means both copies of the gene in each cell have mutations. The parents of an individual with an autosomal recessive condition each carry one copy of the mutated gene, but they typically do not show signs and symptoms of the condition."
        ],
        [
         "freq",
         "20",
         "348"
        ]
       ],
       "shape": {
        "columns": 2,
        "rows": 4
       }
      },
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>question</th>\n",
       "      <th>answer</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>count</th>\n",
       "      <td>16406</td>\n",
       "      <td>16401</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>unique</th>\n",
       "      <td>14981</td>\n",
       "      <td>15811</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>top</th>\n",
       "      <td>What causes Causes of Diabetes ?</td>\n",
       "      <td>This condition is inherited in an autosomal re...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>freq</th>\n",
       "      <td>20</td>\n",
       "      <td>348</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "                                question  \\\n",
       "count                              16406   \n",
       "unique                             14981   \n",
       "top     What causes Causes of Diabetes ?   \n",
       "freq                                  20   \n",
       "\n",
       "                                                   answer  \n",
       "count                                               16401  \n",
       "unique                                              15811  \n",
       "top     This condition is inherited in an autosomal re...  \n",
       "freq                                                  348  "
      ]
     },
     "execution_count": 2,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "qa_df.describe()"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "The dataset consists of 16406 entries of questions and answers related to medical information. \n",
    "\n",
    "## Data Integrity\n",
    "From the table above, we can already identify some questions of interest to investigate about the data:\n",
    "- Why is there a discrepancy in the number of questions and answers?\n",
    "- Why are there several non-unique entries in both questions and answers?\n",
    "\n",
    "\n",
    "Given that the dataset is composed of strings of variable length, and that as such it is hard to fully inspect the data using pandas' methods, let's define a helper function that standardizes printing for us"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 3,
   "metadata": {},
   "outputs": [],
   "source": [
    "def pretty_print_row(row):\n",
    "    print(\"============================\")\n",
    "    print(\"Q:\", row['question'])\n",
    "    print(\"A:\", row['answer'])"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "### Q: Why is there a discrepacy in the number of questions and answers?\n",
    "\n",
    "There appear to be 5 less questions than answers. This probably means that our data contains some NaNs. Let's verify"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 4,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "question    0\n",
       "answer      5\n",
       "dtype: int64"
      ]
     },
     "execution_count": 4,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "qa_df.isna().sum()"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "There are 5 questions that have been left unanswered, which amounts to .03% of the data. Let's see which ones are they"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 5,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "============================\n",
      "Q: What is (are) HELLP syndrome ?\n",
      "A: nan\n",
      "============================\n",
      "Q: What is (are) X-linked lymphoproliferative syndrome ?\n",
      "A: nan\n",
      "============================\n",
      "Q: What is (are) Familial HDL deficiency ?\n",
      "A: nan\n",
      "============================\n",
      "Q: What is (are) Emery-Dreifuss muscular dystrophy, X-linked ?\n",
      "A: nan\n",
      "============================\n",
      "Q: What is (are) Emery-Dreifuss muscular dystrophy, dominant type ?\n",
      "A: nan\n"
     ]
    }
   ],
   "source": [
    "unanswered_df = qa_df[qa_df.isna().any(axis=1)]\n",
    "for _, row in unanswered_df.iterrows():\n",
    "    pretty_print_row(row)"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "Given that these questions have no answer, our best option is to remove them from our dataset. However, as a safety measure, we would like to see if the topics in these questions are covered in the rest of our dataset"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 6,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\n",
      "\n",
      "Questions related to HELLP syndrome:\n",
      "Number of related questions: 3\n",
      "\n",
      "\n",
      "Questions related to X-linked lymphoproliferative syndrome:\n",
      "Number of related questions: 4\n",
      "\n",
      "\n",
      "Questions related to Familial HDL deficiency:\n",
      "Number of related questions: 7\n",
      "\n",
      "\n",
      "Questions related to Emery-Dreifuss muscular dystrophy:\n",
      "Number of related questions: 8\n"
     ]
    }
   ],
   "source": [
    "# Since this is only 5 questions, we can just check directly for relevant information. \n",
    "# If we had more questions to investigate, we would have to find a way to streamline this\n",
    "topics_of_interest = [\"HELLP syndrome\", \"X-linked lymphoproliferative syndrome\", \"Familial HDL deficiency\", \"Emery-Dreifuss muscular dystrophy\"]\n",
    "\n",
    "for topic in topics_of_interest:\n",
    "    print(f\"\\n\\nQuestions related to {topic}:\")\n",
    "    topic_questions = qa_df[qa_df['question'].str.contains(topic, case=False)]\n",
    "    num_questions = len(topic_questions)\n",
    "    print(f\"Number of related questions: {num_questions}\")"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "The unanswered questions appear to be covered by a few other questions in the data, so we can assume that the topics are covered and therefore safe to remove"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 7,
   "metadata": {},
   "outputs": [],
   "source": [
    "qa_df = qa_df.dropna()"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "### Q: Why are there several non-unique entries in both questions and answers?\n",
    "Duplicate entries can be an issue with our dataset, regardless of how it will be used. Duplicate entries will bias the machine learning process, by either acting as a weighting factor in the training process, or by being overrepresented in the evaluation scores. Answering this question will also cover some additional questions:\n",
    "\n",
    "- Is there an intersection between duplicate questions and answers?\n",
    "\n",
    "Additionally, looking at the description of the data, the number of duplicate questions is larger than the number of duplicate answers, so even if assuming that all duplicate answers match with a duplicate question, there would be questions that are repeated but contain different answers\n",
    "\n",
    "- Are duplicate questions with unique answers an issue?\n",
    "\n",
    "### Q: Is there an intersection between duplicate questions and answers?\n",
    "To answer this, we can get the duplicate rows and count how many there are. This would give us an idea of the size of the intersection"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 8,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Number of duplicate questions: 122\n",
      "============================\n",
      "Q: How to diagnose Glomerular Diseases ?\n",
      "A: Patients with glomerular disease have significant amounts of protein in the urine, which may be referred to as \"nephrotic range\" if levels are very high. Red blood cells in the urine are a frequent finding as well, particularly in some forms of glomerular disease. Urinalysis provides information about kidney damage by indicating levels of protein and red blood cells in the urine. Blood tests measure the levels of waste products such as creatinine and urea nitrogen to determine whether the filtering capacity of the kidneys is impaired. If these lab tests indicate kidney damage, the doctor may recommend ultrasound or an x ray to see whether the shape or size of the kidneys is abnormal. These tests are called renal imaging. But since glomerular disease causes problems at the cellular level, the doctor will probably also recommend a kidney biopsya procedure in which a needle is used to extract small pieces of tissue for examination with different types of microscopes, each of which shows a different aspect of the tissue. A biopsy may be helpful in confirming glomerular disease and identifying the cause.\n",
      "============================\n",
      "Q: How to diagnose Glomerular Diseases ?\n",
      "A: Patients with glomerular disease have significant amounts of protein in the urine, which may be referred to as \"nephrotic range\" if levels are very high. Red blood cells in the urine are a frequent finding as well, particularly in some forms of glomerular disease. Urinalysis provides information about kidney damage by indicating levels of protein and red blood cells in the urine. Blood tests measure the levels of waste products such as creatinine and urea nitrogen to determine whether the filtering capacity of the kidneys is impaired. If these lab tests indicate kidney damage, the doctor may recommend ultrasound or an x ray to see whether the shape or size of the kidneys is abnormal. These tests are called renal imaging. But since glomerular disease causes problems at the cellular level, the doctor will probably also recommend a kidney biopsya procedure in which a needle is used to extract small pieces of tissue for examination with different types of microscopes, each of which shows a different aspect of the tissue. A biopsy may be helpful in confirming glomerular disease and identifying the cause.\n",
      "============================\n",
      "Q: How to diagnose Kidney Disease of Diabetes ?\n",
      "A: People with diabetes should be screened regularly for kidney disease. The two key markers for kidney disease are eGFR and urine albumin.\n",
      "                \n",
      "-  eGFR. eGFR stands for estimated glomerular filtration rate. Each kidney contains about 1 million tiny filters made up of blood vessels. These filters are called glomeruli. Kidney function can be checked by estimating how much blood the glomeruli filter in a minute. The calculation of eGFR is based on the amount of creatinine, a waste product, found in a blood sample. As the level of creatinine goes up, the eGFR goes down.  Kidney disease is present when eGFR is less than 60 milliliters per minute.  The American Diabetes Association (ADA) and the National Institutes of Health (NIH) recommend that eGFR be calculated from serum creatinine at least once a year in all people with diabetes.  -  Urine albumin. Urine albumin is measured by comparing the amount of albumin to the amount of creatinine in a single urine sample. When the kidneys are healthy, the urine will contain large amounts of creatinine but almost no albumin. Even a small increase in the ratio of albumin to creatinine is a sign of kidney damage.  Kidney disease is present when urine contains more than 30 milligrams of albumin per gram of creatinine, with or without decreased eGFR.  The ADA and the NIH recommend annual assessment of urine albumin excretion to assess kidney damage in all people with type 2 diabetes and people who have had type 1 diabetes for 5 years or more.\n",
      "                \n",
      "If kidney disease is detected, it should be addressed as part of a comprehensive approach to the treatment of diabetes.\n",
      "============================\n",
      "Q: How to diagnose Kidney Disease of Diabetes ?\n",
      "A: People with diabetes should be screened regularly for kidney disease. The two key markers for kidney disease are eGFR and urine albumin.\n",
      "                \n",
      "-  eGFR. eGFR stands for estimated glomerular filtration rate. Each kidney contains about 1 million tiny filters made up of blood vessels. These filters are called glomeruli. Kidney function can be checked by estimating how much blood the glomeruli filter in a minute. The calculation of eGFR is based on the amount of creatinine, a waste product, found in a blood sample. As the level of creatinine goes up, the eGFR goes down.  Kidney disease is present when eGFR is less than 60 milliliters per minute.  The American Diabetes Association (ADA) and the National Institutes of Health (NIH) recommend that eGFR be calculated from serum creatinine at least once a year in all people with diabetes.  -  Urine albumin. Urine albumin is measured by comparing the amount of albumin to the amount of creatinine in a single urine sample. When the kidneys are healthy, the urine will contain large amounts of creatinine but almost no albumin. Even a small increase in the ratio of albumin to creatinine is a sign of kidney damage.  Kidney disease is present when urine contains more than 30 milligrams of albumin per gram of creatinine, with or without decreased eGFR.  The ADA and the NIH recommend annual assessment of urine albumin excretion to assess kidney damage in all people with type 2 diabetes and people who have had type 1 diabetes for 5 years or more.\n",
      "                \n",
      "If kidney disease is detected, it should be addressed as part of a comprehensive approach to the treatment of diabetes.\n",
      "============================\n",
      "Q: How to diagnose Renal Tubular Acidosis ?\n",
      "A: To diagnose RTA, doctors check the acid-base balance in blood and urine samples. If the blood is more acidic than it should be and the urine less acidic than it should be, RTA may be the reason, but additional information is needed to rule out other causes. If RTA is the reason, additional information about the sodium, potassium, and chloride levels in the urine and the potassium level in the blood will help identify which type of RTA a person has. In all cases, the first goal of therapy is to neutralize acid in the blood, but different treatments may be needed to address the different underlying causes of acidosis.\n",
      "============================\n",
      "Q: How to diagnose Renal Tubular Acidosis ?\n",
      "A: To diagnose RTA, doctors check the acid-base balance in blood and urine samples. If the blood is more acidic than it should be and the urine less acidic than it should be, RTA may be the reason, but additional information is needed to rule out other causes. If RTA is the reason, additional information about the sodium, potassium, and chloride levels in the urine and the potassium level in the blood will help identify which type of RTA a person has. In all cases, the first goal of therapy is to neutralize acid in the blood, but different treatments may be needed to address the different underlying causes of acidosis.\n"
     ]
    }
   ],
   "source": [
    "duplicates_df = qa_df[qa_df['answer'].duplicated(keep=False) & qa_df['question'].duplicated(keep=False)]\n",
    "duplicates_df = duplicates_df.sort_values(by=['question', 'answer'])\n",
    "print(f\"Number of duplicate questions: {len(duplicates_df)}\")\n",
    "\n",
    "for _, row in duplicates_df.iloc[:6].iterrows():\n",
    "    pretty_print_row(row)"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "Out of all the duplicate questions and answers, only 122 are row-level duplicates. These entries are the simplest to handle, which can be done by removing exact duplicates. Before doing so, let's inspect how duplicate questions behave"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 9,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Number of duplicate questions: 2192\n",
      "============================\n",
      "Q: How to diagnose Adrenal Insufficiency and Addison's Disease ?\n",
      "A: After Addisons disease is diagnosed, health care providers may use the following tests to look at the adrenal glands, find out whether the disease is related to TB, or identify antibodies associated with autoimmune Addisons disease.\n",
      "                \n",
      "- Ultrasound of the abdomen. Ultrasound uses a device, called a transducer, that bounces safe, painless sound waves off organs to create an image of their structure. A specially trained technician performs the procedure in a health care providers office, an outpatient center, or a hospital, and a radiologista doctor who specializes in medical imaginginterprets the images; a patient does not need anesthesia. The images can show abnormalities in the adrenal glands, such as enlargement or small size, nodules, or signs of calcium deposits, which may indicate bleeding.   - Tuberculin skin test. A tuberculin skin test measures how a patients immune system reacts to the bacteria that cause TB. A small needle is used to put some testing material, called tuberculin, under the skin. A nurse or lab technician performs the test in a health care providers office; a patient does not need anesthesia. In 2 to 3 days, the patient returns to the health care provider, who will check to see if the patient had a reaction to the test. The test can show if adrenal insufficiency could be related to TB.  To test whether a person has TB infection, which is when TB bacteria live in the body without making the person sick, a special TB blood test is used. To test whether a person has TB disease, which is when TB bacteria are actively attacking a persons lungs and making the person sick, other tests such as a chest x ray and a sample of sputumphlegm that is coughed up from deep in the lungsmay be needed.   - Antibody blood tests. A blood test involves drawing blood at a health care providers office or a commercial facility and sending the sample to a lab for analysis. The blood test can detect antibodiesproteins made by the immune system to protect the body from foreign substancesassociated with autoimmune Addisons disease.\n",
      "                \n",
      "After secondary adrenal insufficiency is diagnosed, health care providers may use the following tests to obtain a detailed view of the pituitary gland and assess how it is functioning:\n",
      "                \n",
      "- Computerized tomography (CT) scan. CT scans use a combination of x rays and computer technology to create images. For a CT scan, the patient may be given a solution to drink and an injection of a special dye, called contrast medium. CT scans require the patient to lie on a table that slides into a tunnel-shaped device where the x rays are taken. An x-ray technician performs the procedure in an outpatient center or a hospital, and a radiologist interprets the images. The patient does not need anesthesia. A CT scan can show size and shape of the pituitary gland to find out if an abnormality is present.   - Magnetic resonance imaging (MRI). MRI machines use radio waves and magnets to produce detailed pictures of the bodys internal organs and soft tissues without using x rays. An MRI may include the injection of contrast medium. With most MRI machines, the patient lies on a table that slides into a tunnel-shaped device that may be open ended or closed at one end; some machines are designed to allow the patient to lie in a more open space. A specially trained technician performs the procedure in an outpatient center or a hospital, and a radiologist interprets the images. The patient does not need anesthesia, though people with a fear of confined spaces may receive light sedation, taken by mouth. MRIs can be used to produce a three-dimensional (3-D) image of the hypothalamus and the pituitary gland to find out if an abnormality is present.   - Hormonal blood tests. Hormonal blood tests can assess how the pituitary gland is functioning and its ability to produce other hormones.\n",
      "============================\n",
      "Q: How to diagnose Adrenal Insufficiency and Addison's Disease ?\n",
      "A: In its early stages, adrenal insufficiency can be difficult to diagnose. A health care provider may suspect it after reviewing a persons medical history and symptoms.\n",
      "                \n",
      "A diagnosis of adrenal insufficiency is confirmed through hormonal blood and urine tests. A health care provider uses these tests first to determine whether cortisol levels are too low and then to establish the cause. Imaging studies of the adrenal and pituitary glands can be useful in helping to establish the cause.\n",
      "                \n",
      "A lab technician performs the following tests in a health care providers office, a commercial facility, or a hospital.\n",
      "                \n",
      "Hormonal Blood and Urine Tests\n",
      "                \n",
      "- ACTH stimulation test. The ACTH stimulation test is the most commonly used test for diagnosing adrenal insufficiency. In this test, the patient is given an intravenous (IV) injection of synthetic ACTH, and samples of blood, urine, or both are taken before and after the injection. The cortisol levels in the blood and urine samples are measured in a lab. The normal response after an ACTH injection is a rise in blood and urine cortisol levels. People with Addisons disease or longstanding secondary adrenal insufficiency have little or no increase in cortisol levels.  Both low- and high-dose ACTH stimulation tests may be used depending on the suspected cause of adrenal insufficiency. For example, if secondary adrenal insufficiency is mild or has only recently occurred, the adrenal glands may still respond to ACTH because they have not yet shut down their own production of hormone. Some studies have suggested a low dose1 microgram (mcg)may be more effective in detecting secondary adrenal insufficiency because the low dose is still enough to raise cortisol levels in healthy people, yet not in people with mild or recent secondary adrenal insufficiency. However, recent research has shown that a significant proportion of healthy children and adults can fail the low-dose test, which may lead to unnecessary treatment. Therefore, some health care providers favor using a 250 mcg ACTH test for more accurate results.   - CRH stimulation test. When the response to the ACTH test is abnormal, a CRH stimulation test can help determine the cause of adrenal insufficiency. In this test, the patient is given an IV injection of synthetic CRH, and blood is taken before and 30, 60, 90, and 120 minutes after the injection. The cortisol levels in the blood samples are measured in a lab. People with Addisons disease respond by producing high levels of ACTH, yet no cortisol. People with secondary adrenal insufficiency do not produce ACTH or have a delayed response. CRH will not stimulate ACTH secretion if the pituitary is damaged, so no ACTH response points to the pituitary as the cause. A delayed ACTH response points to the hypothalamus as the cause.\n",
      "                \n",
      "Diagnosis during Adrenal Crisis\n",
      "                \n",
      "Although a reliable diagnosis is not possible during adrenal crisis, measurement of blood ACTH and cortisol during the crisisbefore treatment with corticosteroids is givenis often enough to make a preliminary diagnosis. Low blood sodium, low blood glucose, and high blood potassium are also sometimes present at the time of adrenal crisis. Once the crisis is controlled, an ACTH stimulation test can be performed to help make a specific diagnosis. More complex lab tests are sometimes used if the diagnosis remains unclear.\n",
      "============================\n",
      "Q: How to diagnose Alzheimer's Caregiving ?\n",
      "A: Now that your family member or friend has received a diagnosis of Alzheimers disease, its important to learn as much as you can about the disease and how to care for someone who has it. You may also want to know the right way to share the news with family and friends. Learning About Alzheimers Sometimes, you may feel that you don't know how to care for the person with Alzheimers. This is a common feeling among caregivers of people with Alzheimers because each day may bring different challenges. Learning about the disease can help you understand and cope with these challenges. Here is some information about Alzheimers and ways you can learn more about it. Alzheimers disease is an illness of the brain. It causes large numbers of nerve cells in the brain to die. This affects a persons ability to remember things and think clearly. People with Alzheimers become forgetful and easily confused and may have a hard time concentrating. They may have trouble taking care of themselves and doing basic things like making meals, bathing, and getting dressed. Alzheimers varies from person to person. It can progress faster in some people than in others, and not everyone will have the same symptoms. In general, though, Alzheimers takes many years to develop, becoming increasingly severe over time. As the disease gets worse, people need more help. Eventually, they require total care. Alzheimer's disease consists of three main stages: mild (sometimes called early-stage), moderate, and severe (sometimes called late-stage). Understanding these stages can help you care for your loved one and plan ahead. Mild Alzheimers Disease In the mild stage of Alzheimers, people often have some memory loss and small changes in personality. They may have trouble remembering recent events or the names of familiar people or things. They may no longer be able to solve simple math problems or balance a checkbook. People with mild Alzheimers also slowly lose the ability to plan and organize. For example, they may have trouble making a grocery list and finding items in the store. Moderate Alzheimers Disease In the moderate stage of Alzheimers, memory loss and confusion become more obvious. People have more trouble organizing, planning, and following instructions. They may need help getting dressed and may start having problems with bladder or bowel control. People with moderate Alzheimers may have trouble recognizing family members and friends. They may not know where they are or what day or year it is. They also may begin to wander, so they should not be left alone. Personality changes can become more serious. For example, people may make threats or accuse others of stealing. Severe Alzheimers Disease In the severe stage of Alzheimer's, people usually need help with all of their daily needs. They may not be able to walk or sit up without help. They may not be able to talk and often cannot recognize family members. They may have trouble swallowing and refuse to eat. For a short overview of Alzheimers, see  Understanding Alzheimers Disease: What You Need to Know. Learn More About Alzheimers Disease So far, there is no cure for Alzheimers, but there are treatments that can prevent some symptoms from getting worse for a limited time. Here are some ways you can learn more about Alzheimers disease. - Talk with a doctor or other healthcare provider who specializes in Alzheimers disease.   - Check out books or videos about Alzheimers from the library.   - Go to educational programs about the disease.   - Visit the website of the National Institute on Agings Alzheimers Disease Education and Referral (ADEAR) Center. The Institute has a guide, Caring for a Person with Alzheimers Disease,which can be viewed online and ordered in print.   - Read about  Alzheimers disease on NIHSeniorHealth.  - Find a support group for caregivers, ideally one in which members are taking care of someone who is in the same stage of Alzheimers as the person you are caring for.  Talk with a doctor or other healthcare provider who specializes in Alzheimers disease. Check out books or videos about Alzheimers from the library. Go to educational programs about the disease. Visit the website of the National Institute on Agings Alzheimers Disease Education and Referral (ADEAR) Center. The Institute has a guide, Caring for a Person with Alzheimers Disease,which can be viewed online and ordered in print. Read about  Alzheimers disease on NIHSeniorHealth. Find a support group for caregivers, ideally one in which members are taking care of someone who is in the same stage of Alzheimers as the person you are caring for. Talking With Family and Friends When you learn that someone has Alzheimers disease, you may wonder when and how to tell your family and friends. You may be worried about how others will react to or treat the person. Others often sense that something is wrong before they are told. Alzheimers disease is hard to keep secret. When the time seems right, be honest with family, friends, and others. Use this as a chance to educate them about Alzheimers disease. You can share information to help them understand what you and the person with Alzheimers are going through. You can also tell them what they can do to help. You can help family and friends understand how to interact with the person who has Alzheimers. - Help them realize what the person can still do and how much he or she can still understand.  - Give them suggestions about how to start talking with the person. For example, \"Hello George, I'm John. We used to work together.\"  - Help them avoid correcting the person with Alzheimers if he or she makes a mistake or forgets something.  - Help them plan fun activities with the person, such as going to family reunions or visiting old friends. Help them realize what the person can still do and how much he or she can still understand. Give them suggestions about how to start talking with the person. For example, \"Hello George, I'm John. We used to work together.\" Help them avoid correcting the person with Alzheimers if he or she makes a mistake or forgets something. Help them plan fun activities with the person, such as going to family reunions or visiting old friends. Helping Children Understand Alzheimers If the person with Alzheimers has young children or grandchildren, you can help them understand what is happening. Answer their questions simply and honestly. For example, you might tell a young child, \"Grandma has an illness that makes it hard for her to remember things.\" Know that their feelings of sadness and anger are normal. Comfort them. Tell them they didn't cause the disease. If the child lives with someone who has Alzheimers, don't expect him or her to \"babysit\" the person. Make sure the child has time for his or her own interests and needs, such as playing with friends and going to school activities. Spend time with the child, so he or she doesn't feel that all your attention is on the person with Alzheimers. Many younger children will look to you to see how to act around the person with Alzheimers disease. Show children they can still talk with the person and help them enjoy things. Doing fun things together, like arts and crafts or looking through photo albums, can help both the child and the person with Alzheimer's. Challenges for Teens A teenager might find it hard to accept how the person with Alzheimers has changed. He or she may find the changes upsetting or embarrassing and not want to be around the person. Talk with teenagers about their concerns and feelings. Don't force them to spend time with the person who has Alzheimers.  Get more information about helping family and friends understand Alzheimers disease.\n",
      "============================\n",
      "Q: How to diagnose Alzheimer's Caregiving ?\n",
      "A: When you learn that someone has Alzheimers disease, you may wonder when and how to tell your family and friends. You may be worried about how others will react to or treat the person. Others often sense that something is wrong before they are told. Alzheimers disease is hard to keep secret. When the time seems right, be honest with family, friends, and others. Use this as a chance to educate them about Alzheimers disease. You can share information to help them understand what you and the person with Alzheimers are going through. You can also tell them what they can do to help. Get more information about helping family and friends understand Alzheimer's disease.\n",
      "============================\n",
      "Q: How to diagnose Alzheimer's Disease ?\n",
      "A: An early, accurate diagnosis of Alzheimer's disease helps people and their families plan for the future. It gives them time to discuss care options, find support, and make legal and financial arrangements while the person with Alzheimers can still take part in making decisions. Also, even though no medicine or other treatment can stop or slow the disease, early diagnosis offers the best chance to treat the symptoms.\n",
      "============================\n",
      "Q: How to diagnose Alzheimer's Disease ?\n",
      "A: The only definitive way to diagnose Alzheimer's disease is to find out whether plaques and tangles exist in brain tissue. To look at brain tissue, doctors perform a brain autopsy, an examination of the brain done after a person dies. Doctors can only make a diagnosis of \"possible\" or probable Alzheimers disease while a person is alive. Doctors with special training can diagnose Alzheimer's disease correctly up to 90 percent of the time. Doctors who can diagnose Alzheimers include geriatricians, geriatric psychiatrists, and neurologists. A geriatrician specializes in the treatment of older adults. A geriatric psychiatrist specializes in mental problems in older adults. A neurologist specializes in brain and nervous system disorders. To diagnose Alzheimer's disease, doctors may - ask questions about overall health, past medical problems, ability to carry out daily activities, and changes in behavior and personality  - conduct tests to measure memory, problem solving, attention, counting, and language skills   - carry out standard medical tests, such as blood and urine tests  - perform brain scans to look for anything in the brain that does not look normal. ask questions about overall health, past medical problems, ability to carry out daily activities, and changes in behavior and personality conduct tests to measure memory, problem solving, attention, counting, and language skills carry out standard medical tests, such as blood and urine tests perform brain scans to look for anything in the brain that does not look normal.\n"
     ]
    }
   ],
   "source": [
    "q_duplicates_df = qa_df[(qa_df['question'].duplicated(keep=False)) & (~qa_df['answer'].duplicated(keep=False))]\n",
    "q_duplicates_df = q_duplicates_df.sort_values(by=['question', 'answer'])\n",
    "print(f\"Number of duplicate questions: {len(q_duplicates_df)}\")\n",
    "\n",
    "for _, row in q_duplicates_df.iloc[:6].iterrows():\n",
    "    pretty_print_row(row)"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "There appear to be a few questions that have different answers. Wether or not this is an issue is debatable, but most often than not it could be considered bad practice. As stated before, duplicate entries will be more representative of the final score, which can bias the analysis towards those questions. If a question has multiple, high quality responses, that are relevant to the question and demonstrate varied ways to answer correctly, it could be an useful way to have more robust evaluations.\n",
    "\n",
    "That being said, a quick inspection of the data demonstrates that some of the duplicate questions contain non-relevant answers. For example: `How to diagnose Alzheimer's disease ?` has two different answers, out of which only one seems to discuss actual methods to diagnose the disease. Assuming lack of expertise from the data scientist, **this should prompt an investigation of the quality of the data from experts in the field**. To avoid possible issues that can arise from this discrepancy, **the duplicate questions will also be removed**.\n",
    "\n",
    "Lastly, let's investigate the duplicate answers"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 10,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Number of duplicate questions: 552\n",
      "============================\n",
      "Q: What is (are) Achondrogenesis ?\n",
      "A: Achondrogenesis is a group of severe disorders that are present from birth and affect the development of cartilage and bone. Infants with achondrogenesis usually have a small body, short arms and legs, and other skeletal abnormalities that cause life-threatening complications.  There are at least three forms of achondrogenesis, type 1A, type 1B and type 2, which are distinguished by signs and symptoms, pattern of inheritance, and the results of imaging studies such as x-rays (radiology), tissue analysis (histology), and genetic testing.  Type 1A and 1B achondrogenesis are both inherited in an autosomal recessive pattern.  Type 1B may be caused by mutations in the SLC26A2 gene.  Type 2 achondrogenesis is inherited in an autosomal dominant pattern and is caused by new (de novo) mutations in the COL2A1 gene.\n",
      "============================\n",
      "Q: What is (are) Achondrogenesis type 1A ?\n",
      "A: Achondrogenesis is a group of severe disorders that are present from birth and affect the development of cartilage and bone. Infants with achondrogenesis usually have a small body, short arms and legs, and other skeletal abnormalities that cause life-threatening complications.  There are at least three forms of achondrogenesis, type 1A, type 1B and type 2, which are distinguished by signs and symptoms, pattern of inheritance, and the results of imaging studies such as x-rays (radiology), tissue analysis (histology), and genetic testing.  Type 1A and 1B achondrogenesis are both inherited in an autosomal recessive pattern.  Type 1B may be caused by mutations in the SLC26A2 gene.  Type 2 achondrogenesis is inherited in an autosomal dominant pattern and is caused by new (de novo) mutations in the COL2A1 gene.\n",
      "============================\n",
      "Q: What is (are) Achondrogenesis type 2 ?\n",
      "A: Achondrogenesis is a group of severe disorders that are present from birth and affect the development of cartilage and bone. Infants with achondrogenesis usually have a small body, short arms and legs, and other skeletal abnormalities that cause life-threatening complications.  There are at least three forms of achondrogenesis, type 1A, type 1B and type 2, which are distinguished by signs and symptoms, pattern of inheritance, and the results of imaging studies such as x-rays (radiology), tissue analysis (histology), and genetic testing.  Type 1A and 1B achondrogenesis are both inherited in an autosomal recessive pattern.  Type 1B may be caused by mutations in the SLC26A2 gene.  Type 2 achondrogenesis is inherited in an autosomal dominant pattern and is caused by new (de novo) mutations in the COL2A1 gene.\n",
      "============================\n",
      "Q: What is (are) Aicardi-Goutieres syndrome type 1 ?\n",
      "A: Aicardi-Goutieres syndrome is an inherited condition that mainly affects the brain, immune system, and skin. It is characterized by early-onset severe brain dysfunction (encephalopathy) that usually results in severe intellectual and physical disability. Additional symptoms may include epilepsy, painful, itchy skin lesion (chilblains), vision problems, and joint stiffness. Symptoms usually progress over several months before the disease course stabilizes. There are six different types of Aicardi-Goutieres syndrome, which are distinguished by the gene that causes the condition: TREX1, RNASEH2A, RNASEH2B, RNASEH2C, SAMHD1, and ADAR genes. Most cases are inherited in an autosomal recessive pattern, although rare autosomal dominant cases have been reported. Treatment is symptomatic and supportive.\n",
      "============================\n",
      "Q: What is (are) Aicardi-Goutieres syndrome type 2 ?\n",
      "A: Aicardi-Goutieres syndrome is an inherited condition that mainly affects the brain, immune system, and skin. It is characterized by early-onset severe brain dysfunction (encephalopathy) that usually results in severe intellectual and physical disability. Additional symptoms may include epilepsy, painful, itchy skin lesion (chilblains), vision problems, and joint stiffness. Symptoms usually progress over several months before the disease course stabilizes. There are six different types of Aicardi-Goutieres syndrome, which are distinguished by the gene that causes the condition: TREX1, RNASEH2A, RNASEH2B, RNASEH2C, SAMHD1, and ADAR genes. Most cases are inherited in an autosomal recessive pattern, although rare autosomal dominant cases have been reported. Treatment is symptomatic and supportive.\n",
      "============================\n",
      "Q: What is (are) Aicardi-Goutieres syndrome type 3 ?\n",
      "A: Aicardi-Goutieres syndrome is an inherited condition that mainly affects the brain, immune system, and skin. It is characterized by early-onset severe brain dysfunction (encephalopathy) that usually results in severe intellectual and physical disability. Additional symptoms may include epilepsy, painful, itchy skin lesion (chilblains), vision problems, and joint stiffness. Symptoms usually progress over several months before the disease course stabilizes. There are six different types of Aicardi-Goutieres syndrome, which are distinguished by the gene that causes the condition: TREX1, RNASEH2A, RNASEH2B, RNASEH2C, SAMHD1, and ADAR genes. Most cases are inherited in an autosomal recessive pattern, although rare autosomal dominant cases have been reported. Treatment is symptomatic and supportive.\n",
      "============================\n",
      "Q: What is (are) Aicardi-Goutieres syndrome type 4 ?\n",
      "A: Aicardi-Goutieres syndrome is an inherited condition that mainly affects the brain, immune system, and skin. It is characterized by early-onset severe brain dysfunction (encephalopathy) that usually results in severe intellectual and physical disability. Additional symptoms may include epilepsy, painful, itchy skin lesion (chilblains), vision problems, and joint stiffness. Symptoms usually progress over several months before the disease course stabilizes. There are six different types of Aicardi-Goutieres syndrome, which are distinguished by the gene that causes the condition: TREX1, RNASEH2A, RNASEH2B, RNASEH2C, SAMHD1, and ADAR genes. Most cases are inherited in an autosomal recessive pattern, although rare autosomal dominant cases have been reported. Treatment is symptomatic and supportive.\n",
      "============================\n",
      "Q: What is (are) Aicardi-Goutieres syndrome type 5 ?\n",
      "A: Aicardi-Goutieres syndrome is an inherited condition that mainly affects the brain, immune system, and skin. It is characterized by early-onset severe brain dysfunction (encephalopathy) that usually results in severe intellectual and physical disability. Additional symptoms may include epilepsy, painful, itchy skin lesion (chilblains), vision problems, and joint stiffness. Symptoms usually progress over several months before the disease course stabilizes. There are six different types of Aicardi-Goutieres syndrome, which are distinguished by the gene that causes the condition: TREX1, RNASEH2A, RNASEH2B, RNASEH2C, SAMHD1, and ADAR genes. Most cases are inherited in an autosomal recessive pattern, although rare autosomal dominant cases have been reported. Treatment is symptomatic and supportive.\n",
      "============================\n",
      "Q: What is (are) Axenfeld-Rieger syndrome type 1 ?\n",
      "A: Axenfeld-Rieger syndrome is a group of eye disorders that affects the development of the eye. Common eye symptoms include cornea defects, which is the clear covering on the front of the eye, and iris defects, which is the colored part of the eye. People with this syndrome may have an off-center pupil (corectopia) or extra holes in the eyes that can look like multiple pupils (polycoria). About 50% of people with this syndrome develop glaucoma, which is a serious condition that increases pressure inside of the eye. This may cause vision loss or blindness. Click here to view a diagram of the eye.  Even though Axenfeld-Rieger syndrome is primarily an eye disorder, this syndrome is also associated with symptoms that affect other parts of the body. Most people with this syndrome have distinctive facial features and many have issues with their teeth, including unusually small teeth (microdontia) or fewer than normal teeth (oligodontia). Some people have extra folds of skin around their belly button, heart defects, or other more rare birth defects. There are three types of Axenfeld-Rieger syndrome and each has a different genetic cause. Axenfeld-Rieger syndrome type 1 is caused by spelling mistakes (mutations) in the PITX2 gene. Axenfeld-Rieger syndrome type 3 is caused by mutations in the FOXC1 gene. The gene that causes Axenfeld-Rieger syndrome type 2 is not known, but it is located on chromosome 13. Axenfeld-Rieger syndrome has an autosomal dominant pattern of inheritance.\n",
      "============================\n",
      "Q: What is (are) Axenfeld-Rieger syndrome type 2 ?\n",
      "A: Axenfeld-Rieger syndrome is a group of eye disorders that affects the development of the eye. Common eye symptoms include cornea defects, which is the clear covering on the front of the eye, and iris defects, which is the colored part of the eye. People with this syndrome may have an off-center pupil (corectopia) or extra holes in the eyes that can look like multiple pupils (polycoria). About 50% of people with this syndrome develop glaucoma, which is a serious condition that increases pressure inside of the eye. This may cause vision loss or blindness. Click here to view a diagram of the eye.  Even though Axenfeld-Rieger syndrome is primarily an eye disorder, this syndrome is also associated with symptoms that affect other parts of the body. Most people with this syndrome have distinctive facial features and many have issues with their teeth, including unusually small teeth (microdontia) or fewer than normal teeth (oligodontia). Some people have extra folds of skin around their belly button, heart defects, or other more rare birth defects. There are three types of Axenfeld-Rieger syndrome and each has a different genetic cause. Axenfeld-Rieger syndrome type 1 is caused by spelling mistakes (mutations) in the PITX2 gene. Axenfeld-Rieger syndrome type 3 is caused by mutations in the FOXC1 gene. The gene that causes Axenfeld-Rieger syndrome type 2 is not known, but it is located on chromosome 13. Axenfeld-Rieger syndrome has an autosomal dominant pattern of inheritance.\n",
      "============================\n",
      "Q: What is (are) Camurati Engelmann disease, type 2 ?\n",
      "A: Camurati-Engelmann disease is a genetic condition that mainly affects the bones. People with this disease have increased bone density, particularly affecting the long bones of the arms and legs. In some cases, the skull and hip bones are also affected. The thickened bones can lead to pain in the arms and legs, a waddling walk, muscle weakness, and extreme tiredness. The age at which affected individuals first experience symptoms varies greatly; however, most people with this condition develop pain or weakness by adolescence. Camurati-Engelmann disease is caused by a mutation in the TGFB1 gene which is inherited in an autosomal dominant fashion. In some instances, people have the gene mutation that causes Camurati-Engelmann disease but never develop the characteristic features of this condition. In others, features are present, but a mutation cannot be identified. These cases are referred to as Camurati-Engelmann disease type II.  Treatment for Camurati-Engelman disease depends on many factors including the signs and symptoms present in each person and the severity of the condition.\n",
      "============================\n",
      "Q: What is (are) Cockayne syndrome type II ?\n",
      "A: Cockayne syndrome is a rare condition which causes short stature, premature aging (progeria), severe photosensitivity, and moderate to severe learning delay. This syndrome also includes failure to thrive in the newborn, microcephaly, and impaired nervous system development. Other symptoms may include hearing loss, tooth decay, and eye and bone abnormalities.  Cockayne syndrome type 1 (type A) is sometimes called classic or \"moderate\" Cockayne syndrome and is diagnosed during early childhood. Cockayne syndrome type 2 (type B) is sometimes referred to as the severe or \"early-onset\" type. This more severe form presents with growth and developmental abnormalities at birth. The third type, Cockayne syndrome type 3 (type C) is a milder form of the disorder. Cockayne syndrome is caused by mutations in either the ERCC8 (CSA) or ERCC6 (CSB) genes and is inherited in an autosomal recessive pattern. The typical lifespan for individuals with Cockayne syndrome type 1 is ten to twenty years. Individuals with type 2 usually do not survive past childhood. Those with type 3 live into middle adulthood.\n"
     ]
    }
   ],
   "source": [
    "a_duplicates_df = qa_df[(~qa_df['question'].duplicated(keep=False)) & (qa_df['answer'].duplicated(keep=False))]\n",
    "a_duplicates_df = a_duplicates_df.sort_values(by=['answer', 'question'])\n",
    "print(f\"Number of duplicate questions: {len(a_duplicates_df)}\")\n",
    "\n",
    "for _, row in a_duplicates_df.iloc[:12].iterrows():\n",
    "    pretty_print_row(row)"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "Duplicate answers to different questions, even if similar, should prompt a re-evaluation of the specificity of the answers. This sets seems to comprise exact answers to more specific questions about some medical topics. For example, exact same responses are given to questions that go deeper into the different types of syndromes of diseases. This might indicate that these entries do not represent helpful answers to the given questions. Still, eliminating all of the answers given above could be wasteful, as they most probably convey information relevant to the questions, even if not specific enough. While in a real life setting it would be best to raise this issue to the stakeholders to ensure it is handled appropiately, for this scenario these duplicate answers will also be removed."
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 11,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "                        question  \\\n",
      "count                      14460   \n",
      "unique                     14460   \n",
      "top     What is (are) Glaucoma ?   \n",
      "freq                           1   \n",
      "\n",
      "                                                   answer  \n",
      "count                                               14460  \n",
      "unique                                              14460  \n",
      "top     Glaucoma is a group of diseases that can damag...  \n",
      "freq                                                    1  \n",
      "Percentage of retained data: 0.8813848591978545\n"
     ]
    }
   ],
   "source": [
    "qa_df = qa_df.drop_duplicates(subset=['question'])\n",
    "qa_df = qa_df.drop_duplicates(subset=['answer'])\n",
    "print(qa_df.describe())\n",
    "\n",
    "print(\"Percentage of retained data:\", len(qa_df) / len(original_qa_df))"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "After cleaning up the data, we retained ~88% of the original dataset. While the amount of dropped rows is significant, the amount of retained entries should still be enough to allow for experimentation and/or evaluation. As discussed before, in a real world scenario some alternative measures can be taken for retaining more entries, by validating the quality of the data on offending entries with some experts on the field"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## Text-related statistics\n",
    "After having validated the integrity of the data, it might be worth to investigate the contents. Some relevant questions to investigate are:\n",
    "- How does the length of the questions and answers behave?\n",
    "- What are relevant representative words?\n",
    "\n",
    "### Q: How does the length of the questions and answers behave?\n",
    "This can give us an idea of the context size that the model should have to be able to provide the expected detail for most if not all responses"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 12,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Question Length Statistics:\n",
      "count    14460.000000\n",
      "mean        51.771024\n",
      "std         16.790032\n",
      "min         16.000000\n",
      "25%         40.000000\n",
      "50%         50.000000\n",
      "75%         62.000000\n",
      "max        191.000000\n",
      "dtype: float64\n",
      "\n",
      "Answer Length Statistics:\n",
      "count    14460.000000\n",
      "mean      1317.253873\n",
      "std       1649.873110\n",
      "min          6.000000\n",
      "25%        512.000000\n",
      "50%        904.000000\n",
      "75%       1605.250000\n",
      "max      27910.000000\n",
      "dtype: float64\n"
     ]
    }
   ],
   "source": [
    "q_len = qa_df.apply(lambda x: len(x['question']), axis=1)\n",
    "a_len = qa_df.apply(lambda x: len(x['answer']), axis=1)\n",
    "\n",
    "print(\"Question Length Statistics:\")\n",
    "print(q_len.describe())\n",
    "print()\n",
    "print(\"Answer Length Statistics:\")\n",
    "print(a_len.describe())"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "The variability of the questions is relatively small, averaging at ~52 characters with a standard deviation of ~17. On the other hand, responses have a wide range of lengths, with a standard deviation of ~1650 and a mean of ~1317. Let's inspect the extremes of both columns"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 13,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "application/vnd.microsoft.datawrangler.viewer.v0+json": {
       "columns": [
        {
         "name": "index",
         "rawType": "int64",
         "type": "integer"
        },
        {
         "name": "question",
         "rawType": "object",
         "type": "string"
        },
        {
         "name": "answer",
         "rawType": "object",
         "type": "string"
        }
       ],
       "conversionMethod": "pd.DataFrame",
       "ref": "fc29cff7-e9f9-4942-9758-33e30c79c8f4",
       "rows": [
        [
         "7881",
         "What is (are)  ?",
         "On this Page General Information What is vancomycin-resistant enterococci? What types of infections does vancomycin-resistant enterococci cause? Are certain people at risk of getting vancomycin-resistant enterococci? What is the treatment for vancomycin-resistant enterococci? How is vancomycin-resistant enterococci spread? How can patients prevent the spread of vancomycin-resistant enterococci? What should a patient do if they think they have vancomycin-resistant enterococci? Recommendations and Guidelines General Information For more images of this bacterium, search the Public Health Image Library What is vancomycin-resistant enterococci? Enteroccocci are bacteria that are normally present in the human intestines and in the female genital tract and are often found in the environment. These bacteria can sometimes cause infections. Vancomycin is an antibiotic that is used to treat some drug-resistant infections caused by enterococci. In some instances, enterococci have become resistant to this drug and thus are called vancomycin-resistant enterococci (VRE). Most VRE infections occur in hospitals. Top of page What types of infections does VRE cause? VRE can live in the human intestines and female genital tract without causing disease (often called colonization). However, sometimes it can cause infections of the urinary tract, the bloodstream, or of wounds associated with catheters or surgical procedures. Top of page Are certain people at risk of getting VRE? The following persons are at increased risk becoming infected with VRE: People who have been previously treated with the antibiotic vancomycin or other antibiotics for long periods of time. People who are hospitalized, particularly when they receive antibiotic treatment for long periods of time. People with weakened immune systems such as patients in intensive care units, or in cancer or transplant wards. People who have undergone surgical procedures such as abdominal or chest surgery. People with medical devices that stay in for some time such as urinary catheters or central intravenous (IV) catheters. People who are colonized with VRE. Top of page What is the treatment for VRE? People with colonized VRE (bacteria are present, but have no symptoms of an infection)  do not need treatment. Most VRE infections can be treated with antibiotics other than vancomycin. Laboratory testing of the VRE can determine which antibiotics will work. For people who get VRE infections in their bladder and have urinary catheters, removal of the catheter when it is no longer needed can also help get rid of the infection. Top of page How is VRE spread? VRE is often passed from person to person by the contaminated hands of caregivers. VRE can get onto a caregiver's hands after they have contact with other people with VRE or after contact with contaminated surfaces. VRE can also be spread directly to people after they touch surfaces that are contaminated with VRE. VRE is not spread through the air by coughing or sneezing. Top of page How can patients prevent the spread of VRE? If a patient or someone in their household has VRE, the following are some things they can do to prevent the spread of VRE: Keep their hands clean. Always wash their hands thoroughly after using the bathroom and before preparing food. Clean their hands after contact with persons who have VRE. Wash with soap and water (particularly when visibly soiled) or use alcohol-based hand rubs. Frequently clean areas of the home, such as bathrooms, that may become contaminated with VRE. Wear gloves if hands may come in contact with body fluids that may contain VRE, such as stool or bandages from infected wounds. Always wash their hands after removing gloves. If someone has VRE, be sure to tell healthcare providers so that they are aware of the infection. Healthcare facilities use special precautions to help prevent the spread of VRE to others. Top of page What should patients do if they think they have vancomycin-resistant enterococci (VRE)? Anyone who thinks they have VRE must talk with their healthcare provider. Top of page Recommendations and Guidelines For more information about prevention and treatment of HAIs, see the resources below: Siegel JD, Rhinehart E, Jackson M, et al. The Healthcare Infection Control Practices Advisory Committee (HICPAC). Management of Multidrug-Resistant Organisms In Healthcare Settings, 2006"
        ],
        [
         "8060",
         "what is botulism?",
         "Botulism is a rare but serious paralytic illness caused by a nerve toxin that is produced by the bacterium Clostridium botulinum and sometimes by strains of Clostridium butyricum and Clostridium baratii. There are five main kinds of botulism. Foodborne botulism is caused by eating foods that contain the botulinum toxin. Wound botulism is caused by toxin produced from a wound infected with Clostridium botulinum. Infant botulism is caused by consuming the spores of the botulinum bacteria, which then grow in the intestines and release toxin. Adult intestinal toxemia (adult intestinal colonization) botulism is a very rare kind of botulism that occurs among adults by the same route as infant botulism. Lastly, iatrogenic botulism can occur from accidental overdose of botulinum toxin. All forms of botulism can be fatal and are considered medical emergencies. Foodborne botulism is a public health emergency because many people can be poisoned by eating a contaminated food."
        ],
        [
         "8079",
         "How to prevent  ?",
         "Vaccines and Preventable Diseases On this Page Vaccine Shortages & Delays Potential New Vaccines Vaccines: The Basics FAQ about Vaccines & Diseases they Prevent   VACCINE-PREVENTABLE DISEASES OR, find it by Vaccine Anthrax Cervical Cancer Diphtheria Hepatitis A Hepatitis B Haemophilus influenzae type b (Hib) Human Papillomavirus (HPV) H1N1 Flu (Swine Flu) Influenza (Seasonal Flu) Japanese Encephalitis (JE) Measles Meningococcal Mumps Pertussis (Whooping Cough) Pneumococcal Poliomyelitis (Polio) Rabies Rotavirus Rubella (German Measles) Shingles (Herpes Zoster) Smallpox Tetanus (Lockjaw) Tuberculosis Typhoid Fever Varicella (Chickenpox) Yellow Fever At a Glance Vaccine-preventable disease levels are at or near record lows. Even though most infants and toddlers have received all recommended vaccines by age 2, many under-immunized children remain, leaving the potential for outbreaks of disease. Many adolescents and adults are under-immunized as well, missing opportunities to protect themselves against diseases such as Hepatitis B, influenza, and pneumococcal disease. CDC works closely with public health agencies and private partners to improve and sustain immunization coverage and to monitor the safety of vaccines so that this public health success story can be maintained and expanded in the century to come. Vaccine Shortages & Delays The latest national information about vaccine supplies and guidance for healthcare providers who are facing vaccine shortages or delays Chart of shortages & delays   Potential New Vaccines Resources for finding information on potential vaccines, research and development status, licensure status, etc. New Vaccine Surveillance Network Program evaluates impact of new vaccines and vaccine policies through a network of 6 US sites Status of Licensure and Recs for New Vaccines American Academy of Pediatrics (AAP) Potential New Vaccines Immunization Action Coalition (IAC)   Vaccines: The Basics Without vaccines, epidemics of many preventable diseases could return, resulting in increased  and unnecessary  illness, disability, and death. All about vaccines How vaccines prevent disease List of all vaccine-preventable diseases List of all vaccines used in United States Photos of vaccine-preventable diseases and/or people affected by them View all...   FAQ about Vaccines & Diseases they Prevent What are the ingredients in vaccines? What vaccines do adults need? What vaccines do children need? What vaccines are used in the United States? What diseases do vaccines prevent? View all...   Related Pages Basics and Common Questions Who Should NOT Get These Vaccines? Unprotected Stories Top of Page   Images and logos on this website which are trademarked/copyrighted or used with permission of the trademark/copyright or logo holder are not in the public domain. These images and logos have been licensed for or used with permission in the materials provided on this website. The materials in the form presented on this website may be used without seeking further permission. Any other use of trademarked/copyrighted images or logos requires permission from the trademark/copyright holder...more This graphic notice means that you are leaving an HHS Web site. For more information, please see the Exit Notification and Disclaimer policy."
        ],
        [
         "689",
         "What causes Gout ?",
         "A Buildup of Uric Acid Most people with gout have too much uric acid in their blood, a condition called hyperuricemia. Uric acid is a substance that results from the breakdown of purines which are a part of all human tissue and found in many foods. Needle-like crystals of uric acid can build up in the connective tissue, in the joint space between two bones, or both. If too many uric acid crystals form as a result of hyperuricemia, gout can develop. Risk Factors These risk factors are associated with gout. - Genetics. Many people with gout have a family history of the disease.  Genetics. Many people with gout have a family history of the disease. - Gender and age. Gout is more common in men than in women and more common in adults than in children. Gender and age. Gout is more common in men than in women and more common in adults than in children. - Weight. Being overweight increases the risk of developing gout because there is more tissue available for turnover or breakdown, which leads to excess uric acid production. Weight. Being overweight increases the risk of developing gout because there is more tissue available for turnover or breakdown, which leads to excess uric acid production. - Alcohol consumption. Drinking too much alcohol can lead to a buildup of uric acid because alcohol interferes with the removal of uric acid from the body. Alcohol consumption. Drinking too much alcohol can lead to a buildup of uric acid because alcohol interferes with the removal of uric acid from the body. - Diet. Eating too many foods that are rich in purines such as liver, dried beans and peas, anchovies and gravies, can cause or aggravate gout in some people. Diet. Eating too many foods that are rich in purines such as liver, dried beans and peas, anchovies and gravies, can cause or aggravate gout in some people. - Lead exposure. In some cases, exposure to lead in the environment can cause gout. Lead exposure. In some cases, exposure to lead in the environment can cause gout. - Other health problems. Renal insufficiency, or the inability of the kidneys to eliminate waste products, is a common cause of gout in older people. Other medical problems that contribute to high blood levels of uric acid include       -  high blood pressure     -  hypothyroidism (underactive thyroid gland)     - conditions that cause an excessively rapid turnover of cells, such as psoriasis, hemolytic anemia, or some cancers     - Kelley-Seegmiller syndrome or Lesch-Nyhan syndrome, two rare conditions in which the enzyme that helps control uric acid levels either is not present or is found in insufficient quantities.     Other health problems. Renal insufficiency, or the inability of the kidneys to eliminate waste products, is a common cause of gout in older people. Other medical problems that contribute to high blood levels of uric acid include     -  high blood pressure    -  hypothyroidism (underactive thyroid gland)    - conditions that cause an excessively rapid turnover of cells, such as psoriasis, hemolytic anemia, or some cancers    - Kelley-Seegmiller syndrome or Lesch-Nyhan syndrome, two rare conditions in which the enzyme that helps control uric acid levels either is not present or is found in insufficient quantities.   -  high blood pressure   -  hypothyroidism (underactive thyroid gland)   - conditions that cause an excessively rapid turnover of cells, such as psoriasis, hemolytic anemia, or some cancers   - Kelley-Seegmiller syndrome or Lesch-Nyhan syndrome, two rare conditions in which the enzyme that helps control uric acid levels either is not present or is found in insufficient quantities. high blood pressure hypothyroidism (underactive thyroid gland) conditions that cause an excessively rapid turnover of cells, such as psoriasis, hemolytic anemia, or some cancers Kelley-Seegmiller syndrome or Lesch-Nyhan syndrome, two rare conditions in which the enzyme that helps control uric acid levels either is not present or is found in insufficient quantities. - Medications. A number of medications may put people at risk for developing hyperuricemia and gout. They include           - diuretics, which are taken to eliminate excess fluid from the body in conditions like hypertension, edema, and heart disease, and which decrease the amount of uric acid passed in the urine     -  salicylate-containing drugs, such as aspirin     - niacin, a vitamin also known as nicotinic acid     - cyclosporine, a medication that suppresses the bodys immune system (the system that protects the body from infection and disease). This medication is used in the treatment of some autoimmune diseases and to prevent the bodys rejection of transplanted organs.    -  levodopa, a medicine used in the treatment of Parkinsons disease.      Medications. A number of medications may put people at risk for developing hyperuricemia and gout. They include         - diuretics, which are taken to eliminate excess fluid from the body in conditions like hypertension, edema, and heart disease, and which decrease the amount of uric acid passed in the urine    -  salicylate-containing drugs, such as aspirin    - niacin, a vitamin also known as nicotinic acid    - cyclosporine, a medication that suppresses the bodys immune system (the system that protects the body from infection and disease). This medication is used in the treatment of some autoimmune diseases and to prevent the bodys rejection of transplanted organs.   -  levodopa, a medicine used in the treatment of Parkinsons disease.    - diuretics, which are taken to eliminate excess fluid from the body in conditions like hypertension, edema, and heart disease, and which decrease the amount of uric acid passed in the urine   -  salicylate-containing drugs, such as aspirin   - niacin, a vitamin also known as nicotinic acid   - cyclosporine, a medication that suppresses the bodys immune system (the system that protects the body from infection and disease). This medication is used in the treatment of some autoimmune diseases and to prevent the bodys rejection of transplanted organs.  -  levodopa, a medicine used in the treatment of Parkinsons disease.  diuretics, which are taken to eliminate excess fluid from the body in conditions like hypertension, edema, and heart disease, and which decrease the amount of uric acid passed in the urine salicylate-containing drugs, such as aspirin niacin, a vitamin also known as nicotinic acid cyclosporine, a medication that suppresses the bodys immune system (the system that protects the body from infection and disease). This medication is used in the treatment of some autoimmune diseases and to prevent the bodys rejection of transplanted organs. levodopa, a medicine used in the treatment of Parkinsons disease."
        ],
        [
         "8269",
         "What causes ARDS ?",
         "Many conditions or factors can directly or indirectly injure the lungs and lead to ARDS. Some common ones are:\n                \nSepsis. This is a condition in which bacteria infect the bloodstream.\n                \nPneumonia. This is an infection in the lungs.\n                \nSevere bleeding caused by an injury to the body.\n                \nAn injury to the chest or head, like a severe blow.\n                \nBreathing in harmful fumes or smoke.\n                \nInhaling vomited stomach contents from the mouth.\n                \nIt's not clear why some very sick or seriously injured people develop ARDS and others don't. Researchers are trying to find out why ARDS develops and how to prevent it."
        ]
       ],
       "shape": {
        "columns": 2,
        "rows": 5
       }
      },
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>question</th>\n",
       "      <th>answer</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>7881</th>\n",
       "      <td>What is (are)  ?</td>\n",
       "      <td>On this Page General Information What is vanco...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>8060</th>\n",
       "      <td>what is botulism?</td>\n",
       "      <td>Botulism is a rare but serious paralytic illne...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>8079</th>\n",
       "      <td>How to prevent  ?</td>\n",
       "      <td>Vaccines and Preventable Diseases On this Page...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>689</th>\n",
       "      <td>What causes Gout ?</td>\n",
       "      <td>A Buildup of Uric Acid Most people with gout h...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>8269</th>\n",
       "      <td>What causes ARDS ?</td>\n",
       "      <td>Many conditions or factors can directly or ind...</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "                question                                             answer\n",
       "7881    What is (are)  ?  On this Page General Information What is vanco...\n",
       "8060   what is botulism?  Botulism is a rare but serious paralytic illne...\n",
       "8079   How to prevent  ?  Vaccines and Preventable Diseases On this Page...\n",
       "689   What causes Gout ?  A Buildup of Uric Acid Most people with gout h...\n",
       "8269  What causes ARDS ?  Many conditions or factors can directly or ind..."
      ]
     },
     "execution_count": 13,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "qa_df.sort_values(by=\"question\", key=lambda x: x.str.len()).head()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 14,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "============================\n",
      "Q: what research (or clinical trials) is being done for National Hormone and Pituitary Program (NHPP): Information for People Treated with Pituitary Human Growth Hormone (Comprehensive Report) ?\n",
      "A: Although CJD is a rare disorder, some of the world's leading researchers are working hard to learn more about this disease.\n",
      "                \n",
      "About 10 percent of the people who get CJD have the inherited type. Some people have gotten CJD from medical procedures such as pituitary hGH injections, tissue grafts, or corneal transplants. Scientists don't fully understand what causes CJD. Evidence suggests that a unique infectious agent called a prion [PREE-on] may be the cause. A prion is an unusual infectious agent because it contains no genetic material. It is a protein that takes on different forms. In its normal, harmless form, the protein is curled into a spiral. In its infectious form, the protein folds into an abnormal shape. Somehow, these abnormal proteins change the shape of normal proteins. This change begins a serious chain reaction that results in brain problems.\n",
      "                \n",
      "People with inherited CJD have an abnormal gene that leads to changes in their prion protein. This gene makes the protein likely to assume the abnormal shape. Exposure to the abnormal form of the protein can also occur through injection of contaminated pituitary hGH, tissue grafts, and corneal transplants and through exposures to infected brain tissue.\n",
      "                \n",
      "If CJD results from a defect in protein folding, it may be possible to identify drugs that can help the prion protein assume its proper shape. Such drugs would slow or stop the progress of the disease. Treatments like these are being studied by researchers. Researchers in both Europe and the United States are also trying to develop a test that will identify CJD before symptoms appear.\n",
      "                \n",
      "More information and medical journal articles about CJD and growth hormone therapy can be found on the National Endocrine and Metabolic Diseases Information Service web page Human Growth Hormone and Creutzfeldt-Jakob Disease Resource List.\n",
      "============================\n",
      "Q: What are the treatments for National Hormone and Pituitary Program (NHPP): Information for People Treated with Pituitary Human Growth Hormone (Comprehensive Report) ?\n",
      "A: Before scientists learned how to make synthetic hormones, many animal hormones, such as insulin, were used to treat human disorders. Growth hormone from animals did not work in humans. Human growth hormone (pituitary hGH) was therefore made from human pituitary glands by the National Hormone and Pituitary Program (NHPP), funded by the U.S. Department of Health and Human Services (HHS). From 1963 to 1985, the NHPP sent pituitary hGH to hundreds of doctors across the country. As a part of research studies, doctors used the hormone to treat nearly 7,700 children for failure to grow.\n",
      "                \n",
      "In 1985, the HHS learned that three young men treated with pituitary hGH died of Creutzfeldt-Jakob disease (CJD), a rare and incurable brain disease. The HHS believed these illnesses were related to pituitary hGH. The HHS immediately stopped the distribution of the hormone and began a national study to learn more about how pituitary hGH treatment may have caused this problem. The HHS continues to monitor individuals who received pituitary hGH through the NHPP for CJD.\n",
      "============================\n",
      "Q: What are the symptoms of National Hormone and Pituitary Program (NHPP): Information for People Treated with Pituitary Human Growth Hormone (Comprehensive Report) ?\n",
      "A: CJD does not cause the same symptoms in everyone. In most people who got CJD from pituitary hGH, the first signs they noticed were difficulty with walking and balance, dizziness, and/or clumsiness. Later, some began to slur words and have jerky movements. They also had trouble seeing, remembering, and/or thinking clearly. The disease becomes worse very quickly. When individuals have symptoms like these over a long period of time (such as a year) without getting much worse, they do not have CJD. Occasional forgetfulness, clumsiness, or headaches do not mean one has CJD. You should discuss concerns with your doctor if you are not sure.\n",
      "                \n",
      "CJD is a rare disease. Most cases of CJD are not linked to pituitary hGH. When CJD is not linked to pituitary hGH, the first symptoms are usually mental changes such as confusion, problems thinking clearly, memory loss, behavior changes, and dementia. Though symptoms may differ, there are similar changes in the brain tissue of all patients with CJD.\n",
      "============================\n",
      "Q: Who is at risk for National Hormone and Pituitary Program (NHPP): Information for People Treated with Pituitary Human Growth Hormone (Comprehensive Report)? ?\n",
      "A: No one can say what an individual person's risk is. Of the approximately 7,700 people who received NHPP pituitary hGH, 29 people got CJD. The two things that seem to be connected with getting CJD after pituitary hGH treatment are\n",
      "                \n",
      "1. How long a person was treated:\n",
      "                \n",
      "- In the United States, the average length of time for pituitary hGH treatment through the NHPP was about 3 years. For those individuals who developed CJD, the average length of treatment was about 8.4 years.  - Even though longer treatment time increased the risk for CJD in the United States, in other countries CJD has developed after shorter treatment periods.\n",
      "                \n",
      "2. When a person was treated:\n",
      "                \n",
      "- All of the 29 individuals treated with NHPP hGH who got CJD in the United States started pituitary hGH before 1977. No CJD has been reported in Americans who began treatment with NHPP hormone after 1977, when production of NHPP hormone was moved to a laboratory (headed by Dr. Albert Parlow) that used a new method of purifying pituitary hGH. Research in animals showed the newer purification steps introduced in 1977 reduced the risk of CJD transmission. Recently, an analysis of NHPP hGH recipients was completed taking into account the differences in follow-up time and the duration of treatment of recipients starting treatment before or after 1977. That analysis found that the new purification steps greatly reduced and may have eliminated the risk for CJD infection.  - Two cases of CJD have been reported in individuals who received commercially prepared pituitary hGH. An Austrian person was treated with pituitary hGH (Crescormon, from Kabi Pharma) for 14 months and died from CJD 22 years later. An American who was too tall to be eligible for NHPP hormone was treated with pituitary hGH made by two pharmaceutical companies (Asellacrin, from Serono, and Crescormon, from Kabi Pharma). This individual was treated with commercial hGH for 23 months and died just over 26 years later. The methods used to produce these commercial hormone preparations were not identical to the method used in Dr. Parlow's laboratory but did include a version of the important new purification step that has been shown to reduce CJD infectivity.  - Overall, one out of about 265 people (29 out of about 7,700 people) who were treated with NHPP pituitary hGH got CJD.  - However, one in about 91 people who began treatment before 1977 got CJD.  - People who started treatment before 1970 are at even higher risk. In that early group, one in about every 48 people (about 2.1 percent) got CJD.  - The appearance of new cases is decreasing, as there has only been one new case in the past 5 years.\n",
      "============================\n",
      "Q: How to diagnose National Hormone and Pituitary Program (NHPP): Information for People Treated with Pituitary Human Growth Hormone (Comprehensive Report) ?\n",
      "A: CJD is usually diagnosed based on signs and symptoms of the illness, how severe they are, and how quickly they become worse. However, doctors must study brain tissue from a biopsy or autopsy in order to make a definite diagnosis of CJD.\n",
      "                \n",
      "Other tests can suggest CJD. In 1996, researchers developed a test that helps doctors diagnose CJD in patients with symptoms. This test detects an abnormal protein in a sample of spinal fluid. When this protein is found, it helps make a diagnosis of CJD. It is much easier and safer to take a sample of spinal fluid than to do a brain biopsy. Unfortunately, this test cannot identify CJD in patients who do not have symptoms. The test cannot predict who may develop CJD in the future.\n",
      "                \n",
      "Researchers from many countries, including the United States, have reported success using MRI to diagnose CJD and vCJD in people with symptoms of the disease. MRI is a safe and painless tool that allows doctors to look at images of the brain and does not involve the collection of brain or spinal fluid samples.\n"
     ]
    }
   ],
   "source": [
    "large_q = qa_df.sort_values(by=\"question\", key=lambda x: x.str.len(), ascending=False).head()\n",
    "\n",
    "for _, row in large_q.iterrows():\n",
    "    pretty_print_row(row)"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "Based on the extreme ends of the question length spectrum, we can identify a few extra issues with the data. Some questions are malformed or incomplete, which means that they should not be included in the dataset. Identifying such questions should be something that is either done, or monitored by an expert in the field. For the purpose of this project, these questions will be left in the data, as identifying troublesome content is out of the scope.\n",
    "\n",
    "On the other end of the spectrum, we can see that some questions are highly specific, possibly referencing specific studies. This may imply that the application will be used for similar queries of other studies. Depending on accessibility, this may guide our architecture towards either implementing and sustaining a RAG system that is constantly being updated with recent studies, or using external services like Tavily for allowing web search access. For now, these will be considered as possible avenues for improvements"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 15,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "============================\n",
      "Q: How to prevent Acanthamoeba - Granulomatous Amebic Encephalitis (GAE); Keratitis ?\n",
      "A: Topics\n",
      "============================\n",
      "Q: What causes Bell's palsy ?\n",
      "A: What causes Bell's palsy?\n",
      "============================\n",
      "Q: Is Williams syndrome inherited ?\n",
      "A: Is Williams syndrome inherited?\n",
      "============================\n",
      "Q: How many people are affected by blepharophimosis, ptosis, and epicanthus inversus syndrome ?\n",
      "A: The prevalence of BPES is unknown.\n",
      "============================\n",
      "Q: What is (are) Parasites - African Trypanosomiasis (also known as Sleeping Sickness) ?\n",
      "A: Frequently Asked Queestions (FAQs)\n",
      "============================\n",
      "Q: What are the treatments for Bell's palsy ?\n",
      "A: How might Bell's palsy be treated?\n",
      "============================\n",
      "Q: Is 48,XXYY syndrome inherited ?\n",
      "A: Can 48,XXYY syndrome be inherited?\n",
      "============================\n",
      "Q: Is Septo-optic dysplasia inherited ?\n",
      "A: Is septo-optic dysplasia inherited?\n",
      "============================\n",
      "Q: What are the symptoms of Bell's palsy ?\n",
      "A: What are the symptoms of Bell's palsy?\n",
      "============================\n",
      "Q: What is the outlook for Agnosia ?\n",
      "A: Agnosia can compromise quality of life.\n"
     ]
    }
   ],
   "source": [
    "short_a = qa_df.sort_values(by=\"answer\", key=lambda x: x.str.len()).head(10)\n",
    "\n",
    "for _, row in short_a.iterrows():\n",
    "    pretty_print_row(row)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 16,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "============================\n",
      "Q: What is (are) Childhood Vascular Tumors ?\n",
      "A: Key Points\n",
      "                    - Childhood vascular tumors form from cells that make blood vessels or lymph vessels.    - Tests are used to detect (find) and diagnose childhood vascular tumors.    - Childhood vascular tumors may be classified into four groups.         - Benign tumors     - Intermediate (locally aggressive) tumors     - Intermediate (rarely metastasizing) tumors     - Malignant tumors\n",
      "                \n",
      "                \n",
      "                    Childhood vascular tumors form from cells that make blood vessels or lymph vessels.\n",
      "                    Vascular tumors can form from abnormal blood vessel or lymph vessel cells anywhere in the body. They may be benign (not cancer) or malignant (cancer). There are many types of vascular tumors. The most common type of childhood vascular tumor is hemangioma, which is a benign tumor that usually goes away on its own.   Because malignant vascular tumors are rare in children, there is not a lot of information about what treatment works best.\n",
      "                               \n",
      "                \n",
      "                    Childhood vascular tumors may be classified into four groups.\n",
      "                    \n",
      "\t\t\t\t\t\t\t\t\t\t\t                    \n",
      "\t\t\t\t\t\t\t\t\t\t\t                    Benign tumors    Benign tumors are not cancer. This summary has information about the following benign vascular tumors:            -  Infantile hemangioma.     -  Congenital hemangioma.     - Benign vascular tumors of the liver.     -  Spindle cell hemangioma.     -  Epithelioid hemangioma.     -  Pyogenic granuloma (lobular capillary hemangioma).     -  Angiofibroma.     -  Juvenile nasopharyngeal angiofibroma.              Intermediate (locally aggressive) tumors    Intermediate tumors that are locally aggressive often spread to the area around the tumor. This summary has information about the following locally aggressive vascular tumors:            -  Kaposiform hemangioendothelioma and tufted angioma.              Intermediate (rarely metastasizing) tumors    Intermediate (rarely metastasizing) tumors sometimes spread to other parts of the body. This summary has information about the following vascular tumors that rarely metastasize:            -  Retiform hemangioendothelioma.     -  Papillary intralymphatic angioendothelioma.     -  Composite hemangioendothelioma.     -  Kaposi sarcoma.              Malignant tumors    Malignant tumors are cancer. This summary has information about the following malignant vascular tumors:            -  Epithelioid hemangioendothelioma.     -  Angiosarcoma of soft tissue.\n",
      "\t\t\t\t\t\t\t\t\t\t\t                    \n",
      "\t\t\t\t\t\t\t\t\t\t\t                             \n",
      "\t\t\t\t\t\t\t\t\t\t\t                    \n",
      "\t\t\t\t\t\t\t\t\t\t\t                    \n",
      "\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t            Benign Tumors\n",
      "\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t            \n",
      "\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t                \n",
      "\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t                    Infantile Hemangioma\n",
      "\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t                    Infantile hemangiomas are the most common type of benign vascular tumor in children. An infantile hemangioma may also be called a \"strawberry mark.\" Immature cells that are meant to form blood vessels form a tumor instead. These tumors are not usually seen at birth but appear when the infant is 3 to 6 weeks old. Most hemangiomas get bigger for about 5 months, then stop growing and slowly fade away completely during the next several years. It is rare for them to come back.   Hemangiomas may be on the skin, in the tissue below the skin, and/or in an organ. They are usually on the head and neck but can be anywhere on or in the body. Hemangiomas may appear as a single lesion, one or more lesions spread over a larger area of the body, or multiple lesions in more than one part of the body. Lesions that are spread over a larger area of the body or multiple lesions are more likely to cause problems.    Risk Factors    Anything that increases your risk of getting a disease is called a risk factor. Having a risk factor does not mean that you will get the disease; not having risk factors doesnt mean that you will not get the disease. Talk with your child's doctor if you think your child may be at risk.   Infantile hemangiomas are more common in the following:          - Girls.    - Whites.    - Premature babies.    -  Twins, triplets, or other multiple births.     - Babies of mothers who are older at time of the pregnancy or who have problems with the placenta during pregnancy.        Other risk factors for infantile hemangiomas include the following:         - Having certain syndromes.               -  PHACE syndrome: A syndrome in which the hemangioma spreads across a large area of the body (usually the head or face). Other health problems involving the large blood vessels, heart, eyes, and/or brain may also occur.       -  LUMBAR/PELVIS/SACRAL syndrome: A syndrome in which the hemangioma spreads across a large area of the lower back. Other health problems that affect the urinary system, genitals, rectum, anus, brain, spinal cord, and nerve function may also occur.                 Having more than one hemangioma or an airway hemangioma increases the risk of having other health problems.         - Multiple hemangiomas: Having more than five hemangiomas on the skin is a sign that there may be hemangiomas in an organ, most commonly the liver. Heart, muscle, and thyroid gland problems can also occur.     - Airway hemangiomas: Hemangiomas in the airway usually occur along with a large, beard-shaped area of hemangioma on the face (from the ears, around the mouth, lower chin, and front of neck). It is important for airway hemangiomas to be treated before the child has trouble breathing.         Signs and Symptoms    Infantile hemangiomas may cause any of the following signs and symptoms. Check with your childs doctor if your child has any of the following:         - Skin lesions: An area of spidery veins or lightened or discolored skin may appear before the hemangioma does. Hemangiomas occur as firm, warm, bright red-blue lesions on the skin. Lesions that form ulcers are also painful. Later, as the hemangiomas go away, they begin fading in the center before flattening and losing color.    - Lesions below the skin: Lesions that grow under the skin in the fat may appear blue or purple. If the lesions are deep enough under the skin surface, they may not be seen.    - Lesions in an organ: There may be no signs that hemangiomas have formed on an organ.        Although most infantile hemangiomas are nothing to worry about, if your child develops any lumps or red or blue marks on the skin check with your child's doctor. He or she can recommend a specialist if needed.     Diagnostic Tests    A physical exam and history are usually all that are needed to diagnose infantile hemangiomas. If there is something about the tumor that looks unusual, a biopsy may be done. If the hemangioma is deeper inside the body with no change to the skin, or the lesions are spread across a large area of the body, an ultrasound or MRI may be done. See the General Information section for a description of these tests and procedures.    If the hemangiomas are part of a syndrome, more tests may be done such as an echocardiogram, magnetic resonance angiogram, and eye exam.    Treatment    Most hemangiomas fade and shrink without treatment. If the hemangioma is large or causing other health problems, treatment may include the following:          -  Propranolol or other beta-blocker therapy.    -  Steroid therapy, before beta-blocker therapy is begun or when beta-blockers cannot be used.    - Pulsed dye laser surgery, for hemangiomas that have ulcers or have not gone away.     -  Surgery (excision) for hemangiomas that have ulcers, cause vision problems, or have not gone away.    -  Topical beta-blocker therapy for hemangiomas that are in one area of the skin.    -  Combined therapy, such as propranolol and steroid therapy or propranolol and topical beta-blocker therapy.\n",
      "\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t                \n",
      "\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t                \n",
      "\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t                    Congenital Hemangioma\n",
      "\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t                    Congenital hemangioma is a benign vascular tumor that begins forming before birth and is fully formed when the baby is born. They're usually on the skin but can be in another organ.   There are three types of congenital hemangiomas:         -  Rapidly Involuting Congenital Hemangioma: These tumors go away on their own 12 to 15 months after birth. They can form ulcers, bleed, and cause temporary heart and blood clotting problems. The skin may look a little different even after the hemangiomas go away.    -  Partial Involuting Congenital Hemangioma: These tumors do not go away completely.    -  Non-Involuting Congenital Hemangioma: These tumors never go away on their own.          Diagnostic Tests    See the General Information section for a description of tests and procedures used to diagnose congenital hemangioma.    Treatment    Treatment of rapidly involuting congenital hemangioma and partial involuting congenital hemangioma may include the following:         -  Observation only.        Treatment of non-involuting congenital hemangioma may include the following:         -  Surgery to remove the tumor depending on where it is and whether it is causing symptoms.\n",
      "\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t                \n",
      "\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t                \n",
      "\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t                    Benign Vascular Tumors of the Liver\n",
      "\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t                    Benign vascular tumors of the liver may be focal (a single lesion in one area of the liver), multifocal (multiple lesions in one area of the liver), or diffuse (multiple lesions in more than one area of the liver).    The liver has many functions, including filtering blood and making proteins needed for blood clotting. Sometimes, blood that normally flows through the liver is blocked or slowed by the tumor. This sends blood directly to the heart without going through the liver and is called a liver shunt. This can cause heart failure and problems with blood clotting.    Focal Tumors    Focal tumors are usually rapidly involuting congenital hemangiomas or non-involuting congenital hemangiomas.    Diagnostic Tests    See the General Information section for a description of tests and procedures used to diagnose focal benign vascular tumors.    Treatment    Treatment of focal tumors of the liver depends on whether symptoms occur and may include the following:         -  Observation.    -  Drugs to manage symptoms, including heart failure and blood clotting problems.    -  Embolization of the liver to manage symptoms, including heart failure.         Multifocal and Diffuse Tumors     Multifocal and diffuse tumors of the liver are usually infantile hemangiomas. Diffuse tumors of the liver can cause serious effects, including problems with the thyroid gland and heart. The liver can enlarge, press on other organs, and cause more symptoms.    Diagnostic Tests    See the General Information section for a description of tests and procedures used to diagnose multifocal or diffuse benign vascular tumors.    Treatment    Treatment of multifocal and diffuse liver tumors may include the following:         - Observation for multifocal tumors of the liver that do not cause symptoms.    -  Beta-blocker therapy (propranolol).    -  Chemotherapy.    -  Steroid therapy.    - Total hepatectomy and liver transplant, when the tumors do not respond to drug therapy. This is only done when the tumors have spread widely in the liver and more than one organ has failed.        If a vascular tumor of the liver does not respond to standard treatments, a biopsy may be done to see if the tumor has become malignant.\n",
      "\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t                \n",
      "\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t                \n",
      "\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t                    Spindle Cell Hemangioma\n",
      "\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t                    Spindle cell hemangiomas contain cells called spindle cells. Under a microscope, spindle cells look long and slender.    Risk Factors    Anything that increases your risk of getting a disease is called a risk factor. Having a risk factor does not mean that you will get the disease; not having risk factors doesnt mean that you will not get the disease. Talk with your child's doctor if you think your child may be at risk. Spindle cell hemangiomas are likely to occur in children with the following syndromes:         -  Maffucci syndrome, which affects cartilage and skin.    -  Klippel-Trenaunay syndrome, which affects blood vessels, soft tissues, and bones.         Signs    Spindle cell hemangiomas appear on or under the skin. They are painful red-brown or bluish lesions that usually appear on the arms or legs. They can begin as one lesion and develop into more lesions over years.     Diagnostic Tests    See the General Information section for a description of tests and procedures used to diagnose spindle cell hemangioma.    Treatment    There is no standard treatment for spindle cell hemangiomas. Treatment may include the following:         -  Surgery to remove the tumor.        Spindle cell hemangiomas may come back after surgery.\n",
      "\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t                \n",
      "\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t                \n",
      "\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t                    Epithelioid Hemangioma\n",
      "\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t                    Epithelioid hemangiomas usually form on or in the skin, especially the head, but can occur in other areas, such as bone.    Signs and Symptoms    Epithelioid hemangiomas are sometimes caused by injury. On the skin, they may appear as firm pink to red bumps and may be itchy. Epithelioid hemangioma of the bone may cause swelling, pain, and weakened bone in the affected area.     Diagnostic Tests    See the General Information section for a description of tests and procedures used to diagnose epithelioid hemangioma.    Treatment    There is no standard treatment for epithelioid hemangiomas. Treatment may include the following:         -  Surgery (curettage or resection).    -  Sclerotherapy.    -  Radiation therapy in rare cases.        Epithelioid hemangiomas often come back after treatment.\n",
      "\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t                \n",
      "\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t                \n",
      "\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t                    Pyogenic Granuloma\n",
      "\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t                    Pyogenic granuloma is also called lobular capillary hemangioma. It is most common in older children and young adults but may occur at any age.    The lesions are sometimes caused by injury or from the use of certain medicines, including birth control pills and retinoids. They may also form for no known reason inside capillaries (the smallest blood vessels) or other places on the body. Usually there is only one lesion, but sometimes multiple lesions occur in the same area or the lesions may spread to other areas of the body.    Signs    Pyogenic granulomas are raised, bright red lesions that may be small or large and smooth or bumpy. They grow quickly over weeks to months and may bleed a lot.    Diagnostic Tests    See the General Information section for a description of tests and procedures used to diagnose pyogenic granuloma.    Treatment    Some pyogenic granulomas go away without treatment. Other pyogenic granulomas need treatment that may include the following:         -  Surgery (excision or curettage) to remove the lesion.    -  Laser photocoagulation.        Pyogenic granulomas often come back after treatment.\n",
      "\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t                \n",
      "\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t                \n",
      "\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t                    Angiofibroma\n",
      "\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t                    Angiofibromas are rare. They are benign skin lesions that usually occur with a condition called tuberous sclerosis (an inherited disorder that causes skin lesions, seizures, and mental disabilities).     Signs    Angiofibromas appear as red bumps on the face.    Diagnostic Tests    See the General Information section for a description of tests and procedures used to diagnose angiofibroma.    Treatment    Treatment of angiofibromas may include the following:         -  Surgery (excision) to remove the tumor.    -  Laser therapy.    -  Targeted therapy (sirolimus).\n",
      "\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t                \n",
      "\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t                \n",
      "\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t                    Juvenile Nasopharyngeal Angiofibroma\n",
      "\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t                    Juvenile nasopharyngeal angiofibromas are benign tumors but they can invade nearby tissue. They begin in the nasal cavity and may spread to the nasopharynx, the paranasal sinuses, the bone around the eyes, and sometimes to the brain.     Diagnostic Tests    See the General Information section for a description of tests and procedures used to diagnose juvenile nasopharyngeal angiofibroma.    Treatment    Treatment of juvenile nasopharyngeal angiofibromas may include the following:         -  Surgery (excision) to remove the tumor.    -  Radiation therapy.    -  Chemotherapy.    -  Immunotherapy (interferon).    -  Targeted therapy (sirolimus).\n",
      "\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t                \n",
      "\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t            \n",
      "\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t        \n",
      "\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t        \n",
      "\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t            Intermediate Tumors that Spread Locally\n",
      "\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t            \n",
      "\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t                \n",
      "\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t                    Kaposiform Hemangioendothelioma and Tufted Angioma\n",
      "\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t                    Kaposiform hemangioendotheliomas and tufted angiomas are blood vessel tumors that occur in infants or during early childhood. These tumors can cause Kasabach-Merritt phenomenon, a condition in which the blood is not able to clot and serious bleeding may occur. In Kasabach-Merritt phenomenon the tumor traps and destroys platelets (blood-clotting cells). Then there aren't enough platelets in the blood when needed to stop bleeding. This type of vascular tumor is not related to Kaposi sarcoma.    Signs and Symptoms    Kaposiform hemangioendotheliomas and tufted angiomas usually occur on the skin of the arms and legs, but may also form in deeper tissues, such as muscle or bone. Signs and symptoms may include the following:         - Firm, painful areas of skin that look bruised.    - Purple or brownish-red areas of skin.    - Easy bruising.    -  Bleeding more than the usual amount from mucous membranes, wounds, and other tissues.    -  Anemia (weakness, feeling tired, or looking pale).         Diagnostic Tests    See the General Information section for a description of tests and procedures used to diagnose kaposiform hemangioendothelioma.   If a physical exam and MRI clearly show the tumor is a kaposiform hemangioendothelioma or a tufted angioma, a biopsy may not be needed. A biopsy is not always done because serious bleeding can occur.    Treatment    Treatment of kaposiform hemangioendotheliomas and tufted angiomas depends on the child's symptoms. Infection, delay in treatment, and surgery can cause bleeding that is life-threatening. Kaposiform hemangioendotheliomas and tufted angiomas are best treated by a vascular anomaly specialist.   Treatment and supportive care to manage bleeding may include the following:         -  Steroid therapy which may be followed by chemotherapy.    -  Non-steroidal anti-inflammatory drugs (NSAID), such as aspirin.    -  Immunotherapy (interferon).    -  Antifibrinolytic therapy to improve blood clotting.    -  Chemotherapy with one or more anticancer drugs.    -  Beta-blocker therapy (propranolol).    -  Surgery (excision) to remove the tumor, with or without embolization.    -  Targeted therapy (sirolimus).    - A clinical trial of targeted therapy (sirolimus) and steroid therapy.        Even with treatment, these tumors do not fully go away and can come back. Long-term effects include chronic pain, heart failure, bone problems, and lymphedema (the build up of lymph fluid in tissues).\n",
      "\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t                \n",
      "\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t            \n",
      "\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t        \n",
      "\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t        \n",
      "\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t            Intermediate Tumors that Rarely Spread\n",
      "\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t            \n",
      "\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t                \n",
      "\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t                    Retiform Hemangioendothelioma\n",
      "\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t                    Retiform hemangioendotheliomas are slow growing, flat tumors that occur in young adults and sometimes children. These tumors usually occur on or under the skin of the arms, legs, and trunk. These tumors often come back after treatment, but they usually do not spread to other parts of the body.    Diagnostic Tests    See the General Information section for a description of tests and procedures used to diagnose retiform hemangioendothelioma.    Treatment    Treatment of retiform hemangioendotheliomas may include the following:         -  Surgery (excision) to remove the tumor. Follow up will include monitoring to see if the tumor comes back.    -  Radiation therapy and chemotherapy when surgery cannot be done or when the tumor has come back.\n",
      "\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t                \n",
      "\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t                \n",
      "\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t                    Papillary Intralymphatic Angioendothelioma\n",
      "\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t                    Papillary intralymphatic angioendotheliomas are also called Dabska tumors. These tumors form in or under the skin anywhere on the body. The tumors contain channels that look like lymph vessels. Lymph nodes are sometimes affected.    Signs    Papillary intralymphatic angioendotheliomas may appear as firm, raised, purplish bumps, which may be small or large. These tumors grow slowly over time.    Diagnostic Tests    See the General Information section for a description of tests and procedures used to diagnose papillary intralymphatic angioendothelioma.    Treatment    Treatment of papillary intralymphatic angioendotheliomas may include the following:         -  Surgery (excision) to remove the tumor.\n",
      "\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t                \n",
      "\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t                \n",
      "\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t                    Composite Hemangioendothelioma\n",
      "\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t                    Composite hemangioendotheliomas have features of both benign and malignant vascular tumors. These tumors usually occur on or under the skin on the arms or legs. They may also occur on the head, neck, or chest. Composite hemangioendotheliomas are not likely to metastasize (spread) but they may come back in the same place. When the tumors metastasize, they usually spread to nearby lymph nodes.     Diagnostic Tests    See the General Information section for a description of tests and procedures used to diagnose composite hemangioendothelioma and find out whether the tumor has spread.     Treatment     Treatment of composite hemangioendotheliomas may include the following:         -  Surgery to remove the tumor.    -  Radiation therapy and chemotherapy for tumors that have spread.\n",
      "\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t                \n",
      "\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t                \n",
      "\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t                    Kaposi Sarcoma\n",
      "\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t                    Kaposi sarcoma is a cancer that causes lesions to grow in the skin; the mucous membranes lining the mouth, nose, and throat; lymph nodes; or other organs. It is caused by the Kaposi sarcoma herpes virus (KSHV). In the United States, it usually occurs in people who have a weak immune system caused by AIDS or by drugs used in organ transplants. It is very rare in children and can be caused by HIV infection and rare immune system disorders.    Signs     Signs in children may include the following:         - Lesions in the skin, mouth, or throat. Skin lesions are red, purple, or brown and change from flat, to raised, to scaly areas called plaques, to nodules.    - Swollen lymph nodes.         Diagnostic Tests    See the General Information section for a description of tests and procedures used to diagnose Kaposi sarcoma.    Treatment    Treatment of Kaposi sarcoma may include the following:         -  Chemotherapy.        See the PDQ summary on Kaposi Sarcoma Treatment for information about Kaposi sarcoma in adults.\n",
      "\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t                \n",
      "\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t            \n",
      "\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t        \n",
      "\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t        \n",
      "\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t            Malignant Tumors\n",
      "\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t            \n",
      "\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t                \n",
      "\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t                    Epithelioid Hemangioendothelioma\n",
      "\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t                    Epithelioid hemangioendotheliomas can occur in children, but are most common in adults between 30 and 50 years of age. They usually occur in the liver, lung, or in bone. They may be either fast growing or slow growing. In about a third of cases, the tumor spreads to other parts of the body very quickly.     Signs and Symptoms     Signs and symptoms depend on where the tumor is:          - On the skin, the tumors can be raised and rounded or flat, red-brown patches that feel warm.     - In the lung, there may be no early symptoms. Signs and symptoms that occur may include:               -  Chest pain.       - Spitting up blood.      -  Anemia (weakness, feeling tired, or looking pale).      - Trouble breathing (from scarred lung tissue).              - In bone, the tumors can cause breaks.         Diagnostic Tests    Epithelioid hemangioendotheliomas in the liver are found with CT scans and MRI scans. See the General Information section for a description of these tests and procedures used to diagnose epithelioid hemangioendothelioma and find out whether the tumor has spread. X-rays may also be done.    Treatment    Treatment of slow-growing epithelioid hemangioendotheliomas includes the following:         -  Observation.        Treatment of fast-growing epithelioid hemangioendotheliomas may include the following:         -  Surgery to remove the tumor when possible.    -  Immunotherapy (interferon) and targeted therapy (thalidomide, sorafenib, pazopanib, sirolimus) for tumors that are likely to spread.    -  Chemotherapy.    - Total hepatectomy and liver transplant when the tumor is in the liver.\n",
      "\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t                \n",
      "\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t                \n",
      "\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t                    Angiosarcoma of the Soft Tissue\n",
      "\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t                    Angiosarcomas are fast-growing tumors that form in blood vessels or lymph vessels in any part of the body, usually in soft tissue. Most angiosarcomas are in or near the skin. Those in deeper soft tissue can form in the liver, spleen, and lung.   These tumors are very rare in children. Children sometimes have more than one tumor in the skin and/or liver.    Risk Factors    Anything that increases your risk of getting a disease is called a risk factor. Having a risk factor does not mean that you will get the disease; not having risk factors doesnt mean that you will not get the disease. Talk with your child's doctor if you think your child may be at risk. Risk factors for angiosarcomas include the following:         - Being exposed to radiation.    -  Chronic (long-term) lymphedema, a condition in which extra lymph fluid builds up in tissues and causes swelling.     - Having a benign vascular tumor. A benign tumor, such as a hemangioma, may become an angiosarcoma but this rare.         Signs    Signs of angiosarcoma depend on where the tumor is and may include the following:         - Red patches on the skin that bleed easily.    - Purple tumors.         Diagnostic Tests    See the General Information section for a description of tests and procedures used to diagnose angiosarcoma and find out whether the tumor has spread.     Treatment    Treatment of angiosarcoma may include the following:         -  Surgery to completely remove the tumor.    - A combination of surgery, chemotherapy, and radiation therapy for angiosarcomas that have spread.    -  Targeted therapy (bevacizumab) and chemotherapy for angiosarcomas that began as infantile hemangiomas.    - A clinical trial of targeted therapy, radiation therapy, and surgery with or without chemotherapy.\n",
      "============================\n",
      "Q: What are the treatments for Childhood Soft Tissue Sarcoma ?\n",
      "A: Key Points\n",
      "                    - There are different types of treatment for patients with childhood soft tissue sarcoma.    - Children with childhood soft tissue sarcoma should have their treatment planned by a team of health care providers who are experts in treating cancer in children.    - Treatment for childhood soft tissue sarcoma may cause side effects.    - Eight types of standard treatment are used:         - Surgery     - Radiation therapy     - Chemotherapy     - Observation     - Hormone therapy     - Nonsteroidal anti-inflammatory drugs     - Targeted therapy     - Immunotherapy        - New types of treatment are being tested in clinical trials.         - Gene therapy        - Patients may want to think about taking part in a clinical trial.    - Patients can enter clinical trials before, during, or after starting their cancer treatment.    - Follow-up tests may be needed.\n",
      "                \n",
      "                \n",
      "                    There are different types of treatment for patients with childhood soft tissue sarcoma.\n",
      "                    Different types of treatments are available for patients with childhood soft tissue sarcoma. Some treatments are standard (the currently used treatment), and some are being tested in clinical trials. A treatment clinical trial is a research study meant to help improve current treatments or obtain information on new treatments for patients with cancer. When clinical trials show that a new treatment is better than the standard treatment, the new treatment may become the standard treatment.   Because cancer in children is rare, taking part in a clinical trial should be considered. Some clinical trials are open only to patients who have not started treatment.\n",
      "                \n",
      "                \n",
      "                    Children with childhood soft tissue sarcoma should have their treatment planned by a team of health care providers who are experts in treating cancer in children.\n",
      "                    Treatment will be overseen by a pediatric oncologist, a doctor who specializes in treating children with cancer. The pediatric oncologist works with other health care providers who are experts in treating children with soft tissue sarcoma and who specialize in certain areas of medicine. These may include a pediatric surgeon with special training in the removal of soft tissue sarcomas. The following specialists may also be included:         -  Pediatrician.    -  Radiation oncologist.    -  Pediatric hematologist.    -  Pediatric nurse specialist.    -  Rehabilitation specialist.    -  Psychologist.    -  Social worker.    -  Child-life specialist.\n",
      "                \n",
      "                \n",
      "                    Treatment for childhood soft tissue sarcoma may cause side effects.\n",
      "                    For information about side effects that begin during treatment for cancer, see our Side Effects page.   Side effects from cancer treatment that begin after treatment and continue for months or years are called late effects. Late effects of cancer treatment may include:          - Physical problems.    - Changes in mood, feelings, thinking, learning, or memory.    -  Second cancers (new types of cancer).        Some late effects may be treated or controlled. It is important to talk with your child's doctors about the effects cancer treatment can have on your child. (See the PDQ summary on Late Effects of Treatment for Childhood Cancer for more information.)\n",
      "                \n",
      "                \n",
      "                    Eight types of standard treatment are used:\n",
      "                    Surgery     Surgery to completely remove the soft tissue sarcoma is done when possible. If the tumor is very large, radiation therapy or chemotherapy may be given first, to make the tumor smaller and decrease the amount of tissue that needs to be removed during surgery. This is called neoadjuvant therapy.    The following types of surgery may be used:            -  Wide local excision: Removal of the tumor along with some normal tissue around it.      -  Amputation: Surgery to remove all or part of the limb or appendage with cancer, such as the arm or hand.     -  Lymphadenectomy: Removal of the lymph nodes with cancer.      -  Mohs surgery: A surgical procedure used to treat cancer in the skin. Individual layers of cancer tissue are removed and checked under a microscope one at a time until all cancer tissue has been removed. This type of surgery is used to treat dermatofibrosarcoma protuberans. It is also called Mohs micrographic surgery.     -  Hepatectomy: Surgery to remove all or part of the liver.           A second surgery may be needed to:            - Remove any remaining cancer cells.     - Check the area around where the tumor was removed for cancer cells and then remove more tissue if needed.           If cancer is in the liver, a hepatectomy and liver transplant may be done (the liver is removed and replaced with a healthy one from a donor).    Even if the doctor removes all the cancer that can be seen at the time of the surgery, some patients may be given radiation therapy or chemotherapy after surgery to kill any cancer cells that are left. Treatment given after the surgery, to lower the risk that the cancer will come back, is called adjuvant therapy.       Radiation therapy    Radiation therapy is a cancer treatment that uses high-energy x-rays or other types of radiation to kill cancer cells or keep them from growing. There are two types of radiation therapy:            -  External radiation therapy uses a machine outside the body to send radiation toward the cancer. Certain ways of giving radiation therapy can help keep radiation from damaging nearby healthy tissue. This type of radiation therapy may include the following:                  -  Stereotactic body radiation therapy: Stereotactic body radiation therapy is a type of external radiation therapy. Special equipment is used to place the patient in the same position for each radiation treatment. Once a day for several days, a radiation machine aims a larger than usual dose of radiation directly at the tumor. By having the patient in the same position for each treatment, there is less damage to nearby healthy tissue. This procedure is also called stereotactic external-beam radiation therapy and stereotaxic radiation therapy.                -  Internal radiation therapy uses a radioactive substance sealed in needles, seeds, wires, or catheters that are placed directly into or near the cancer.            The way the radiation therapy is given depends on the type and stage of the cancer being treated and whether the tumor was completely removed by surgery. External and internal radiation therapy are used to treat childhood soft tissue sarcoma.       Chemotherapy    Chemotherapy is a cancer treatment that uses drugs to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. When chemotherapy is taken by mouth or injected into a vein or muscle, the drugs enter the bloodstream and can reach cancer cells throughout the body (systemic chemotherapy). When chemotherapy is placed directly into the cerebrospinal fluid, an organ, or a body cavity such as the abdomen, the drugs mainly affect cancer cells in those areas (regional chemotherapy). Combination chemotherapy is the use of more than one anticancer drug. The way the chemotherapy is given depends on the type of cancer being treated.     Most types of soft tissue sarcoma do not respond to treatment with chemotherapy.    See Drugs Approved for Soft Tissue Sarcoma for more information.       Observation     Observation is closely monitoring a patients condition without giving any treatment until signs or symptoms appear or change. Observation may be done when:             - Complete removal of the tumor is not possible.     - No other treatments are available.     - The tumor is not likely to damage any vital organs.              Hormone therapy     Hormone therapy is a cancer treatment that removes hormones or blocks their action and stops cancer cells from growing. Hormones are substances made by glands in the body and circulated in the bloodstream. Some hormones can cause certain cancers to grow. If tests show that the cancer cells have places where hormones can attach (receptors), drugs, surgery, or radiation therapy is used to reduce the production of hormones or block them from working. Antiestrogens (drugs that block estrogen), such as tamoxifen, may be used to treat desmoid-type fibromatosis.       Nonsteroidal anti-inflammatory drugs     Nonsteroidal anti-inflammatory drugs (NSAIDs) are drugs (such as aspirin, ibuprofen, and naproxen) that are commonly used to decrease fever, swelling, pain, and redness. In the treatment of desmoid-type fibromatosis, an NSAID called sulindac may be used to help block the growth of cancer cells.       Targeted therapy     Targeted therapy is a type of treatment that uses drugs or other substances to attack cancer cells. Targeted therapies usually cause less harm to normal cells than chemotherapy or radiation do.     Kinase inhibitors are a type of targeted therapy that block an enzyme called kinase (a type of protein). There are different types of kinases in the body that have different actions.             -  ALK inhibitors may stop the cancer from growing and spreading:                  -  Crizotinib may be used to treat inflammatory myofibroblastic tumor.                -  Tyrosine kinase inhibitors (TKIs) block signals needed for tumors to grow:                   -  Imatinib is used to treat dermatofibrosarcoma protuberans.       -  Pazopanib may be used to treat recurrent and progressive soft tissue sarcoma. It is being studied for many types of newly diagnosed soft tissue sarcoma.       - Sorafenib may be used to treat desmoid-type fibromatosis.                      New types of tyrosine kinase inhibitors are being studied such as LOXO-101 and entrectinib for infantile fibrosarcoma.    Other types of targeted therapy are being studied in clinical trials, including the following:            -  mTOR inhibitors are a type of targeted therapy that stops the protein that helps cells divide and survive. mTOR inhibitors are being studied to treat perivascular epithelioid cell tumors (PEComas) and epithelioid hemangioendothelioma. Sirolimus is a type of mTOR inhibitor therapy.      -  Angiogenesis inhibitors are a type of targeted therapy that prevent the growth of new blood vessels needed for tumors to grow. Angiogenesis inhibitors, such as cediranib, sunitinib, and thalidomide are being studied to treat alveolar soft part sarcoma and epithelioid hemangioendothelioma. Bevacizumab is being studied for blood vessel tumors.     -  Histone methyltransferase (HMT) inhibitors are targeted therapy drugs that work inside cancer cells and block signals needed for tumors to grow. HMT inhibitors are being studied for the treatment of epithelioid sarcoma, malignant peripheral nerve sheath tumor, extrarenal (extracranial) rhabdoid tumor, extraskeletal myxoid chondrosarcoma, and synovial sarcoma.      -  Heat-shock protein inhibitors block certain proteins that protect tumor cells and help them grow. Ganetespib is a heat shock protein inhibitor being studied in combination with the mTOR inhibitor sirolimus for malignant peripheral nerve sheath tumors that cannot be removed by surgery.     -  Antibody-drug conjugates are made up of a monoclonal antibody attached to a drug. The monoclonal antibody binds to specific proteins or receptors found on certain cells, including cancer cells. The drug enters these cells and kills them without harming other cells. Lorvotuzumab mertansine is an antibody-drug conjugate being studied for the treatment of rhabdomyosarcoma, malignant peripheral nerve sheath tumor, and synovial sarcoma.           See Drugs Approved for Soft Tissue Sarcoma for more information.       Immunotherapy     Immunotherapy is a treatment that uses the patients immune system to fight disease. Substances made by the body or made in a laboratory are used to boost, direct, or restore the bodys natural defenses against disease.     Interferon is a type of immunotherapy used to treat epithelioid hemangioendothelioma. It interferes with the division of tumor cells and can slow tumor growth.\n",
      "                         \n",
      "                \n",
      "                    Follow-up tests may be needed.\n",
      "                    Some of the tests that were done to diagnose the cancer or to find out the stage of the cancer may be repeated. Some tests will be repeated in order to see how well the treatment is working. Decisions about whether to continue, change, or stop treatment may be based on the results of these tests.   Some of the tests will continue to be done from time to time after treatment has ended. The results of these tests can show if your child's condition has changed or if the cancer has recurred (come back). These tests are sometimes called follow-up tests or check-ups.\n",
      "                \n",
      "                 \n",
      "\t\t\t\t\t\t\t            Treatment Options for Childhood Soft Tissue Sarcoma\n",
      "\t\t\t\t\t\t\t            \n",
      "\t\t\t\t\t\t\t                \n",
      "\t\t\t\t\t\t\t                    Newly Diagnosed Childhood Soft Tissue Sarcoma\n",
      "\t\t\t\t\t\t\t                    Fat Tissue Tumors       Liposarcoma     Treatment of liposarcoma may include the following:               -  Surgery to completely remove the tumor. If the cancer is not completely removed, a second surgery may be done.      -  Chemotherapy to shrink the tumor, followed by surgery.      -  Radiation therapy before or after surgery.      - A clinical trial of targeted therapy, radiation therapy, and surgery with or without chemotherapy.                    Bone and Cartilage Tumors       Extraskeletal mesenchymal chondrosarcoma     Treatment of extraskeletal mesenchymal chondrosarcoma may include the following:                -  Surgery to completely remove the tumor. Radiation therapy may be given before and/or after surgery.      -  Chemotherapy followed by surgery. Chemotherapy with or without radiation therapy is given after surgery.      - A clinical trial of targeted therapy, radiation therapy, and surgery with or without chemotherapy.                    Extraskeletal osteosarcoma     Treatment of extraskeletal osteosarcoma may include the following:               -  Surgery to completely remove the tumor, followed by chemotherapy.      - A clinical trial of targeted therapy, radiation therapy, and surgery with or without chemotherapy.               See the PDQ summary on Osteosarcoma and Malignant Fibrous Histiocytoma of Bone Treatment for more information.          Fibrous (Connective) Tissue Tumors       Desmoid-type fibromatosis     Treatment of desmoid-type fibromatosis may include the following:               -  Surgery to completely remove the tumor. Treatment before surgery may include the following:                     -  Observation.        -  Chemotherapy.        -  Radiation therapy.        -  Antiestrogen drug therapy.        -  Nonsteroidal anti-inflammatory drug (NSAID) therapy.              If the tumor is not completely removed by surgery, treatment may include the following:                     - Observation, if other treatment options are not possible.        - Radiation therapy.                   - Radiation therapy or chemotherapy for tumors that cannot be removed by surgery.      - A clinical trial of targeted therapy.       - A clinical trial of targeted therapy, radiation therapy, and surgery with or without chemotherapy.               Treatment of desmoid-type fibromatosis that has come back may include the following:               - Observation and possibly surgery at a later time.      - Chemotherapy.                   Dermatofibrosarcoma protuberans     Treatment of dermatofibrosarcoma protuberans may include the following:               -  Surgery to completely remove the tumor when possible. This may include Mohs surgery.      -  Radiation therapy before or after surgery.      -  Targeted therapy (imatinib) if the tumor cannot be removed or has come back.      - A clinical trial of targeted therapy, radiation therapy, and surgery with or without chemotherapy.                    Fibrosarcoma         Infantile fibrosarcoma      Treatment of infantile fibrosarcoma may include the following:                  -  Surgery to remove the tumor when possible, followed by observation.       - Surgery followed by chemotherapy.       - Chemotherapy to shrink the tumor, followed by surgery.       - A clinical trial of targeted therapy, radiation therapy, and surgery with or without chemotherapy.        - A clinical trial of targeted therapy (tyrosine kinase inhibitor).                        Adult-type fibrosarcoma      Treatment of adult-type fibrosarcoma may include the following:                  -  Surgery to completely remove the tumor when possible.                         Inflammatory myofibroblastic tumor     Treatment of inflammatory myofibroblastic tumor may include the following:               -  Surgery to completely remove the tumor when possible.      -  Chemotherapy.       -  Steroid therapy.       -  Nonsteroidal anti-inflammatory drug (NSAID) therapy.      -  Targeted therapy (ALK inhibitors).      - A clinical trial of targeted therapy, radiation therapy, and surgery with or without chemotherapy.                    Low-grade fibromyxoid sarcoma     Treatment of low-grade fibromyxoid sarcoma may include the following:               -  Surgery to completely remove the tumor.      - A clinical trial of targeted therapy, radiation therapy, and surgery with or without chemotherapy.                    Myxofibrosarcoma     Treatment of myxofibrosarcoma may include the following:               -  Surgery to completely remove the tumor.      - A clinical trial of targeted therapy, radiation therapy, and surgery with or without chemotherapy.                    Sclerosing epithelioid fibrosarcoma     Treatment of sclerosing epithelioid fibrosarcoma may include the following:               -  Surgery to completely remove the tumor.      - A clinical trial of targeted therapy, radiation therapy, and surgery with or without chemotherapy.                    Skeletal Muscle Tumors       Rhabdomyosarcoma     See the PDQ summary on Childhood Rhabdomyosarcoma Treatment.          Smooth Muscle Tumors       Leiomyosarcoma     Treatment of leiomyosarcoma may include the following:                -  Chemotherapy.      - A clinical trial of targeted therapy, radiation therapy, and surgery with or without chemotherapy.                    So-called Fibrohistiocytic Tumors       Plexiform fibrohistiocytic tumor     Treatment of plexiform fibrohistiocytic tumor may include the following:               -  Surgery to completely remove the tumor.      - A clinical trial of targeted therapy, radiation therapy, and surgery with or without chemotherapy.                    Peripheral Nervous System Tumors       Ectomesenchymoma     Treatment of ectomesenchymoma may include the following:               -  Surgery and chemotherapy.       -  Radiation therapy.                   Malignant peripheral nerve sheath tumor     Treatment of malignant peripheral nerve sheath tumor may include the following:                -  Surgery to completely remove the tumor when possible.       -  Radiation therapy before or after surgery.      -  Chemotherapy, for tumors that cannot be removed by surgery.      - A clinical trial of targeted therapy, radiation therapy, and surgery with or without chemotherapy.       - A clinical trial of targeted therapy, for tumors that cannot be removed by surgery.      - A clinical trial of targeted therapy (histone methyltransferase inhibitor).      - A clinical trial of an antibody-drug conjugate.              It is not clear whether giving radiation therapy or chemotherapy after surgery improves the tumor's response to treatment.          Malignant triton tumor      Malignant triton tumors may be treated the same as rhabdomyosarcomas and include surgery, chemotherapy, or radiation therapy. A regimen of targeted therapy, radiation therapy, and surgery with or without chemotherapy is being studied.           Pericytic (Perivascular) Tumors       Infantile hemangiopericytoma     Treatment of infantile hemangiopericytoma may include the following:                -  Chemotherapy.                   Infantile myofibromatosis     Treatment of infantile myofibromatosis may include the following:               -  Combination chemotherapy.                   Tumors of Unknown Origin (the place where the tumor first formed is not known)       Alveolar soft part sarcoma      Treatment of alveolar soft part sarcoma may include the following:               -  Surgery to completely remove the tumor when possible.      -  Radiation therapy before or after surgery, if the tumor cannot be completely removed by surgery.       -  Targeted therapy (angiogenesis inhibitor).      - A clinical trial of targeted therapy (angiogenesis inhibitor) for children.      - A clinical trial of targeted therapy, radiation therapy, and surgery with or without chemotherapy.                    Clear cell sarcoma of soft tissue     Treatment of clear cell sarcoma of soft tissue may include the following:                -  Surgery to remove the tumor when possible.       -  Radiation therapy before or after surgery.      - A clinical trial of targeted therapy, radiation therapy, and surgery with or without chemotherapy.                    Desmoplastic small round cell tumor     There is no standard treatment for desmoplastic small round cell tumor. Treatment may include the following:               -  Surgery to completely remove the tumor when possible.      -  Chemotherapy followed by surgery.      -  Radiation therapy.                   Epithelioid sarcoma     Treatment of epithelioid sarcoma may include the following:               -  Surgery to remove the tumor when possible.      -  Chemotherapy before or after surgery.      -  Radiation therapy before or after surgery.      - A clinical trial of targeted therapy (histone methyltransferase inhibitor).                    Extrarenal (extracranial) rhabdoid tumor     Treatment of extrarenal (extracranial) rhabdoid tumor may include the following:               - A combination of surgery to remove the tumor when possible, chemotherapy, and radiation therapy.      - A clinical trial of targeted therapy (histone methyltransferase inhibitor).                   Extraskeletal myxoid chondrosarcoma     Treatment of extraskeletal myxoid chondrosarcoma may include the following:               -  Surgery to remove the tumor when possible.      -  Radiation therapy.      - A clinical trial of targeted therapy, radiation therapy, and surgery with or without chemotherapy.       - A clinical trial of targeted therapy (histone methyltransferase inhibitor).                   Perivascular epithelioid cell tumors (PEComas)     Treatment of perivascular epithelioid cell tumors may include the following:               -  Surgery to remove the tumor.      -  Observation followed by surgery.      -  Targeted therapy (mTOR inhibitor), for tumors that have certain gene changes and cannot be removed by surgery.      - A clinical trial of targeted therapy, radiation therapy, and surgery with or without chemotherapy.                    Primitive neuroectodermal tumor (PNET)/extraskeletal Ewing tumor     See the PDQ summary on Ewing Sarcoma Treatment.          Synovial sarcoma     Treatment of synovial sarcoma may include the following:                -  Chemotherapy.      -  Surgery. Radiation therapy and/or chemotherapy may be given before or after surgery.      - A clinical trial of gene therapy.      - A clinical trial of targeted therapy, radiation therapy, and surgery with or without chemotherapy.       - A clinical trial of targeted therapy (histone methyltransferase inhibitor).       - A clinical trial of an antibody-drug conjugate.                   Undifferentiated/unclassified sarcoma     These tumors include undifferentiated pleomorphic sarcoma /malignant fibrous histiocytoma (high-grade). There is no standard treatment for these tumors. Treatment may include the following:               - A clinical trial of targeted therapy, radiation therapy, and surgery with or without chemotherapy.               See the PDQ summary on Osteosarcoma and Malignant Fibrous Histiocytoma of Bone Treatment for information about the treatment of malignant fibrous histiocytoma of bone.          Blood Vessel Tumors       Angiosarcoma of soft tissue     Treatment of angiosarcoma may include the following:               -  Surgery to completely remove the tumor.      - A combination of surgery, chemotherapy, and radiation therapy for angiosarcomas that have spread.      -  Targeted therapy (bevacizumab) and chemotherapy for angiosarcomas that began as infantile hemangiomas.      - A clinical trial of targeted therapy, radiation therapy, and surgery with or without chemotherapy.                    Epithelioid hemangioendothelioma     Treatment of epithelioid hemangioendothelioma may include the following:                -  Surgery to remove the tumor when possible.      -  Immunotherapy (interferon) and targeted therapy (thalidomide, sorafenib, pazopanib, sirolimus) for tumors that are likely to spread.      -  Chemotherapy.      - Total hepatectomy and liver transplant when the tumor is in the liver.                   Metastatic Childhood Soft Tissue Sarcoma    Treatment of childhood soft tissue sarcoma that has spread to other parts of the body at diagnosis may include the following:            -  Chemotherapy and radiation therapy. Surgery may be done to remove tumors that have spread to the lung.      -  Stereotactic body radiation therapy for tumors that have spread to the lung.           For treatment of specific tumor types, see the Treatment Options for Childhood Soft Tissue Sarcoma section.     Check the list of NCI-supported cancer clinical trials that are now accepting patients with nonmetastatic childhood soft tissue sarcoma and metastatic childhood soft tissue sarcoma. For more specific results, refine the search by using other search features, such as the location of the trial, the type of treatment, or the name of the drug. Talk with your child's doctor about clinical trials that may be right for your child. General information about clinical trials is available from the NCI website.\n",
      "\t\t\t\t\t\t\t                \n",
      "\t\t\t\t\t\t\t                \n",
      "\t\t\t\t\t\t\t                    Recurrent and Progressive Childhood Soft Tissue Sarcoma\n",
      "\t\t\t\t\t\t\t                    Treatment of recurrent or progressive childhood soft tissue sarcoma may include the following:         -  Surgery to remove cancer that has come back where it first formed or that has spread to the lung.    - Surgery followed by external or internal radiation therapy, if radiation therapy has not already been given.    - Surgery to remove the arm or leg with cancer, if radiation therapy was already given.    -  Chemotherapy.    -  Targeted therapy (tyrosine kinase inhibitor).    - A clinical trial of a new chemotherapy regimen.        Check the list of NCI-supported cancer clinical trials that are now accepting patients with recurrent childhood soft tissue sarcoma. For more specific results, refine the search by using other search features, such as the location of the trial, the type of treatment, or the name of the drug. Talk with your child's doctor about clinical trials that may be right for your child. General information about clinical trials is available from the NCI website.\n",
      "============================\n",
      "Q: What are the treatments for Sickle Cell Disease ?\n",
      "A: Health Maintenance To Prevent Complications\n",
      "                \n",
      "Babies with sickle cell disease (SCD) should be referred to a doctor or provider group that has experience taking care of people with this disease. The doctor might be a hematologist (a doctor with special training in blood diseases) or an experienced general pediatrician, internist, or family practitioner.\n",
      "                \n",
      "For infants, the first SCD visit should take place before 8 weeks of age.\n",
      "                \n",
      "If someone was born in a country that doesnt perform newborn SCD screening, he or she might be diagnosed with SCD later in childhood. These people should also be referred as soon as possible for special SCD care.\n",
      "                \n",
      "\n",
      "                \n",
      "\n",
      "                \n",
      "Examining the person\n",
      "                \n",
      "Giving medicines and immunizations\n",
      "                \n",
      "Performing tests\n",
      "                \n",
      "Educating families about the disease and what to watch out for\n",
      "                \n",
      "\n",
      "                \n",
      "Preventing Infection\n",
      "                \n",
      "In SCD, the spleen doesnt work properly or doesnt work at all. This problem makes people with SCD more likely to get severe infections.\n",
      "                \n",
      "Penicillin\n",
      "                \n",
      "In children with SCD, taking penicillin two times a day has been shown to reduce the chance of having a severe infection caused by the pneumococcus bacteria. Infants need to take liquid penicillin. Older children can take tablets.\n",
      "                \n",
      "Many doctors will stop prescribing penicillin after a child has reached the age of 5. Some prefer to continue this antibiotic throughout life, particularly if a person has hemoglobin SS or hemoglobin S0 thalassemia, since people with SCD are still at risk. All people who have had surgical removal of the spleen, called a splenectomy, or a past infection with pneumococcus should keep taking penicillin throughout life.\n",
      "                \n",
      "Immunizations\n",
      "                \n",
      "People with SCD should receive all recommended childhood vaccines. They should also receive additional vaccines to prevent other infections.\n",
      "                \n",
      "Pneumococcus. Even though all children routinely receive the vaccine against pneumococcus (PCV13), children with SCD should also receive a second kind of vaccine against pneumococcus (PPSV23). This second vaccine is given after 24 months of age and again 5 years later. Adults with SCD who have not received any pneumococcal vaccine should get a dose of the PCV13 vaccine. They should later receive the PPSV23 if they have not already received it or it has been more than 5 years since they did. A person should follow these guidelines even if he or she is still taking penicillin.\n",
      "                \n",
      "Influenza. All people with SCD should receive an influenza shot every year at the start of flu season. This should begin at 6 months of age. Only the inactivated vaccine, which comes as a shot, should be used in people with SCD.\n",
      "                \n",
      "Meningococcus. A child with SCD should receive this vaccine (Menactra or Menveo) at 2, 4, 6, and 1215 months of age. The child should receive a booster vaccine 3 years after this series of shots, then every 5 years after that.\n",
      "                \n",
      "Screening Tests and Evaluations\n",
      "                \n",
      "Height, Weight, Blood Pressure, and Oxygen Saturation\n",
      "                \n",
      "Doctors will monitor height and weight to be sure that a child is growing properly and that a person with SCD is maintaining a healthy weight.\n",
      "                \n",
      "Doctors will also track a persons blood pressure. When a person with SCD has high blood pressure, it needs to be treated promptly because it can increase the risk of stroke.\n",
      "                \n",
      "Oxygen saturation testing provides information about how much oxygen the blood is carrying.\n",
      "                \n",
      "Blood and Urine Testing\n",
      "                \n",
      "People with SCD need to have frequent lab tests.\n",
      "                \n",
      "Blood tests help to establish a persons baseline for problems like anemia. Blood testing also helps to show whether a person has organ damage, so that it can be treated early.\n",
      "                \n",
      "Urine testing can help to detect early kidney problems or infections.\n",
      "                \n",
      "Transcranial Doppler (TCD) Ultrasound Screening\n",
      "                \n",
      "Children who have hemoglobin SS or hemoglobin S0 thalassemia and are between the ages of 2 and 16 should have TCD testing once a year.\n",
      "                \n",
      "This study can find out whether a child is at higher risk for stroke. When the test is abnormal, regular blood transfusions can decrease the chances of having a stroke.\n",
      "                \n",
      "The child is awake during the TCD exam. The test does not hurt at all. The TCD machine uses sound waves to measure blood flow like the ultrasound machine used to examine pregnant women.\n",
      "                \n",
      "Eye Examinations\n",
      "                \n",
      "An eye doctor, or ophthalmologist, should examine a persons eyes every 12 years from the age of 10 onwards.\n",
      "                \n",
      "These exams can detect if there are SCD-related problems of the eye. Regular exams can help doctors find and treat problems early to prevent loss of vision. A person should see his or her doctor right away for any sudden change in vision.\n",
      "                \n",
      "Pulmonary Hypertension\n",
      "                \n",
      "Doctors have different approaches to screening for pulmonary hypertension. This is because studies have not given clear information as to when and how a person should receive the screening. People with SCD and their caretakers should discuss with their doctor whether screening makes sense for them.\n",
      "                \n",
      "Cognitive Screening\n",
      "                \n",
      "People with sickle cell disease can develop cognitive (thinking) problems that may be hard to notice early in life.\n",
      "                \n",
      "Sometimes these problems are caused by silent strokes that can only be seen with magnetic resonance imaging (MRI) of the brain.\n",
      "                \n",
      "People with SCD should tell their doctors or nurses if they have thinking problems, such as difficulties learning in school, slowed decision making, or trouble organizing their thoughts.\n",
      "                \n",
      "People can be referred for cognitive testing. This testing can identify areas in which a person could use extra help.\n",
      "                \n",
      "Children with SCD who have thinking problems may qualify for an Individualized Education Program, or IEP. An IEP is a plan that helps students to reach their educational goals. Adults may be able to enroll in vocational rehabilitation programs that can help them with job training.\n",
      "                \n",
      "Education and Guidance\n",
      "                \n",
      "Doctors and other providers will talk with people who have SCD and their caretakers about complications and also review information at every visit.\n",
      "                \n",
      "Because there are a lot of things to discuss, new topics are often introduced as a child or adult reaches an age when that subject is important to know about.\n",
      "                \n",
      "Doctors and nurses know that there is a lot of information to learn, and they dont expect people to know everything after one discussion. People with SCD and their families should not be afraid to ask questions.\n",
      "                \n",
      "Topics that are usually covered include:\n",
      "                \n",
      "Hours that medical staff are available and contact information to use when people with SCD or caretakers have questions\n",
      "                \n",
      "A plan for what to do and where to get care if a person has a fever, pain, or other signs of SCD complications that need immediate attention\n",
      "                \n",
      "How SCD is inherited and the risk of having a child with SCD\n",
      "                \n",
      "The importance of regular medical visits, screening tests, and evaluations\n",
      "                \n",
      "How to recognize and manage pain\n",
      "                \n",
      "How to palpate (feel) a childs spleen. Because of the risk of splenic sequestration crisis, caretakers should learn how to palpate a childs spleen. They should try to feel for the spleen daily and more frequently when the child is ill. If they feel that the spleen is bigger than usual, they should call the care provider. \n",
      "                \n",
      "Transitioning Care\n",
      "                \n",
      "When children with SCD become adolescents or young adults, they often need to transition from a pediatric care team to an adult care team. This period has been shown to be associated with increased hospital admissions and medical problems. There seem to be many reasons for this.\n",
      "                \n",
      "Some of the increased risk is directly related to the disease. As people with SCD get older, they often develop more organ damage and more disabilities.\n",
      "                \n",
      "The shift in care usually occurs at the same time that adolescents are undergoing many changes in their emotional, social, and academic lives. The transition to more independent self-management may be difficult, and following treatment plans may become less likely.\n",
      "                \n",
      "When compared with pediatrics, there are often fewer adult SCD programs available in a given region. This makes it more difficult for a person with SCD to find appropriate doctors, particularly those with whom they feel comfortable.\n",
      "                \n",
      "To improve use of regular medical care by people with SCD and to reduce age-related complications, many SCD teams have developed special programs that the make transition easier. Such programs should involve the pediatric and the adult care teams. They should also start early and continue over several years.\n",
      "                \n",
      "Managing Some Complications of SCD\n",
      "                \n",
      "Acute Pain\n",
      "                \n",
      "Each person with SCD should have a home treatment regimen that is best suited to their needs. The providers on the SCD team usually help a person develop a written, tailored care plan. If possible, the person with SCD should carry this plan with them when they go to the emergency room.\n",
      "                \n",
      "When an acute crisis is just starting, most doctors will advise the person to drink lots of fluids and to take a non-steroidal anti-inflammatory (NSAID) pain medication, such as ibuprofen. When a person has kidney problems, acetaminophen is often preferred.\n",
      "                \n",
      "If pain persists, many people will find that they need a stronger medicine.\n",
      "                \n",
      "Combining additional interventions, such as massage, relaxation methods, or a heating pad, may also help.\n",
      "                \n",
      "If a person with SCD cannot control the pain at home, he or she should go to an SCD day hospital/outpatient unit or an emergency room to receive additional, stronger medicines and intravenous (IV) fluids.\n",
      "                \n",
      "Some people may be able to return home once their pain is under better control. In this case, the doctor may prescribe additional pain medicines for a short course of therapy.\n",
      "                \n",
      "People often need to be admitted to the hospital to fully control an acute pain crisis.\n",
      "                \n",
      "When taken daily, hydroxyurea has been found to decrease the number and severity of pain episodes.\n",
      "                \n",
      "Chronic Pain\n",
      "                \n",
      "Sometimes chronic pain results from a complication, such as a leg ulcer or aseptic necrosis of the hip. In this case, doctors try to treat the complication causing the pain.\n",
      "                \n",
      "While chronic pain is common in adults with SCD, the cause is often poorly understood. Taking pain medicines daily may help to decrease the pain. Some examples of these medicines include:\n",
      "                \n",
      "NSAID drugs, such as ibuprofen\n",
      "                \n",
      "Duloxetine\n",
      "                \n",
      "Gabapentin\n",
      "                \n",
      "Amitriptyline\n",
      "                \n",
      "Strong pain medicines, such as opiates\n",
      "                \n",
      "Other approaches, such as massage, heat, or acupuncture may be helpful in some cases. Chronic pain often comes with feelings of depression and anxiety. Supportive counseling and, sometimes, antidepressant medicines may help. (See coping and emotional issues.)\n",
      "                \n",
      "Severe Anemia\n",
      "                \n",
      "People should see their doctors or go to a hospital right away if they develop anemia symptoms from a splenic sequestration crisis or an aplastic crisis. These conditions can be life-threatening, and the person will need careful monitoring and treatment in the hospital. A person also usually needs a blood transfusion.\n",
      "                \n",
      "People with SCD and symptoms of severe anemia from other causes should also see a doctor right away.\n",
      "                \n",
      "Infections\n",
      "                \n",
      "Fever is a medical emergency in SCD. All caretakers of infants and children with SCD should take their child to their doctor or go to a hospital right away when their child has a fever. Adults with SCD should also seek care for fever or other signs of infection.\n",
      "                \n",
      "All children and adults who have SCD and a fever (over 38.50 C or 101.30 F) must be seen by a doctor and treated with antibiotics right away.\n",
      "                \n",
      "Some people will need to be hospitalized, while others may receive care and follow-up as an outpatient.\n",
      "                \n",
      "Acute Chest Syndrome\n",
      "                \n",
      "People with SCD and symptoms of acute chest syndrome should see their doctor or go to a hospital right away.\n",
      "                \n",
      "They will need to be admitted to the hospital where they should receive antibiotics and close monitoring. They may need oxygen therapy and a blood transfusion.\n",
      "                \n",
      "When taken daily, the medicine hydroxyurea has been found to decrease the number and severity of acute chest events.\n",
      "                \n",
      "Clinical Stroke\n",
      "                \n",
      "People with SCD who have symptoms of stroke should be brought to the hospital right away by an ambulance. If a person is having symptoms of stroke, someone should call 9-1-1.\n",
      "                \n",
      "Symptoms of stroke may include:\n",
      "                \n",
      "Weakness of an arm or leg on one side of the body\n",
      "                \n",
      "Trouble speaking, walking, or understanding\n",
      "                \n",
      "Loss of balance\n",
      "                \n",
      "Severe headache\n",
      "                \n",
      "If imaging studies reveal that the person has had an acute stroke, he or she may need an exchange transfusion. This procedure involves slowly removing an amount of the persons blood and replacing it with blood from a donor who does not have SCD or sickle cell trait. Afterward, the person may need to receive monthly transfusions or other treatments to help to prevent another stroke.\n",
      "                \n",
      "Silent Stroke and Cognitive Problems\n",
      "                \n",
      "Children and adults with SCD and cognitive problems may be able to get useful help based upon the results of their testing. For instance, children may qualify for an IEP. Adults may be able to enroll in vocational, or job, training programs.\n",
      "                \n",
      "Priapism\n",
      "                \n",
      "Sometimes, a person may be able to relieve priapism by:\n",
      "                \n",
      "Emptying the bladder by urinating\n",
      "                \n",
      "Taking medicine\n",
      "                \n",
      "Increasing fluid intake\n",
      "                \n",
      "Doing light exercise\n",
      "                \n",
      "If a person has an episode that lasts for 4 hours or more, he should go to the hospital to see a hematologist and urologist.\n",
      "                \n",
      "Pregnancy\n",
      "                \n",
      "Pregnant women with SCD are at greater risk for problems. They should always see an obstetrician, or OB, who has experience with SCD and high-risk pregnancies and deliveries.\n",
      "                \n",
      "The obstetrician should work with a hematologist or primary medical doctor who is well informed about SCD and its complications.\n",
      "                \n",
      "Pregnant women with SCD need more frequent medical visits so that their doctors can follow them closely. The doctor may prescribe certain vitamins and will be careful to prescribe pain medicines that are safe for the baby.\n",
      "                \n",
      "A pregnant woman with SCD may need to have one or more blood transfusions during her pregnancy to treat complications, such as worsening anemia or an increased number of pain or acute chest syndrome events.\n",
      "                \n",
      "Hydroxyurea\n",
      "                \n",
      "What Is Hydroxyurea?\n",
      "                \n",
      "Hydroxyurea is an oral medicine that has been shown to reduce or prevent several SCD complications.\n",
      "                \n",
      "This medicine was studied in patients with SCD because it was known to increase the amount of fetal hemoglobin (hemoglobin F) in the blood. Increased hemoglobin F provides some protection against the effects of hemoglobin S.\n",
      "                \n",
      "Hydroxyurea was later found to have several other benefits for a person with SCD, such as decreasing inflammation.\n",
      "                \n",
      "Use in adults. Many studies of adults with hemoglobin SS or hemoglobin S thalassemia showed that hydroxyurea reduced the number of episodes of pain crises and acute chest syndrome. It also improved anemia and decreased the need for transfusions and hospital admissions.\n",
      "                \n",
      "Use in children. Studies in children with severe hemoglobin SS or S thalassemia showed that hydroxyurea reduced the number of vaso-occlusive crises and hospitalizations. A study of very young children (between the ages of 9 and 18 months) with hemoglobin SS or hemoglobin S thalassemia also showed that hydroxyurea decreased the number of episodes of pain and dactylitis.\n",
      "                \n",
      "Who Should Use Hydroxyurea?\n",
      "                \n",
      "Since hydroxyurea can decrease several complications of SCD, most experts recommend that children and adults with hemoglobin SS or S0 thalassemia who have frequent painful episodes, recurrent chest crises, or severe anemia take hydroxyurea daily.\n",
      "                \n",
      "Some experts offer hydroxyurea to all infants over 9 months of age and young children with hemoglobin SS or S0 thalassemia, even if they do not have severe clinical problems, to prevent or reduce the chance of complications. There is no information about how safe or effective hydroxyurea is in children under 9 months of age.\n",
      "                \n",
      "Some experts will prescribe hydroxyurea to people with other types of SCD who have severe, recurrent pain. There is little information available about how effective hydroxyurea is for these types of SCD.\n",
      "                \n",
      "In all situations, people with SCD should discuss with their doctors whether or not hydroxyurea is an appropriate medication for them.\n",
      "                \n",
      "Pregnant women should not use hydroxyurea.\n",
      "                \n",
      "How Is Hydroxyurea Taken?\n",
      "                \n",
      "To work properly, hydroxyurea should be taken by mouth daily at the prescribed dose. When a person does not take it regularly, it will not work as well, or it wont work at all.\n",
      "                \n",
      "A person with SCD who is taking hydroxyurea needs careful monitoring. This is particularly true in the early weeks of taking the medicine. Monitoring includes regular blood testing and dose adjustments.\n",
      "                \n",
      "What Are the Risks of Hydroxyurea?\n",
      "                \n",
      "Hydroxyurea can cause the bloods white cell count or platelet count to drop. In rare cases, it can worsen anemia. These side effects usually go away quickly if a person stops taking the medication. When a person restarts it, a doctor usually prescribes a lower dose.\n",
      "                \n",
      "Other short-term side effects are less common.\n",
      "                \n",
      "It is still unclear whether hydroxyurea can cause problems later in life in people with SCD who take it for many years. Studies so far suggest that it does not put people at a higher risk of cancer and does not affect growth in children. But further studies are needed.\n",
      "                \n",
      "Red Blood Cell Transfusions\n",
      "                \n",
      "Doctors may use acute and chronic red blood cell transfusions to treat and prevent certain SCD complications. The red blood cells in a transfusion have normal hemoglobin in them.\n",
      "                \n",
      "A transfusion helps to raise the number of red blood cells and provides normal red blood cells that are more flexible than red blood cells with sickle hemoglobin. These cells live longer in the circulation. Red blood cell transfusions decrease vaso-occlusion (blockage in the blood vessel) and improve oxygen delivery to the tissues and organs.\n",
      "                \n",
      "Acute Transfusion in SCD\n",
      "                \n",
      "Doctors use blood transfusions in SCD for complications that cause severe anemia. They may also use them when a person has an acute stroke, in many cases of acute chest crises, and in multi-organ failure.\n",
      "                \n",
      "A person with SCD usually receives blood transfusions before surgery to prevent SCD-related complications afterwards.\n",
      "                \n",
      "Chronic Transfusion\n",
      "                \n",
      "Doctors recommend regular or ongoing blood transfusions for people who have had an acute stroke, since transfusions decrease the chances of having another stroke.\n",
      "                \n",
      "Doctors also recommend chronic blood transfusions for children who have abnormal TCD ultrasound results because transfusions can reduce the chance of having a first stroke.\n",
      "                \n",
      "Some doctors use this approach to treat complications that do not improve with hydroxyurea. They may also use transfusions in people who have too many side effects from hydroxyurea.\n",
      "                \n",
      "What Are the Risks of Transfusion Therapy?\n",
      "                \n",
      "Possible complications include:\n",
      "                \n",
      "Hemolysis\n",
      "                \n",
      "Iron overload, particularly in people receiving chronic transfusions (can severely impair heart and lung function)\n",
      "                \n",
      "Infection\n",
      "                \n",
      "Alloimmunization (can make it hard to find a matching unit of blood for a future transfusion)\n",
      "                \n",
      "All blood banks and hospital personnel have adopted practices to reduce the risk of transfusion problems.\n",
      "                \n",
      "People with SCD who receive transfusions should be monitored for and immunized against hepatitis. They should also receive regular screenings for iron overload. If a person has iron overload, the doctor will give chelation therapy, a medicine to reduce the amount of iron in the body and the problems that iron overload causes.\n",
      "                \n",
      "\n",
      "                \n",
      "Hematopoietic Stem Cell Transplantation\n",
      "                \n",
      "At the present time, hematopoietic stem cell transplantation (HSCT) is the only cure for SCD. People with SCD and their families should ask their doctor about this procedure.\n",
      "                \n",
      "What Are Stem Cells?\n",
      "                \n",
      "Stem cells are special cells that can divide over and over again. After they divide, these cells can go on to become blood red cells, white cells, or platelets.\n",
      "                \n",
      "A person with SCD has stem cells that make red blood cells that can sickle. People without SCD have stem cells that make red cells that usually wont sickle.\n",
      "                \n",
      "What Stem Cells Are Used in HSCT?\n",
      "                \n",
      "In HSCT, stem cells are taken from the bone marrow or blood of a person who does not have sickle cell disease (the donor). The donor, however, may have sickle cell trait.\n",
      "                \n",
      "The donor is often the persons sister or brother. This is because the safest and most successful transplants use stem cells that are matched for special proteins called HLA antigens. Since these antigens are inherited from parents, a sister or brother is the most likely person to have the same antigens as the person with SCD.\n",
      "                \n",
      "What Happens During HSCT?\n",
      "                \n",
      "First, stem cells are taken from the donor. After this, the person with SCD (the recipient) is treated with drugs that destroy or reduce his or her own bone marrow stem cells.\n",
      "                \n",
      "The donor stem cells are then injected into the persons vein. The injected cells will make a home in the recipients bone marrow, gradually replacing the recipients cells. The new stem cells will make red cells that do not sickle.\n",
      "                \n",
      "Which People Receive HSCT?\n",
      "                \n",
      "At the present time, most SCD transplants are performed in children who have had complications such as strokes, acute chest crises, and recurring pain crises. These transplants usually use a matched donor.\n",
      "                \n",
      "Because only about 1 in 10 children with SCD has a matched donor without SCD in their families, the number of people with SCD who get transplants is low.\n",
      "                \n",
      "HSCT is more risky in adults, and that is why most transplants are done in children.\n",
      "                \n",
      "There are several medical centers that are researching new SCD HSCT techniques in children and adults who dont have a matched donor in the family or are older than most recipients. Hopefully, more people with SCD will be able to receive a transplant in the future, using these new methods.\n",
      "                \n",
      "What Are the Risks?\n",
      "                \n",
      "HSCT is successful in about 85 percent of children when the donor is related and HLA matched. Even with this high success rate, HSCT still has risks.\n",
      "                \n",
      "Complications can include severe infections, seizures, and other clinical problems. About 5 percent of people have died. Sometimes transplanted cells attack the recipients organs (graft versus host disease).\n",
      "                \n",
      "Medicines are given to prevent many of the complications, but they still can happen.\n",
      "============================\n",
      "Q: What are the treatments for Childhood Acute Lymphoblastic Leukemia ?\n",
      "A: Key Points\n",
      "                    - There are different types of treatment for childhood acute lymphoblastic leukemia (ALL).     - Children with ALL should have their treatment planned by a team of doctors who are experts in treating childhood leukemia.    - Children and adolescents may have treatment-related side effects that appear months or years after treatment for acute lymphoblastic leukemia.    - The treatment of childhood ALL usually has three phases.    - Four types of standard treatment are used:         - Chemotherapy      - Radiation therapy      - Chemotherapy with stem cell transplant     - Targeted therapy         - Treatment is given to kill leukemia cells that have spread or may spread to the brain, spinal cord, or testicles.    - New types of treatment are being tested in clinical trials.          - Chimeric antigen receptor (CAR) T-cell therapy        - Patients may want to think about taking part in a clinical trial.    - Patients can enter clinical trials before, during, or after starting their cancer treatment.    - Follow-up tests may be needed.\n",
      "                \n",
      "                \n",
      "                    There are different types of treatment for childhood acute lymphoblastic leukemia (ALL).\n",
      "                    Different types of treatment are available for children with acute lymphoblastic leukemia (ALL). Some treatments are standard (the currently used treatment), and some are being tested in clinical trials. A treatment clinical trial is a research study meant to help improve current treatments or obtain information on new treatments for patients with cancer. When clinical trials show that a new treatment is better than the standard treatment, the new treatment may become the standard treatment.   Because cancer in children is rare, taking part in a clinical trial should be considered. Some clinical trials are open only to patients who have not started treatment.\n",
      "                \n",
      "                \n",
      "                    Children with ALL should have their treatment planned by a team of doctors who are experts in treating childhood leukemia.\n",
      "                    Treatment will be overseen by a pediatric oncologist, a doctor who specializes in treating children with cancer. The pediatric oncologist works with other pediatric health professionals who are experts in treating children with leukemia and who specialize in certain areas of medicine. These may include the following specialists:         -  Pediatrician.    -  Hematologist.    -  Medical oncologist.    -  Pediatric surgeon.    -  Radiation oncologist.    -  Neurologist.    -  Pathologist.    -  Radiologist.    -  Pediatric nurse specialist.    -  Social worker.    -  Rehabilitation specialist.    -  Psychologist.    -  Child-life specialist.\n",
      "                \n",
      "                \n",
      "                    Children and adolescents may have treatment-related side effects that appear months or years after treatment for acute lymphoblastic leukemia.\n",
      "                    Regular follow-up exams are very important. Treatment can cause side effects long after it has ended. These are called late effects.   Late effects of cancer treatment may include:         - Physical problems, including problems with the heart, blood vessels, liver, or bones, and fertility. When dexrazoxane is given with chemotherapy drugs called anthracyclines, the risk of late heart effects is lessened.    - Changes in mood, feelings, thinking, learning, or memory. Children younger than 4 years who have received radiation therapy to the brain have a higher risk of these effects.    -  Second cancers (new types of cancer) or other conditions, such as brain tumors, thyroid cancer, acute myeloid leukemia, and myelodysplastic syndrome.        Some late effects may be treated or controlled. It is important to talk with your child's doctors about the possible late effects caused by some treatments. See the PDQ summary on Late Effects of Treatment for Childhood Cancer.\n",
      "                \n",
      "                \n",
      "                    The treatment of childhood ALL usually has three phases.\n",
      "                    The treatment of childhood ALL is done in phases:         -  Remission induction: This is the first phase of treatment. The goal is to kill the leukemia cells in the blood and bone marrow. This puts the leukemia into remission.     -  Consolidation /intensification: This is the second phase of treatment. It begins once the leukemia is in remission. The goal of consolidation/intensification therapy is to kill any leukemia cells that remain in the body and may cause a relapse.    -  Maintenance: This is the third phase of treatment. The goal is to kill any remaining leukemia cells that may regrow and cause a relapse. Often the cancer treatments are given in lower doses than those used during the remission induction and consolidation/intensification phases. Not taking medication as ordered by the doctor during maintenance therapy increases the chance the cancer will come back. This is also called the continuation therapy phase.\n",
      "                \n",
      "                \n",
      "                    Four types of standard treatment are used:\n",
      "                    Chemotherapy     Chemotherapy is a cancer treatment that uses drugs to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. When chemotherapy is taken by mouth or injected into a vein or muscle, the drugs enter the bloodstream and can reach cancer cells throughout the body (systemic chemotherapy). When chemotherapy is placed directly into the cerebrospinal fluid (intrathecal), an organ, or a body cavity such as the abdomen, the drugs mainly affect cancer cells in those areas (regional chemotherapy). Combination chemotherapy is treatment using more than one anticancer drug.     The way the chemotherapy is given depends on the child's risk group. Children with high-risk ALL receive more anticancer drugs and higher doses of anticancer drugs than children with standard-risk ALL. Intrathecal chemotherapy may be used to treat childhood ALL that has spread, or may spread, to the brain and spinal cord.    See Drugs Approved for Acute Lymphoblastic Leukemia for more information.       Radiation therapy     Radiation therapy is a cancer treatment that uses high-energy x-rays or other types of radiation to kill cancer cells or keep them from growing. There are two types of radiation therapy:            -  External radiation therapy uses a machine outside the body to send radiation toward the cancer.     -  Internal radiation therapy uses a radioactive substance sealed in needles, seeds, wires, or catheters that are placed directly into or near the cancer.           The way the radiation therapy is given depends on the type of cancer being treated. External radiation therapy may be used to treat childhood ALL that has spread, or may spread, to the brain, spinal cord, or testicles. It may also be used to prepare the bone marrow for a stem cell transplant.       Chemotherapy with stem cell transplant    Stem cell transplant is a method of giving high doses of chemotherapy and sometimes total-body irradiation, and then replacing the blood-forming cells destroyed by the cancer treatment. Stem cells (immature blood cells) are removed from the blood or bone marrow of a donor. After the patient receives treatment, the donor's stem cells are given to the patient through an infusion. These reinfused stem cells grow into (and restore) the patient's blood cells. The stem cell donor doesn't have to be related to the patient.    Stem cell transplant is rarely used as initial treatment for children and adolescents with ALL. It is used more often as part of treatment for ALL that relapses (comes back after treatment).    See Drugs Approved for Acute Lymphoblastic Leukemia for more information.        Targeted therapy      Targeted therapy is a treatment that uses drugs or other substances to identify and attack specific cancer cells without harming normal cells.      Tyrosine kinase inhibitors (TKIs) are targeted therapy drugs that block the enzyme, tyrosine kinase, which causes stem cells to become more white blood cells or blasts than the body needs. Imatinib mesylate is a TKI used in the treatment of children with Philadelphia chromosome positive ALL. Dasatinib and ruxolitinib are TKIs that are being studied in the treatment of newly diagnosed high-risk ALL.     Monoclonal antibody therapy is a cancer treatment that uses antibodies made in the laboratory, from a single type of immune system cell. These antibodies can identify substances on cancer cells or normal substances that may help cancer cells grow. The antibodies attach to the substances and kill the cancer cells, block their growth, or keep them from spreading. Monoclonal antibodies are given by infusion. They may be used alone or to carry drugs, toxins, or radioactive material directly to cancer cells. Blinatumomab and inotuzumab are monoclonal antibodies being studied in the treatment of refractory childhood ALL.    New kinds of targeted therapies are also being studied in the treatment of childhood ALL.    See Drugs Approved for Acute Lymphoblastic Leukemia for more information.\n",
      "                \n",
      "                \n",
      "                    Treatment is given to kill leukemia cells that have spread or may spread to the brain, spinal cord, or testicles.\n",
      "                    Treatment to kill leukemia cells or prevent the spread of leukemia cells to the brain and spinal cord (central nervous system; CNS) is called CNS-directed therapy. Chemotherapy may be used to treat leukemia cells that have spread, or may spread, to the brain and spinal cord. Because standard doses of chemotherapy may not reach leukemia cells in the CNS, the cells are able to hide in the CNS. Systemic chemotherapy given in high doses or intrathecal chemotherapy (into the cerebrospinal fluid) is able to reach leukemia cells in the CNS. Sometimes external radiation therapy to the brain is also given.    These treatments are given in addition to treatment that is used to kill leukemia cells in the rest of the body. All children with ALL receive CNS-directed therapy as part of induction therapy and consolidation/intensification therapy and sometimes during maintenance therapy.    If the leukemia cells spread to the testicles, treatment includes high doses of systemic chemotherapy and sometimes radiation therapy.\n",
      "                \n",
      "                \n",
      "                    New types of treatment are being tested in clinical trials.\n",
      "                    This summary section describes treatments that are being studied in clinical trials. It may not mention every new treatment being studied. Information about clinical trials is available from the NCI website.     Chimeric antigen receptor (CAR) T-cell therapy     CAR T-cell therapy is a type of immunotherapy that changes the patient's T cells (a type of immune system cell) so they will attack certain proteins on the surface of cancer cells. T cells are taken from the patient and special receptors are added to their surface in the laboratory. The changed cells are called chimeric antigen receptor (CAR) T cells. The CAR T cells are grown in the laboratory and given to the patient by infusion. The CAR T cells multiply in the patient's blood and attack cancer cells. CAR T-cell therapy is being studied in the treatment of childhood ALL that has relapsed (come back) a second time.\n",
      "                \n",
      "                \n",
      "                    Patients may want to think about taking part in a clinical trial.\n",
      "                    For some patients, taking part in a clinical trial may be the best treatment choice. Clinical trials are part of the cancer research process. Clinical trials are done to find out if new cancer treatments are safe and effective or better than the standard treatment.   Many of today's standard treatments for cancer are based on earlier clinical trials. Patients who take part in a clinical trial may receive the standard treatment or be among the first to receive a new treatment.   Patients who take part in clinical trials also help improve the way cancer will be treated in the future. Even when clinical trials do not lead to effective new treatments, they often answer important questions and help move research forward.\n",
      "                \n",
      "                \n",
      "                    Patients can enter clinical trials before, during, or after starting their cancer treatment.\n",
      "                    Some clinical trials only include patients who have not yet received treatment. Other trials test treatments for patients whose cancer has not gotten better. There are also clinical trials that test new ways to stop cancer from recurring (coming back) or reduce the side effects of cancer treatment.   Clinical trials are taking place in many parts of the country. See the Treatment Options section that follows for links to current treatment clinical trials. These have been retrieved from NCI's listing of clinical trials.\n",
      "                \n",
      "                \n",
      "                    Follow-up tests may be needed.\n",
      "                    Some of the tests that were done to diagnose the cancer or to find out the stage of the cancer may be repeated. Some tests will be repeated in order to see how well the treatment is working. Decisions about whether to continue, change, or stop treatment may be based on the results of these tests.   Some of the tests will continue to be done from time to time after treatment has ended. The results of these tests can show if your child's condition has changed or if the cancer has recurred (come back). These tests are sometimes called follow-up tests or check-ups.    Bone marrow aspiration and biopsy is done during all phases of treatment to see how well the treatment is working.\n",
      "                                \n",
      "                \n",
      "\t\t\t\t\t\t            Treatment Options for Childhood Acute Lymphoblastic Leukemia\n",
      "\t\t\t\t\t\t            \n",
      "\t\t\t\t\t\t                \n",
      "\t\t\t\t\t\t                    Newly Diagnosed Childhood Acute Lymphoblastic Leukemia (Standard Risk)\n",
      "\t\t\t\t\t\t                    The treatment of standard-risk childhood acute lymphoblastic leukemia (ALL) during the remission induction, consolidation /intensification, and maintenance phases always includes combination chemotherapy. When children are in remission after remission induction therapy, a stem cell transplant using stem cells from a donor may be done. When children are not in remission after remission induction therapy, further treatment is usually the same treatment given to children with high-risk ALL.    Intrathecal chemotherapy is given to prevent the spread of leukemia cells to the brain and spinal cord.   Treatments being studied in clinical trials for standard-risk ALL include new chemotherapy regimens.   Check the list of NCI-supported cancer clinical trials that are now accepting patients with untreated childhood acute lymphoblastic leukemia. For more specific results, refine the search by using other search features, such as the location of the trial, the type of treatment, or the name of the drug. Talk with your child's doctor about clinical trials that may be right for your child. General information about clinical trials is available from the NCI website.\n",
      "\t\t\t\t\t\t                \n",
      "\t\t\t\t\t\t                \n",
      "\t\t\t\t\t\t                    Newly Diagnosed Childhood Acute Lymphoblastic Leukemia (High Risk)\n",
      "\t\t\t\t\t\t                    The treatment of high-risk childhood acute lymphoblastic leukemia (ALL) during the remission induction, consolidation /intensification, and maintenance phases always includes combination chemotherapy. Children in the high-risk ALL group are given more anticancer drugs and higher doses of anticancer drugs, especially during the consolidation/intensification phase, than children in the standard-risk group.    Intrathecal and systemic chemotherapy are given to prevent or treat the spread of leukemia cells to the brain and spinal cord. Sometimes radiation therapy to the brain is also given.   Treatments being studied in clinical trials for high-risk ALL include new chemotherapy regimens with or without targeted therapy or stem cell transplant.   Check the list of NCI-supported cancer clinical trials that are now accepting patients with untreated childhood acute lymphoblastic leukemia. For more specific results, refine the search by using other search features, such as the location of the trial, the type of treatment, or the name of the drug. Talk with your child's doctor about clinical trials that may be right for your child. General information about clinical trials is available from the NCI website.\n",
      "\t\t\t\t\t\t                \n",
      "\t\t\t\t\t\t                \n",
      "\t\t\t\t\t\t                    Newly Diagnosed Childhood Acute Lymphoblastic Leukemia (Very High Risk)\n",
      "\t\t\t\t\t\t                    The treatment of very highrisk childhood acute lymphoblastic leukemia (ALL) during the remission induction, consolidation /intensification, and maintenance phases always includes combination chemotherapy. Children in the very highrisk ALL group are given more anticancer drugs than children in the high-risk group. It is not clear whether a stem cell transplant during first remission will help the child live longer.    Intrathecal and systemic chemotherapy are given to prevent or treat the spread of leukemia cells to the brain and spinal cord. Sometimes radiation therapy to the brain is also given.   Treatments being studied in clinical trials for very highrisk ALL include new chemotherapy regimens with or without targeted therapy.   Check the list of NCI-supported cancer clinical trials that are now accepting patients with untreated childhood acute lymphoblastic leukemia. For more specific results, refine the search by using other search features, such as the location of the trial, the type of treatment, or the name of the drug. Talk with your child's doctor about clinical trials that may be right for your child. General information about clinical trials is available from the NCI website.\n",
      "\t\t\t\t\t\t                \n",
      "\t\t\t\t\t\t                \n",
      "\t\t\t\t\t\t                    Newly Diagnosed Childhood Acute Lymphoblastic Leukemia (Special Groups)\n",
      "\t\t\t\t\t\t                    T-cell childhood acute lymphoblastic leukemia    The treatment of T-cell childhood acute lymphoblastic leukemia (ALL) during the remission induction, consolidation /intensification, and maintenance phases always includes combination chemotherapy. Children with T-cell ALL are given more anticancer drugs and higher doses of anticancer drugs than children in the newly diagnosed standard-risk group.     Intrathecal and systemic chemotherapy are given to prevent the spread of leukemia cells to the brain and spinal cord. Sometimes radiation therapy to the brain is also given.    Treatments being studied in clinical trials for T-cell ALL include new anticancer agents and chemotherapy regimens with or without targeted therapy.       Infants with ALL    The treatment of infants with ALL during the remission induction, consolidation /intensification, and maintenance phases always includes combination chemotherapy. Infants with ALL are given different anticancer drugs and higher doses of anticancer drugs than children 1 year and older in the standard-risk group. It is not clear whether a stem cell transplant during first remission will help the child live longer.     Intrathecal and systemic chemotherapy are given to prevent the spread of leukemia cells to the brain and spinal cord.     Treatments being studied in clinical trials for infants with ALL include the following:            - A clinical trial of chemotherapy followed by a donor stem cell transplant for infants with certain gene changes.               Children 10 years and older and adolescents with ALL    The treatment of ALL in children and adolescents (10 years and older) during the remission induction, consolidation /intensification, and maintenance phases always includes combination chemotherapy. Children 10 years and older and adolescents with ALL are given more anticancer drugs and higher doses of anticancer drugs than children in the standard-risk group.     Intrathecal and systemic chemotherapy are given to prevent the spread of leukemia cells to the brain and spinal cord. Sometimes radiation therapy to the brain is also given.    Treatments being studied in clinical trials for children 10 years and older and adolescents with ALL include new anticancer agents and chemotherapy regimens with or without targeted therapy.       Philadelphia chromosomepositive ALL    The treatment of Philadelphia chromosome positive childhood ALL during the remission induction, consolidation /intensification, and maintenance phases may include the following:            -  Combination chemotherapy and targeted therapy with a tyrosine kinase inhibitor (imatinib mesylate) with or without a stem cell transplant using stem cells from a donor.            Check the list of NCI-supported cancer clinical trials that are now accepting patients with T-cell childhood acute lymphoblastic leukemia and Philadelphia chromosome positive childhood precursor acute lymphoblastic leukemia. For more specific results, refine the search by using other search features, such as the location of the trial, the type of treatment, or the name of the drug. Talk with your child's doctor about clinical trials that may be right for your child. General information about clinical trials is available from the NCI website.\n",
      "\t\t\t\t\t\t                \n",
      "\t\t\t\t\t\t                \n",
      "\t\t\t\t\t\t                    Refractory Childhood Acute Lymphoblastic Leukemia\n",
      "\t\t\t\t\t\t                    There is no standard treatment for the treatment of refractory childhood acute lymphoblastic leukemia (ALL).    Some of the treatments being studied in clinical trials for refractory childhood ALL include:         -  Targeted therapy (blinatumomab or inotuzumab).     -  Chimeric antigen receptor (CAR) T-cell therapy.\n",
      "\t\t\t\t\t\t                \n",
      "\t\t\t\t\t\t                \n",
      "\t\t\t\t\t\t                    Relapsed Childhood Acute Lymphoblastic Leukemia\n",
      "\t\t\t\t\t\t                    Standard treatment of relapsed childhood acute lymphoblastic leukemia (ALL) that comes back in the bone marrow may include the following:         -  Combination chemotherapy.    -  Chemotherapy with or without total-body irradiation followed by a stem cell transplant, using stem cells from a donor.        Standard treatment of relapsed childhood acute lymphoblastic leukemia (ALL) that comes back outside the bone marrow may include the following:         -  Systemic chemotherapy and intrathecal chemotherapy with radiation therapy to the brain and/or spinal cord for cancer that comes back in the brain and spinal cord only.    - Combination chemotherapy and radiation therapy for cancer that comes back in the testicles only.    - Stem cell transplant for cancer that has recurred in the brain and/or spinal cord.        Some of the treatments being studied in clinical trials for relapsed childhood ALL include:         - New anticancer drugs and new combination chemotherapy treatments.    - Combination chemotherapy and new kinds of targeted therapies (blinatumomab or inotuzumab).     -  Chimeric antigen receptor (CAR) T-cell therapy.        Check the list of NCI-supported cancer clinical trials that are now accepting patients with recurrent childhood acute lymphoblastic leukemia. For more specific results, refine the search by using other search features, such as the location of the trial, the type of treatment, or the name of the drug. Talk with your child's doctor about clinical trials that may be right for your child. General information about clinical trials is available from the NCI website.\n",
      "============================\n",
      "Q: What are the treatments for Childhood Acute Myeloid Leukemia and Other Myeloid Malignancies ?\n",
      "A: Key Points\n",
      "                    - There are different types of treatment for children with acute myeloid leukemia (AML), chronic myelogenous leukemia (CML), juvenile myelomonocytic leukemia (JMML), or myelodysplastic syndromes (MDS).     - Treatment is planned by a team of health care providers who are experts in treating childhood leukemia and other diseases of the blood.    - Some cancer treatments cause side effects months or years after treatment has ended.     - The treatment of childhood AML usually has two phases.    - Seven types of standard treatment are used for childhood AML, childhood CML, JMML, or MDS.         - Chemotherapy      - Radiation therapy     - Stem cell transplant     - Targeted therapy     - Other drug therapy     - Watchful waiting     - Supportive care        -  New types of treatment are being tested in clinical trials.          - Biologic therapy        - Patients may want to think about taking part in a clinical trial.    - Patients can enter clinical trials before, during, or after starting their cancer treatment.    - Follow-up tests may be needed.\n",
      "                \n",
      "                \n",
      "                    There are different types of treatment for children with acute myeloid leukemia (AML), chronic myelogenous leukemia (CML), juvenile myelomonocytic leukemia (JMML), or myelodysplastic syndromes (MDS).\n",
      "                    Different types of treatment are available for children with AML, CML, JMML, or MDS. Some treatments are standard (the currently used treatment), and some are being tested in clinical trials. A treatment clinical trial is a research study meant to help improve current treatments or obtain information on new treatments for patients with cancer. When clinical trials show that a new treatment is better than the standard treatment, the new treatment may become the standard treatment.    Because cancer in children is rare, taking part in a clinical trial should be considered. Some clinical trials are open only to patients who have not started treatment.\n",
      "                \n",
      "                \n",
      "                    Treatment is planned by a team of health care providers who are experts in treating childhood leukemia and other diseases of the blood.\n",
      "                    Treatment will be overseen by a pediatric oncologist, a doctor who specializes in treating children with cancer. The pediatric oncologist works with other healthcare providers who are experts in treating children with leukemia and who specialize in certain areas of medicine. These may include the following specialists:         -  Pediatrician.    -  Hematologist.    -  Medical oncologist.    -  Pediatric surgeon.    -  Radiation oncologist.    -  Neurologist.    -  Neuropathologist.    -  Neuroradiologist.    -  Pediatric nurse specialist.    -  Social worker.    -  Rehabilitation specialist.    -  Psychologist.\n",
      "                \n",
      "                \n",
      "                    Some cancer treatments cause side effects months or years after treatment has ended.\n",
      "                    Regular follow-up exams are very important. Some cancer treatments cause side effects that continue or appear months or years after cancer treatment has ended. These are called late effects. Late effects of cancer treatment may include:         - Physical problems.    - Changes in mood, feelings, thinking, learning, or memory.    -  Second cancers (new types of cancer).        Some late effects may be treated or controlled. It is important that parents of children who are treated for AML or other blood diseases talk with their doctors about the effects cancer treatment can have on their child. (See the PDQ summary on Late Effects of Treatment for Childhood Cancer for more information).\n",
      "                \n",
      "                \n",
      "                    The treatment of childhood AML usually has two phases.\n",
      "                    The treatment of childhood AML is done in phases:         -  Induction therapy: This is the first phase of treatment. The goal is to kill the leukemia cells in the blood and bone marrow. This puts the leukemia into remission.    -  Consolidation /intensification therapy: This is the second phase of treatment. It begins once the leukemia is in remission. The goal of therapy is to kill any remaining leukemia cells that may not be active but could begin to regrow and cause a relapse.        Treatment called central nervous system (CNS) sanctuary therapy may be given during the induction phase of therapy. Because standard doses of chemotherapy may not reach leukemia cells in the CNS (brain and spinal cord), the cells are able to find sanctuary (hide) in the CNS. Intrathecal chemotherapy is able to reach leukemia cells in the CNS. It is given to kill the leukemia cells and lessen the chance the leukemia will recur (come back). CNS sanctuary therapy is also called CNS prophylaxis.\n",
      "                \n",
      "                \n",
      "                    Seven types of standard treatment are used for childhood AML, childhood CML, JMML, or MDS.\n",
      "                    Chemotherapy      Chemotherapy is a cancer treatment that uses drugs to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. When chemotherapy is taken by mouth or injected into a vein or muscle, the drugs enter the bloodstream and can reach cancer cells throughout the body (systemic chemotherapy). When chemotherapy is placed directly into the cerebrospinal fluid (intrathecal chemotherapy), an organ, or a body cavity such as the abdomen, the drugs mainly affect cancer cells in those areas (regional chemotherapy). Combination chemotherapy is treatment using more than one anticancer drug.     The way the chemotherapy is given depends on the type of cancer being treated.    In AML, the leukemia cells may spread to the brain and/or spinal cord. Chemotherapy given by mouth or vein to treat AML may not cross the blood-brain barrier to get into the fluid that surrounds the brain and spinal cord. Instead, chemotherapy is injected into the fluid-filled space to kill leukemia cells that may have spread there (intrathecal chemotherapy).       See Drugs Approved for Acute Myeloid Leukemia for more information.       Radiation therapy     Radiation therapy is a cancer treatment that uses high-energy x-rays or other types of radiation to kill cancer cells or keep them from growing. There are two types of radiation therapy:             -  External radiation therapy uses a machine outside the body to send radiation toward the cancer.     -  Internal radiation therapy uses a radioactive substance sealed in needles, seeds, wires, or catheters that are placed directly into or near the cancer.           The way the radiation therapy is given depends on the type of the cancer being treated. In childhood AML, external radiation therapy may be used to treat a chloroma that does not respond to chemotherapy.       Stem cell transplant     Stem cell transplant is a way of giving chemotherapy and replacing blood-forming cells that are abnormal or destroyed by the cancer treatment. Stem cells (immature blood cells) are removed from the blood or bone marrow of the patient or a donor and are frozen and stored. After the chemotherapy is completed, the stored stem cells are thawed and given back to the patient through an infusion. These reinfused stem cells grow into (and restore) the body's blood cells.        Targeted therapy     Targeted therapy is a type of treatment that uses drugs or other substances to identify and attack specific cancer cells without harming normal cells. Types of targeted therapy include the following:            -   Tyrosine kinase inhibitor therapy: Tyrosine kinase inhibitor (TKI) therapy blocks signals needed for tumors to grow. TKIs block the enzyme (tyrosine kinase) that causes stem cells to become more white blood cells (granulocytes or blasts) than the body needs. TKIs may be used with other anticancer drugs as adjuvant therapy (treatment given after the initial treatment, to lower the risk that the cancer will come back).                   -  Imatinib is a type of TKI that is approved to treat childhood CML.        -  Sorafenib, dasatinib, and nilotinib are being studied in the treatment of childhood leukemia.                -   Monoclonal antibody therapy: Monoclonal antibody therapy uses antibodies made in the laboratory, from a single type of immune system cell. These antibodies can identify substances on cancer cells or normal substances that may help cancer cells grow. The antibodies attach to the substances and kill the cancer cells, block their growth, or keep them from spreading. Monoclonal antibodies are given by infusion. They may be used alone or to carry drugs, toxins, or radioactive material directly to cancer cells.                   -  Gemtuzumab is a type of monoclonal antibody used in the treatment of a subtype of AML called acute promyelocytic leukemia (APL). Gemtuzumab is not available in the United States unless special approval is given. Monoclonal antibodies may be used with chemotherapy as adjuvant therapy.                -   Proteasome inhibitor therapy: Proteasome inhibitors break down proteins in cancer cells and kill them.                   -  Bortezomib is a proteasome inhibitor used to treat childhood APL.                      See Drugs Approved for Leukemia for more information.       Other drug therapy     Lenalidomide may be used to lessen the need for transfusions in patients who have myelodysplastic syndromes caused by a specific chromosome change.     Arsenic trioxide and all-trans retinoic acid (ATRA) are anticancer drugs that kill leukemia cells, stop the leukemia cells from dividing, or help the leukemia cells mature into white blood cells. These drugs are used in the treatment of acute promyelocytic leukemia.    See Drugs Approved for Acute Myeloid Leukemia for more information.       Watchful waiting     Watchful waiting is closely monitoring a patients condition without giving any treatment until signs or symptoms appear or change. It is sometimes used to treat MDS or TMD.       Supportive care     Supportive care is given to lessen the problems caused by the disease or its treatment. Supportive care may include the following:            -  Transfusion therapy: A way of giving red blood cells, white blood cells, or platelets to replace blood cells destroyed by disease or cancer treatment. The blood may be donated from another person or it may have been taken from the patient earlier and stored until needed.     -  Drug therapy, such as antibiotics or antifungal agents.     -  Leukapheresis: A procedure in which a special machine is used to remove white blood cells from the blood. Blood is taken from the patient and put through a blood cell separator where the white blood cells are removed. The rest of the blood is then returned to the patient's bloodstream.\n",
      "                \n",
      "                \n",
      "                    New types of treatment are being tested in clinical trials.\n",
      "                    This summary section describes treatments that are being studied in clinical trials. It may not mention every new treatment being studied. Information about clinical trials is available from the NCI website.     Biologic therapy     Biologic therapy is a treatment that uses the patients immune system to fight cancer. Substances made by the body or made in a laboratory are used to boost, direct, or restore the bodys natural defenses against cancer. This type of cancer treatment is also called biotherapy or immunotherapy.     Natural killer (NK) cells are a type of biologic therapy. NK cells are white blood cells that can kill tumor cells. These may be taken from a donor and given to the patient by infusion to help kill leukemia cells.\n",
      "                \n",
      "                \n",
      "                    Patients may want to think about taking part in a clinical trial.\n",
      "                    For some patients, taking part in a clinical trial may be the best treatment choice. Clinical trials are part of the cancer research process. Clinical trials are done to find out if new cancer treatments are safe and effective or better than the standard treatment.   Many of today's standard treatments for cancer are based on earlier clinical trials. Patients who take part in a clinical trial may receive the standard treatment or be among the first to receive a new treatment.   Patients who take part in clinical trials also help improve the way cancer will be treated in the future. Even when clinical trials do not lead to effective new treatments, they often answer important questions and help move research forward.\n",
      "                \n",
      "                \n",
      "                    Patients can enter clinical trials before, during, or after starting their cancer treatment.\n",
      "                    Some clinical trials only include patients who have not yet received treatment. Other trials test treatments for patients whose cancer has not gotten better. There are also clinical trials that test new ways to stop cancer from recurring (coming back) or reduce the side effects of cancer treatment.   Clinical trials are taking place in many parts of the country. See the Treatment Options section that follows for links to current treatment clinical trials. These have been retrieved from NCI's listing of clinical trials.\n",
      "                \n",
      "                \n",
      "                    Follow-up tests may be needed.\n",
      "                    Some of the tests that were done to diagnose the cancer or to find out the stage of the cancer may be repeated. Some tests will be repeated in order to see how well the treatment is working. Decisions about whether to continue, change, or stop treatment may be based on the results of these tests.   Some of the tests will continue to be done from time to time after treatment has ended. The results of these tests can show if your child's condition has changed or if the cancer has recurred (come back). These tests are sometimes called follow-up tests or check-ups.\n",
      "                \n",
      "                        \n",
      "\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t            Treatment Options for Childhood Acute Myeloid Leukemia, Childhood Chronic Myelogenous Leukemia, Juvenile Myelomonocytic Leukemia, and Myelodysplastic Syndromes\n",
      "\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t            \n",
      "\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t                \n",
      "\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t                    Newly Diagnosed Childhood Acute Myeloid Leukemia\n",
      "\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t                    Treatment of newly diagnosed childhood acute myeloid leukemia may include the following:         -  Combination chemotherapy plus central nervous system sanctuary therapy with intrathecal chemotherapy.    - A clinical trial comparing different chemotherapy regimens (doses and schedules of treatment).    - A clinical trial of combination chemotherapy and targeted therapy with a proteasome inhibitor or a tyrosine kinase inhibitor with or without stem cell transplant.         Treatment of newly diagnosed childhood acute leukemia with a granulocytic sarcoma (chloroma) may include chemotherapy with or without radiation therapy.   Treatment of therapy -related AML is usually the same as for newly diagnosed AML, followed by stem cell transplant.   Check the list of NCI-supported cancer clinical trials that are now accepting patients with untreated childhood acute myeloid leukemia and other myeloid malignancies. For more specific results, refine the search by using other search features, such as the location of the trial, the type of treatment, or the name of the drug. Talk with your child's doctor about clinical trials that may be right for your child. General information about clinical trials is available from the NCI website.\n",
      "\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t                \n",
      "\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t                \n",
      "\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t                    Children with Newly Diagnosed Childhood AML and Down Syndrome\n",
      "\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t                    Treatment of acute myeloid leukemia (AML) in children aged 4 years or younger who have Down syndrome may include the following:          -  Combination chemotherapy plus central nervous system sanctuary therapy with intrathecal chemotherapy.        Treatment of AML in children older than 4 years who have Down syndrome may be the same as treatment for children without Down syndrome.\n",
      "\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t                \n",
      "\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t                \n",
      "\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t                    Childhood Acute Myeloid Leukemia in Remission\n",
      "\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t                    Treatment of childhood acute myeloid leukemia (AML) during the remission phase (consolidation /intensification therapy) depends on the subtype of AML and may include the following:          -  Combination chemotherapy.     -  High-dose chemotherapy followed by stem cell transplant using blood stem cells from a donor.     - A clinical trial of chemotherapy followed by an infusion of natural killer cells.    - A clinical trial of combination chemotherapy and targeted therapy with a proteasome inhibitor or a tyrosine kinase inhibitor with or without stem cell transplant.         Check the list of NCI-supported cancer clinical trials that are now accepting patients with childhood acute myeloid leukemia in remission. For more specific results, refine the search by using other search features, such as the location of the trial, the type of treatment, or the name of the drug. Talk with your child's doctor about clinical trials that may be right for your child. General information about clinical trials is available from the NCI website.\n",
      "\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t                \n",
      "\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t                \n",
      "\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t                    Recurrent Childhood Acute Myeloid Leukemia\n",
      "\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t                    Treatment of recurrent childhood acute myeloid leukemia (AML) may include the following:         -  Combination chemotherapy.    - Combination chemotherapy and stem cell transplant.    - A second stem cell transplant.    - A clinical trial of combinations of new anticancer drugs, new biologic agents, and stem cell transplant using different sources of stem cells.        Treatment of recurrent AML in children with Down syndrome is chemotherapy. It is not clear if stem cell transplant after chemotherapy is helpful in treating these children.   Check the list of NCI-supported cancer clinical trials that are now accepting patients with recurrent childhood acute myeloid leukemia. For more specific results, refine the search by using other search features, such as the location of the trial, the type of treatment, or the name of the drug. Talk with your child's doctor about clinical trials that may be right for your child. General information about clinical trials is available from the NCI website.\n",
      "\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t                \n",
      "\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t                \n",
      "\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t                    Acute Promyelocytic Leukemia\n",
      "\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t                    Treatment of acute promyelocytic leukemia may include the following:         -  All-trans retinoic acid (ATRA) plus chemotherapy.    -  Arsenic trioxide therapy.    -  Central nervous system sanctuary therapy with intrathecal chemotherapy.        Check the list of NCI-supported cancer clinical trials that are now accepting patients with childhood acute promyelocytic leukemia (M3). For more specific results, refine the search by using other search features, such as the location of the trial, the type of treatment, or the name of the drug. Talk with your child's doctor about clinical trials that may be right for your child. General information about clinical trials is available from the NCI website.\n",
      "\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t                \n",
      "\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t                \n",
      "\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t                    Recurrent Acute Promyelocytic Leukemia\n",
      "\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t                    Treatment of recurrent acute promyelocytic leukemia may include the following:         -  All-trans retinoic acid therapy (ATRA) plus chemotherapy.    -  Arsenic trioxide therapy.    -  Targeted therapy with a monoclonal antibody (gemtuzumab), if special approval is given.     -  Stem cell transplant using blood stem cells from the patient or a donor.\n",
      "\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t                \n",
      "\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t                \n",
      "\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t                    Childhood Chronic Myelogenous Leukemia\n",
      "\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t                    Treatment for childhood chronic myelogenous leukemia may include the following:         -  Targeted therapy with a tyrosine kinase inhibitor (imatinib).    - A clinical trial of targeted therapy with other tyrosine kinase inhibitors.        For patients whose disease does not respond to therapy with imatinib or whose disease comes back after treatment, treatment may include the following:         -  Stem cell transplant using blood stem cells from a donor.    - A clinical trial of targeted therapy with other tyrosine kinase inhibitors.        Check the list of NCI-supported cancer clinical trials that are now accepting patients with childhood chronic myelogenous leukemia. For more specific results, refine the search by using other search features, such as the location of the trial, the type of treatment, or the name of the drug. Talk with your child's doctor about clinical trials that may be right for your child. General information about clinical trials is available from the NCI website.\n",
      "\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t                \n",
      "\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t                \n",
      "\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t                    Juvenile Myelomonocytic Leukemia\n",
      "\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t                    Treatment of juvenile myelomonocytic leukemia (JMML) may include the following:         -  Combination chemotherapy followed by stem cell transplant. If JMML recurs after stem cell transplant, a second stem cell transplant may be done.        Check the list of NCI-supported cancer clinical trials that are now accepting patients with juvenile myelomonocytic leukemia. For more specific results, refine the search by using other search features, such as the location of the trial, the type of treatment, or the name of the drug. Talk with your child's doctor about clinical trials that may be right for your child. General information about clinical trials is available from the NCI website.\n",
      "\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t                \n",
      "\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t                \n",
      "\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t                    Myelodysplastic Syndromes\n",
      "\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t                    Treatment of myelodysplastic syndromes (MDS) may include the following:         -  Watchful waiting.    -  Stem cell transplant using blood stem cells from a donor.    -  Combination chemotherapy.    -  Lenalidomide therapy.    - A clinical trial of stem cell transplant using lower doses of chemotherapy.    - A clinical trial of a new anticancer drug or targeted therapy.        If the MDS becomes acute myeloid leukemia (AML), treatment will be the same as treatment for newly diagnosed AML.   Treatment of therapy-related MDS is usually the same as for newly diagnosed AML, followed by stem cell transplant.   Transient myeloproliferative disorder (TMD), a type of MDS, usually goes away on its own. For TMD that does not go away on its own, treatment may include the following:         -  Transfusion therapy.    -  Leukapheresis.    -  Chemotherapy.        Check the list of NCI-supported cancer clinical trials that are now accepting patients with childhood myelodysplastic syndromes. For more specific results, refine the search by using other search features, such as the location of the trial, the type of treatment, or the name of the drug. Talk with your child's doctor about clinical trials that may be right for your child. General information about clinical trials is available from the NCI website.\n"
     ]
    }
   ],
   "source": [
    "large_a = qa_df.sort_values(by=\"answer\", key=lambda x: x.str.len(), ascending=False).head()\n",
    "\n",
    "for _, row in large_a.iterrows():\n",
    "    pretty_print_row(row)"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "When it comes to answers, the extremes appear to demonstrate non-helpful responses to the given queries. Short answers are usually follow-up questions, or don't provide the expected level of detail. For longer responses, the answers appear to repeat content, as well as go beyond the specific question, complementing with additional questions. It might be safe to assume that the extremes for questions are not useful for our task. Let's visualize the response length distribution"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 20,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "<Axes: >"
      ]
     },
     "execution_count": 20,
     "metadata": {},
     "output_type": "execute_result"
    },
    {
     "data": {
      "image/png": "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",
      "text/plain": [
       "<Figure size 800x400 with 2 Axes>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "\n",
    "a_len_df = qa_df.apply(lambda x: len(x['answer']), axis=1)\n",
    "plt.figure(figsize=(8, 4))\n",
    "\n",
    "plt.subplot(1, 2, 1)\n",
    "sns.histplot(a_len_df, bins=40, kde=True)\n",
    "\n",
    "plt.subplot(1, 2, 2)\n",
    "sns.boxplot(a_len_df)"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "We can observe an extreme right-skewed distribution. A simple method to handle outliers due to response length is by imposing a limit based on quantiles. Given the skewness, we will use a more conservative value for our lower limit of 1% of the data, while for the upper limit we will use the standard 95%."
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 30,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Upper limit for answer length: 3356.199999999997\n",
      "Lower limit for answer length: 73.0\n",
      "============================\n",
      "Q: How to diagnose Diabetic Heart Disease ?\n",
      "A: Your doctor will diagnose diabetic heart disease (DHD) based on your signs and symptoms, medical and family histories, a physical exam, and the results from tests and procedures.\n",
      "                \n",
      "Doctors and researchers are still trying to find out whether routine testing for DHD will benefit people who have diabetes but no heart disease symptoms.\n",
      "                \n",
      "Initial Tests\n",
      "                \n",
      "No single test can diagnose DHD, which may involve coronary heart disease (CHD), heart failure, and/or diabetic cardiomyopathy. Initially, your doctor may recommend one or more of the following tests.\n",
      "                \n",
      "Blood Pressure Measurement\n",
      "                \n",
      "To measure your blood pressure, your doctor or nurse will use some type of a gauge, a stethoscope (or electronic sensor), and a blood pressure cuff.\n",
      "                \n",
      "Most often, you'll sit or lie down with the cuff around your arm as your doctor or nurse checks your blood pressure. If he or she doesn't tell you what your blood pressure numbers are, you should ask.\n",
      "                \n",
      "Blood Tests\n",
      "                \n",
      "Blood tests check the levels of certain fats, cholesterol, sugar, and proteins in your blood. Abnormal levels of these substances may show that you're at risk for DHD.\n",
      "                \n",
      "A blood test also can check the level of a hormone called BNP (brain natriuretic peptide) in your blood. The heart makes BNP, and the level of BNP rises during heart failure.\n",
      "                \n",
      "Chest X Ray\n",
      "                \n",
      "A chest x ray takes pictures of the organs and structures inside your chest, such as your heart, lungs, and blood vessels. A chest x ray can reveal signs of heart failure.\n",
      "                \n",
      "EKG (Electrocardiogram)\n",
      "                \n",
      "An EKG is a simple, painless test that detects and records your heart's electrical activity. The test shows how fast your heart is beating and its rhythm (steady or irregular). An EKG also records the strength and timing of electrical signals as they pass through your heart.\n",
      "                \n",
      "An EKG can show signs of heart damage due to CHD and signs of a previous or current heart attack.\n",
      "                \n",
      "Stress Test\n",
      "                \n",
      "Some heart problems are easier to diagnose when your heart is working hard and beating fast. Stress testing gives your doctor information about how your heart works during physical stress.\n",
      "                \n",
      "During a stress test, you exercise (walk or run on a treadmill or pedal a bicycle) to make your heart work hard and beat fast. Tests are done on your heart while you exercise. If you cant exercise, you may be given medicine to raise your heart rate.\n",
      "                \n",
      "Urinalysis\n",
      "                \n",
      "For this test, you'll give a sample of urine for analysis. The sample is checked for abnormal levels of protein or blood cells. In people who have diabetes, protein in the urine is a risk factor for DHD.\n",
      "                \n",
      "Other Tests and Procedures\n",
      "                \n",
      "Your doctor may refer you to a cardiologist if your initial test results suggest that you have a form of DHD. A cardiologist is a doctor who specializes in diagnosing and treating heart diseases and conditions.\n",
      "                \n",
      "The cardiologist may recommend other tests or procedures to get more detailed information about the nature and extent of your DHD.\n",
      "                \n",
      "For more information about other tests and procedures, go to the diagnosis sections of the Health Topics Coronary Heart Disease, Heart Failure, and Cardiomyopathy articles.\n",
      "============================\n",
      "Q: Who is at risk for Iron-Deficiency Anemia? ?\n",
      "A: Infants and Young Children\n",
      "                \n",
      "Infants and young children need a lot of iron to grow and develop. The iron that full-term infants have stored in their bodies is used up in the first 4 to 6 months of life.\n",
      "                \n",
      "Premature and low-birth-weight babies (weighing less than 5.5 pounds) are at even greater risk for iron-deficiency anemia. These babies don't have as much iron stored in their bodies as larger, full-term infants.\n",
      "                \n",
      "Iron-fortified baby food or iron supplements, when used properly, can help prevent iron-deficiency anemia in infants and young children. Talk with your child's doctor about your child's diet.\n",
      "                \n",
      "Young children who drink a lot of cow's milk may be at risk for iron-deficiency anemia. Milk is low in iron, and too much milk may take the place of iron-rich foods in the diet. Too much milk also may prevent children's bodies from absorbing iron from other foods.\n",
      "                \n",
      "Children who have lead in their blood also may be at risk for iron-deficiency anemia. Lead can interfere with the body's ability to make hemoglobin. Lead may get into the body from breathing in lead dust, eating lead in paint or soil, or drinking water that contains lead.\n",
      "                \n",
      "Teens\n",
      "                \n",
      "Teens are at risk for iron-deficiency anemia if they're underweight or have chronic (ongoing) illnesses. Teenage girls who have heavy periods also are at increased risk for the condition.\n",
      "                \n",
      "Women\n",
      "                \n",
      "Women of childbearing age are at higher risk for iron-deficiency anemia because of blood loss during their monthly periods. About 1 in 5 women of childbearing age has iron-deficiency anemia.\n",
      "                \n",
      "Pregnant women also are at higher risk for the condition because they need twice as much iron as usual. The extra iron is needed for increased blood volume and for the fetus' growth.\n",
      "                \n",
      "About half of all pregnant women develop iron-deficiency anemia. The condition can increase a pregnant woman's risk for a premature or low-birth-weight baby.\n",
      "                \n",
      "Adults Who Have Internal Bleeding\n",
      "                \n",
      "Adults who have internal bleeding, such as intestinal bleeding, can develop iron-deficiency anemia due to blood loss. Certain conditions, such as colon cancer and bleeding ulcers, can cause blood loss. Some medicines, such as aspirin, also can cause internal bleeding.\n",
      "                \n",
      "Other At-Risk Groups\n",
      "                \n",
      "People who get kidney dialysis treatment may develop iron-deficiency anemia. This is because blood is lost during dialysis. Also, the kidneys are no longer able to make enough of a hormone that the body needs to produce red blood cells.\n",
      "                \n",
      "People who have gastric bypass surgery also may develop iron-deficiency anemia. This type of surgery can prevent the body from absorbing enough iron.\n",
      "                \n",
      "Certain eating patterns or habits may put you at higher risk for iron-deficiency anemia. This can happen if you:\n",
      "                \n",
      "Follow a diet that excludes meat and fish, which are the best sources of iron. However, vegetarian diets can provide enough iron if you eat the right foods. For example, good nonmeat sources of iron include iron-fortified breads and cereals, beans, tofu, dried fruits, and spinach and other dark green leafy vegetables.\n",
      "                \n",
      "Eat poorly because of money, social, health, or other problems.\n",
      "                \n",
      "Follow a very low-fat diet over a long time. Some higher fat foods, like meat, are the best sources of iron.\n",
      "                \n",
      "Follow a high-fiber diet. Large amounts of fiber can slow the absorption of iron.\n",
      "============================\n",
      "Q: What is (are) abdominal wall defect ?\n",
      "A: An abdominal wall defect is an opening in the abdomen through which various abdominal organs can protrude. This opening varies in size and can usually be diagnosed early in fetal development, typically between the tenth and fourteenth weeks of pregnancy. There are two main types of abdominal wall defects: omphalocele and gastroschisis. Omphalocele is an opening in the center of the abdominal wall where the umbilical cord meets the abdomen. Organs (typically the intestines, stomach, and liver) protrude through the opening into the umbilical cord and are covered by the same protective membrane that covers the umbilical cord. Gastroschisis is a defect in the abdominal wall, usually to the right of the umbilical cord, through which the large and small intestines protrude (although other organs may sometimes bulge out). There is no membrane covering the exposed organs in gastroschisis.  Fetuses with omphalocele may grow slowly before birth (intrauterine growth retardation) and they may be born prematurely. Individuals with omphalocele frequently have multiple birth defects, such as a congenital heart defect. Additionally, underdevelopment of the lungs is often associated with omphalocele because the abdominal organs normally provide a framework for chest wall growth. When those organs are misplaced, the chest wall does not form properly, providing a smaller than normal space for the lungs to develop. As a result, many infants with omphalocele have respiratory insufficiency and may need to be supported with a machine to help them breathe (mechanical ventilation). Rarely, affected individuals who have breathing problems in infancy experience recurrent lung infections or asthma later in life. Affected infants often have gastrointestinal problems including a backflow of stomach acids into the esophagus (gastroesophageal reflux) and feeding difficulty; these problems can persist even after treatment of omphalocele. Large omphaloceles or those associated with multiple additional health problems are more often associated with fetal death than cases in which omphalocele occurs alone (isolated).  Omphalocele is a feature of many genetic syndromes. Nearly half of individuals with omphalocele have a condition caused by an extra copy of one of the chromosomes in each of their cells (trisomy). Up to one-third of people born with omphalocele have a genetic condition called Beckwith-Wiedemann syndrome. Affected individuals may have additional signs and symptoms associated with these genetic conditions.  Individuals who have gastroschisis rarely have other birth defects and seldom have chromosome abnormalities or a genetic condition. Most affected individuals experience intrauterine growth retardation and are small at birth; many affected infants are born prematurely.  With gastroschisis, the protruding organs are not covered by a protective membrane and are susceptible to damage due to direct contact with amniotic fluid in the womb. Components of the amniotic fluid may trigger immune responses and inflammatory reactions against the intestines that can damage the tissue. Constriction around exposed organs at the abdominal wall opening late in fetal development may also contribute to organ injury. Intestinal damage causes impairment of the muscle contractions that move food through the digestive tract (peristalsis) in most children with gastroschisis. In these individuals, peristalsis usually improves in a few months and intestinal muscle contractions normalize. Rarely, children with gastroschisis have a narrowing or absence of a portion of intestine (intestinal atresia) or twisting of the intestine. After birth, these intestinal malformations can lead to problems with digestive function, further loss of intestinal tissue, and a condition called short bowel syndrome that occurs when areas of the small intestine are missing, causing dehydration and poor absorption of nutrients. Depending on the severity of the condition, intravenous feedings (parenteral nutrition) may be required.  The health of an individual with gastroschisis depends largely on how damaged his or her intestine was before birth. When the abdominal wall defect is repaired and normal intestinal function is recovered, the vast majority of affected individuals have no health problems related to the repaired defect later in life.\n",
      "============================\n",
      "Q: What are the symptoms of Opitz G/BBB syndrome ?\n",
      "A: What are the signs and symptoms of Opitz G/BBB syndrome? Opitz G/BBB syndrome mainly affects structures along the midline of the body. The most common features of the condition are wide-spaced eyes (hypertelorism); defects of the larynx, trachea, and/or esophagus causing breathing problems and difficulty swallowing (dysphagia); and in males, the urethra opening on the underside of the penis (hypospadias). Mild intellectual disability and developmental delay occur in about 50 percent of people with Opitz G/BBB syndrome. Delays in motor skills, speech delays, and learning difficulties may also occur. Some individuals with Opitz G/BBB syndrome have features similar to autistic spectrum disorders, including impaired communication and socialization skills. About half of affected individuals also have cleft lip with or without a cleft palate. Some have cleft palate alone. Heart defects, an obstruction of the anal opening (imperforate anus), and brain defects such as an absence of the tissue connecting the left and right halves of the brain (agenesis of the corpus callosum) occur in less than 50 percent of those affected. Facial abnormalities that may be seen in this disorder can include a flat nasal bridge, thin upper lip, and low set ears. These features vary among affected individuals, even within the same family. The signs and symptoms of the autosomal dominant form of the condition are comparable to those seen in the X-linked form. However, the X-linked form of Opitz G/BBB syndrome tends to include cleft lip with or without cleft palate, while cleft palate alone is more common in the autosomal dominant form. Females with X-linked Opitz G/BBB syndrome are usually mildly affected, as hypertelorism may be the only sign of the disorder. The Human Phenotype Ontology provides the following list of signs and symptoms for Opitz G/BBB syndrome. If the information is available, the table below includes how often the symptom is seen in people with this condition. You can use the MedlinePlus Medical Dictionary to look up the definitions for these medical terms. Signs and Symptoms Approximate number of patients (when available) Abnormality of the pharynx 90% Anteverted nares 90% Displacement of the external urethral meatus 90% Epicanthus 90% Abnormality of the voice 50% Cognitive impairment 50% Respiratory insufficiency 50% Increased number of teeth 7.5% Low-set, posteriorly rotated ears 7.5% Pectus carinatum 7.5% Pectus excavatum 7.5% Prominent metopic ridge 7.5% Reduced number of teeth 7.5% Sensorineural hearing impairment 7.5% Craniosynostosis 5% Abnormality of cardiovascular system morphology - Abnormality of the kidney - Abnormality of the nasopharynx - Abnormality of the ureter - Absent gallbladder - Agenesis of corpus callosum - Anal atresia - Anal stenosis - Aplasia/Hypoplasia of the cerebellar vermis - Aspiration - Atria septal defect - Autosomal dominant inheritance - Bifid scrotum - Bifid uvula - Cavum septum pellucidum - Cerebellar vermis hypoplasia - Cerebral cortical atrophy - Cleft palate - Cleft upper lip - Coarctation of aorta - Conductive hearing impairment - Cranial asymmetry - Cryptorchidism - Depressed nasal bridge - Diastasis recti - Dysphagia - Frontal bossing - Gastroesophageal reflux - Hiatus hernia - High palate - Hypertelorism - Hypospadias - Inguinal hernia - Intellectual disability - Laryngeal cleft - Muscular hypotonia - Patent ductus arteriosus - Posterior pharyngeal cleft - Posteriorly rotated ears - Prominent forehead - Pulmonary hypertension - Pulmonary hypoplasia - Short lingual frenulum - Smooth philtrum - Strabismus - Telecanthus - Tracheoesophageal fistula - Umbilical hernia - Ventricular septal defect - Ventriculomegaly - Weak cry - Wide nasal bridge - Widow's peak - X-linked recessive inheritance - The Human Phenotype Ontology (HPO) has collected information on how often a sign or symptom occurs in a condition. Much of this information comes from Orphanet, a European rare disease database. The frequency of a sign or symptom is usually listed as a rough estimate of the percentage of patients who have that feature. The frequency may also be listed as a fraction. The first number of the fraction is how many people had the symptom, and the second number is the total number of people who were examined in one study. For example, a frequency of 25/25 means that in a study of 25 people all patients were found to have that symptom. Because these frequencies are based on a specific study, the fractions may be different if another group of patients are examined. Sometimes, no information on frequency is available. In these cases, the sign or symptom may be rare or common.\n",
      "============================\n",
      "Q: How to prevent Coronary Microvascular Disease ?\n",
      "A: No specific studies have been done on how to prevent coronary microvascular disease.\n",
      "                \n",
      "Researchers dont yet know how or in what way preventing coronary microvascular disease differs from preventing coronary heart disease. Coronary microvascular disease affects the tiny coronary arteries; coronary heart disease affects the large coronary arteries.\n",
      "                \n",
      "Taking action to control risk factors for heart disease can help prevent or delay coronary heart disease. You cant control some risk factors, such as older age and family history of heart disease. However, you can take steps to prevent or control other risk factors, such as high blood pressure, overweight and obesity, high blood cholesterol, diabetes, and smoking.\n",
      "                \n",
      "Heart-healthy lifestyle changes and ongoing medical care can help you lower your risk for heartdisease.\n",
      "                \n",
      "Heart-Healthy Lifestyle Changes\n",
      "                \n",
      "Your doctor may recommend heart-healthy lifestyle changes if you have coronary microvascular disease. Heart-healthy lifestyle changes include:\n",
      "                \n",
      "Heart-healthy eating\n",
      "                \n",
      "Maintaining a healthy weight\n",
      "                \n",
      "Managing stress\n",
      "                \n",
      "Physical activity\n",
      "                \n",
      "Quitting smoking\n",
      "                \n",
      "Heart-Healthy Eating\n",
      "                \n",
      "Your doctor may recommend a heart-healthy eating plan, which should include:\n",
      "                \n",
      "Fat-free or low-fat dairy products, such as skim milk\n",
      "                \n",
      "Fish high in omega-3 fatty acids, such as salmon, tuna, and trout, about twice a week\n",
      "                \n",
      "Fruits, such as apples, bananas, oranges, pears, and prunes\n",
      "                \n",
      "Legumes, such as kidney beans, lentils, chickpeas, black-eyed peas, and lima beans\n",
      "                \n",
      "Vegetables, such as broccoli, cabbage, and carrots\n",
      "                \n",
      "Whole grains, such as oatmeal, brown rice, and corn tortillas.\n",
      "                \n",
      "When following a heart-healthy diet, you should avoid eating:\n",
      "                \n",
      "A lot of red meat\n",
      "                \n",
      "Palm and coconut oils\n",
      "                \n",
      "Sugary foods and beverages\n",
      "                \n",
      "Two nutrients in your diet make blood cholesterol levels rise:\n",
      "                \n",
      "Saturated fatfound mostly in foods that come from animals\n",
      "                \n",
      "Trans fat (trans fatty acids)found in foods made with hydrogenated oils and fats, such as stick margarine; baked goods, such as cookies, cakes, and pies; crackers; frostings; and coffee creamers. Some trans fats also occur naturally in animal fats andmeats.\n",
      "                \n",
      "Saturated fat raises your blood cholesterol more than anything else in your diet. When you follow a heart-healthy eating plan, only 5 percent to 6 percent of your daily calories should come from saturated fat. Food labels list the amounts of saturated fat. To help you stay on track, here are some examples:\n",
      "                \n",
      "1,200 calories a day\n",
      "                \n",
      "8 grams of saturated fat a day\n",
      "                \n",
      "1,500 calories a day\n",
      "                \n",
      "10 grams of saturated fat a day\n",
      "                \n",
      "1,800 calories a day\n",
      "                \n",
      "12 grams of saturated fat a day\n",
      "                \n",
      "2,000 calories a day\n",
      "                \n",
      "13 grams of saturated fat a day\n",
      "                \n",
      "2,500 calories a day\n",
      "                \n",
      "17 grams of saturated fat a day\n",
      "                \n",
      "Not all fats are bad. Monounsaturated and polyunsaturated fats actually help lower blood cholesterollevels.\n",
      "                \n",
      "Some sources of monounsaturated and polyunsaturated fats are:\n",
      "                \n",
      "Avocados\n",
      "                \n",
      "Corn, sunflower, and soybean oils\n",
      "                \n",
      "Nuts and seeds, such as walnuts\n",
      "                \n",
      "Olive, canola, peanut, safflower, and sesame oils\n",
      "                \n",
      "Peanut butter\n",
      "                \n",
      "Salmon and trout\n",
      "                \n",
      "Tofu\n",
      "                \n",
      "Sodium\n",
      "                \n",
      "You should try to limit the amount of sodium that you eat. This means choosing and preparing foods that are lower in salt and sodium. Try to use low-sodium and no added salt foods and seasonings at the table or while cooking. Food labels tell you what you need to know about choosing foods that are lower in sodium. Try to eat no more than 2,300 milligrams of sodium a day. If you have high blood pressure, you may need to restrict your sodium intake even more.\n",
      "                \n",
      "Dietary Approaches to Stop Hypertension\n",
      "                \n",
      "Your doctor may recommend the Dietary Approaches to Stop Hypertension (DASH) eating plan if you have high blood pressure. The DASH eating plan focuses on fruits, vegetables, whole grains, and other foods that are heart healthy and low in fat, cholesterol, and sodium and salt.\n",
      "                \n",
      "The DASH eating plan is a good heart-healthy eating plan, even for those who dont have high blood pressure. Read more about DASH.\n",
      "                \n",
      "Alcohol\n",
      "                \n",
      "Try to limit alcohol intake. Too much alcohol canraise your blood pressure and triglyceride levels, a type of fat found in the blood. Alcohol also adds extra calories, which may cause weight gain.\n",
      "                \n",
      "Men should have no more than two drinks containing alcohol a day. Women should have no more than one drink containing alcohol a day. One drink is:\n",
      "                \n",
      "12 ounces of beer\n",
      "                \n",
      "5 ounces of wine\n",
      "                \n",
      "1 ounces of liquor\n",
      "                \n",
      "Maintaining a Healthy Weight\n",
      "                \n",
      "Maintaining a healthy weight is important for overall health and can lower your risk for coronary heart disease. Aim for a Healthy Weight by following a heart-healthy eating plan and keeping physically active.\n",
      "                \n",
      "Knowing your body mass index (BMI) helps you find out if youre a healthy weight in relation to your height and gives an estimate of your total body fat. To figure out your BMI, check out the National Heart, Lung, and Blood Institutes (NHLBI) online BMI calculator or talk to your doctor. A BMI:\n",
      "                \n",
      "Below 18.5 is a sign that you are underweight.\n",
      "                \n",
      "Between 18.5 and 24.9 is in the normal range.\n",
      "                \n",
      "Between 25 and 29.9 is considered overweight.\n",
      "                \n",
      "Of 30 or more is considered obese.\n",
      "                \n",
      "A general goal to aim for is a BMI below 25. Your doctor or health care provider can help you set an appropriate BMI goal.\n",
      "                \n",
      "Measuring waist circumference helps screen for possible health risks. If most of your fat is around your waist rather than at your hips, youre at a higher risk for heart disease and type 2 diabetes. This risk may be high with a waist size that is greater than 35 inches for women or greater than 40 inches for men. To learn how to measure your waist, visit Assessing Your Weight and Health Risk.\n",
      "                \n",
      "If youre overweight or obese, try to lose weight. A loss of just 3 percent to 5 percent of your current weight can lower your triglycerides, blood glucose, and the risk of developing type 2 diabetes. Greater amounts of weight loss can improve blood pressure readings, lower LDL cholesterol, and increase HDL cholesterol.\n",
      "                \n",
      "Managing Stress\n",
      "                \n",
      "Research shows that the most commonly reported trigger for a heart attack is an emotionally upsetting eventparticularly one involving anger. Also, some of the ways people cope with stresssuch as drinking, smoking, or overeatingarent healthy.\n",
      "                \n",
      "Learning how to manage stress, relax, and cope with problems can improve your emotional and physical health. Consider healthy stress-reducing activities, such as:\n",
      "                \n",
      "A stress management program\n",
      "                \n",
      "Meditation\n",
      "                \n",
      "Physical activity\n",
      "                \n",
      "Relaxation therapy\n",
      "                \n",
      "Talking things out with friends or family\n",
      "                \n",
      "Physical Activity\n",
      "                \n",
      "Routine physical activity can lower many coronary heart disease risk factors, including LDL (bad) cholesterol, high blood pressure, and excess weight. Physical activity also can lower your risk for diabetes and raise your HDL cholesterol level. HDL is the good cholesterol that helps prevent coronary heart disease.\n",
      "                \n",
      "Everyone should try to participate in moderate-intensity aerobic exercise at least 2hours and 30minutes per week, or vigorous aerobic exercise for 1hour and 15minutes per week. Aerobic exercise, such as brisk walking, is any exercise in which your heart beats faster and you use more oxygen than usual. The more active you are, the more you will benefit. Participate in aerobic exercise for at least 10minutes at a time spread throughout the week.\n",
      "                \n",
      "Read more about physical activity at:\n",
      "                \n",
      "Physical Activity and Your Heart\n",
      "                \n",
      "U.S. Department of Health and Human Services 2008 Physical Activity Guidelines forAmericans\n",
      "                \n",
      "Talk with your doctor before you start a new exercise plan. Ask your doctor how much and what kinds of physical activity are safe for you.\n",
      "                \n",
      "Quitting Smoking\n",
      "                \n",
      "If you smoke, quit. Smoking can raise your risk for coronary heart disease and heart attack and worsen other coronary heart disease risk factors. Talk with your doctor about programs and products that can help you quit smoking. Also, try to avoid secondhand smoke.\n",
      "                \n",
      "If you have trouble quitting smoking on your own, consider joining a support group. Many hospitals, workplaces, and community groups offer classes to help people quit smoking.\n",
      "                \n",
      "Read more about quitting smoking at Smoking and Your Heart.\n",
      "                \n",
      "Ongoing Medical Care\n",
      "                \n",
      "Learn more about heart disease and the traits, conditions, and habits that can raise your risk for developing it. Talk with your doctor about your risk factors for heart disease and how to controlthem.\n",
      "                \n",
      "If lifestyle changes arent enough, your doctor may prescribe medicines to control your risk factors. Take all of your medicines as your doctor advises. Visit your doctor regularly and have recommended testing.\n",
      "                \n",
      "Know your numbers. Ask your doctor for these three tests and have the results explained toyou:\n",
      "                \n",
      "Blood pressure measurement.\n",
      "                \n",
      "Fasting blood glucose. This test is for diabetes.\n",
      "                \n",
      "Lipoprotein panel. This test measures total cholesterol, LDL (bad) cholesterol, HDL (good) cholesterol, and triglycerides (a type of fat in the blood).\n",
      "                \n",
      "Finally, know your family history of heart disease. If you or someone in your family has heart disease, tell your doctor.\n"
     ]
    }
   ],
   "source": [
    "upper_limit = qa_df['answer'].apply(lambda x: len(x)).quantile(0.95)\n",
    "print(\"Upper limit for answer length:\", upper_limit)\n",
    "\n",
    "lower_limit = qa_df['answer'].apply(lambda x: len(x)).quantile(0.01)\n",
    "print(\"Lower limit for answer length:\", lower_limit)\n",
    "\n",
    "len_outliers = qa_df[(qa_df['answer'].apply(lambda x: len(x)) > upper_limit) | (qa_df['answer'].apply(lambda x: len(x)) < lower_limit)]\n",
    "\n",
    "for _, row in len_outliers.sample(5).iterrows():\n",
    "    pretty_print_row(row)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 32,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "application/vnd.microsoft.datawrangler.viewer.v0+json": {
       "columns": [
        {
         "name": "index",
         "rawType": "object",
         "type": "string"
        },
        {
         "name": "question",
         "rawType": "object",
         "type": "unknown"
        },
        {
         "name": "answer",
         "rawType": "object",
         "type": "unknown"
        }
       ],
       "conversionMethod": "pd.DataFrame",
       "ref": "21f6317d-b8ce-4a10-8021-5395a858df13",
       "rows": [
        [
         "count",
         "13593",
         "13593"
        ],
        [
         "unique",
         "13593",
         "13593"
        ],
        [
         "top",
         "What is (are) Glaucoma ?",
         "Glaucoma is a group of diseases that can damage the eye's optic nerve and result in vision loss and blindness. The most common form of the disease is open-angle glaucoma. With early treatment, you can often protect your eyes against serious vision loss. (Watch the video to learn more about glaucoma. To enlarge the video, click the brackets in the lower right-hand corner. To reduce the video, press the Escape (Esc) button on your keyboard.)  See this graphic for a quick overview of glaucoma, including how many people it affects, whos at risk, what to do if you have it, and how to learn more.  See a glossary of glaucoma terms."
        ],
        [
         "freq",
         "1",
         "1"
        ]
       ],
       "shape": {
        "columns": 2,
        "rows": 4
       }
      },
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>question</th>\n",
       "      <th>answer</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>count</th>\n",
       "      <td>13593</td>\n",
       "      <td>13593</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>unique</th>\n",
       "      <td>13593</td>\n",
       "      <td>13593</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>top</th>\n",
       "      <td>What is (are) Glaucoma ?</td>\n",
       "      <td>Glaucoma is a group of diseases that can damag...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>freq</th>\n",
       "      <td>1</td>\n",
       "      <td>1</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "                        question  \\\n",
       "count                      13593   \n",
       "unique                     13593   \n",
       "top     What is (are) Glaucoma ?   \n",
       "freq                           1   \n",
       "\n",
       "                                                   answer  \n",
       "count                                               13593  \n",
       "unique                                              13593  \n",
       "top     Glaucoma is a group of diseases that can damag...  \n",
       "freq                                                    1  "
      ]
     },
     "execution_count": 32,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "qa_df = qa_df[(qa_df['answer'].apply(lambda x: len(x)) <= upper_limit) & (qa_df['answer'].apply(lambda x: len(x)) >= lower_limit)]\n",
    "qa_df.describe()"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "After outlier handling, our dataset is now comprised of 13593 cases. This is still a relatively large dataset, and we have now taken some measurements to identify and handle issues.\n",
    "\n",
    "### Q. What are relevant representative words?\n",
    "\n",
    "Understanding which words are representative on the dataset can help us identify possible external datasets that are related and can therefore add value to the task. For this, we can use NLTK to remove stop words and lemmatize the text. By standardizing and removing noise, we should be able to detect relevant words in the data"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 46,
   "metadata": {},
   "outputs": [
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "[nltk_data] Downloading package punkt_tab to\n",
      "[nltk_data]     /Users/alejandroaristizabal/nltk_data...\n",
      "[nltk_data]   Package punkt_tab is already up-to-date!\n"
     ]
    }
   ],
   "source": [
    "import re\n",
    "import nltk\n",
    "from nltk.corpus import stopwords\n",
    "from nltk.tokenize import word_tokenize\n",
    "from nltk.stem import WordNetLemmatizer\n",
    "\n",
    "nltk.download('punkt_tab')\n",
    "\n",
    "stop_words = set(stopwords.words('english'))\n",
    "lemmatizer = WordNetLemmatizer()\n",
    "\n",
    "def remove_stopwords(text: str) -> str:\n",
    "    # nltk doesn't remove punctuation, so let's do that with regex\n",
    "    text = re.sub(r'[^\\w]', ' ', text)\n",
    "    word_tokens = word_tokenize(text)\n",
    "    filtered_sentence = [w for w in word_tokens if w.lower() not in stop_words]\n",
    "    return ' '.join(filtered_sentence)\n",
    "\n",
    "def lemmatize(text: str) -> str:\n",
    "    word_tokens = word_tokenize(text)\n",
    "    lemmatized_sentence = [lemmatizer.lemmatize(w) for w in word_tokens]\n",
    "    return ' '.join(lemmatized_sentence)\n",
    "\n",
    "answer_words_df = qa_df['answer'].apply(remove_stopwords).apply(lemmatize).str.split()\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 48,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "answer\n",
       "symptom        24124\n",
       "may            18166\n",
       "people         14629\n",
       "sign           14369\n",
       "condition      13658\n",
       "frequency      10703\n",
       "gene           10596\n",
       "information    10351\n",
       "patient         9712\n",
       "syndrome        9299\n",
       "number          9296\n",
       "disease         9146\n",
       "cell            8869\n",
       "cause           8297\n",
       "also            7651\n",
       "90              7170\n",
       "available       7010\n",
       "study           6987\n",
       "5               6847\n",
       "often           6825\n",
       "Name: count, dtype: int64"
      ]
     },
     "execution_count": 48,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "answer_word_count = answer_words_df.explode().value_counts()\n",
    "answer_word_count.head(20)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 49,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "answer\n",
       "polariscopic             1\n",
       "intensely                1\n",
       "osteoma                  1\n",
       "Fundic                   1\n",
       "Fibroadenoma             1\n",
       "Odontogenic              1\n",
       "Osteoma                  1\n",
       "Sulindac                 1\n",
       "striped                  1\n",
       "delirious                1\n",
       "ectropium                1\n",
       "penetrate                1\n",
       "Classically              1\n",
       "appreciated              1\n",
       "disputed                 1\n",
       "acetylglucosaminidase    1\n",
       "Mitten                   1\n",
       "Phimosis                 1\n",
       "alkalization             1\n",
       "fork                     1\n",
       "Name: count, dtype: int64"
      ]
     },
     "execution_count": 49,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "answer_word_count.tail(20)"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## Exploring other datasets\n",
    "The dataset provided for the task demonstrates the desired behavior of our machine learning pipeline. Because of this, it might be useful to consider it for evaluation purposes, while using other sources to complement our pipeline. Because of this, we want to explore what other relevant sources are there and how they can be used. Huggingface provides a huge repository of data for different topics, needs and use-cases. From a quick investigation of their repositories, the following dataset comes to mind:\n",
    "\n",
    "- `gamino/wiki_medical_terms`: This dataset contains ~6.86k rows of medical terms, accompanied of detailed description of each term, including signs, symptoms, causes, etc of conditions.\n",
    "\n",
    "We've also identified `keivalya/MedQuad-MedicalQnADataset` as the source of the originally provided datset."
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 62,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Page Title: Paracetamol poisoning\n",
      "Page Text: Paracetamol poisoning, also known as acetaminophen poisoning, is caused by excessive use of the medication paracetamol (acetaminophen). Most people have few or non-specific symptoms in the first 24 hours following overdose. These include feeling tired, abdominal pain, or nausea. This is typically followed by a couple of days without any symptoms, after which yellowish skin, blood clotting problems, and confusion occurs as a result of liver failure. Additional complications may include kidney fai\n",
      "\n",
      "\n",
      "Page Title: Acromegaly\n",
      "Page Text: Acromegaly is a disorder that results from excess growth hormone (GH) after the growth plates have closed. The initial symptom is typically enlargement of the hands and feet. There may also be an enlargement of the forehead, jaw, and nose. Other symptoms may include joint pain, thicker skin, deepening of the voice, headaches, and problems with vision. Complications of the disease may include type 2 diabetes, sleep apnea, and high blood pressure.Acromegaly is usually caused by the pituitary gland\n",
      "\n",
      "\n",
      "Page Title: Actinic keratosis\n",
      "Page Text: Actinic keratosis (AK), sometimes called solar keratosis or senile keratosis, is a pre-cancerous area of thick, scaly, or crusty skin. Actinic keratosis is a disorder (-osis) of epidermal keratinocytes that is induced by ultraviolet (UV) light exposure (actin-). These growths are more common in fair-skinned people and those who are frequently in the sun. They are believed to form when skin gets damaged by UV radiation from the sun or indoor tanning beds, usually over the course of decades. Given\n",
      "\n",
      "\n",
      "Page Title: Congenital adrenal hyperplasia\n",
      "Page Text: Congenital adrenal hyperplasia (CAH) is a group of autosomal recessive disorders characterized by impaired cortisol synthesis. It results from the deficiency of one of the five enzymes required for the synthesis of cortisol in the adrenal cortex. Most of these disorders involve excessive or deficient production of hormones such as glucocorticoids, mineralocorticoids, or sex steroids, and can alter development of primary or secondary sex characteristics in some affected infants, children, or adul\n",
      "\n",
      "\n",
      "Page Title: Adrenocortical carcinoma\n",
      "Page Text: Adrenocortical carcinoma  (ACC) is an aggressive cancer originating in the cortex (steroid hormone-producing tissue) of the adrenal gland.\n",
      "Adrenocortical carcinoma is remarkable for the many hormonal syndromes that can occur in patients with steroid hormone-producing (\"functional\") tumors, including Cushings syndrome, Conn syndrome, virilization, and feminization. Adrenocortical carcinoma has often invaded nearby tissues or metastasized to distant organs at the time of diagnosis, and the overall\n",
      "\n",
      "\n"
     ]
    }
   ],
   "source": [
    "from datasets import load_dataset\n",
    "\n",
    "wiki_medical = load_dataset(\"gamino/wiki_medical_terms\")\n",
    "for i in range(5):\n",
    "    print(\"Page Title:\", wiki_medical['train']['page_title'][i])\n",
    "    print(\"Page Text:\", wiki_medical['train']['page_text'][i][:500])\n",
    "    print(\"\\n\")"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "This dataset has the potential of being a source of truth for unseen queries, which points towards implementing a RAG system as a plausible solution to our problem. A great advantage of a RAG system is that it doesn't require model fine-tuning, since it instead uses a vector database to retrieve relevant information and enrich the prompt context. This makes it a low-cost first step solution, that can usually be sufficient for the needs of the stakeholders.\n",
    "\n",
    "## Conclusion\n",
    "After analyzing the original dataset, we were able to identify and resolve several issues with the data. We ended up with approximately 13600 examples of medical-related questions and their accompanying answers. We also provided some next steps that could be taken to improve the quality and quantity of the data.\n",
    "\n",
    "We determined that a RAG system would be a suitable solution, and established that the original data could be used for evaluating the performance of such system. Since RAGs don't require model training or fine-tuning, the data will not be used for that purpose.\n",
    "\n",
    "Finally, we identified a potential data source to complement our task, which seems to be a suitable source-of-truth to construct our RAG system. "
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": []
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": ".venv",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.10.15"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 2
}
